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Abstract 
Treatment options for patients with advanced prostate cancer (PC) still remain 
limited and rarely curative. The prostatic acid phosphatase (PAP) is prostate specific 
protein over-expressed in more than 90% of prostate tumours. Although an FDA-
approved vaccine for the treatment of advanced prostate disease, 
PROVENGE® (sipuleucel-T), has been shown to prolong survival, the precise 
sequence of the PAP protein responsible for the outcome remains unknown. As the 
PAP antigen is one of the very few prostate-specific antigens for which there is a 
rodent equivalent with high homology, pre-clinical studies using PAP have the 
potential to be directly relevant to the clinical setting. The current study identified 
HLA-A2 and HLA-DR1 PAP-derived peptides using the transgenic HHDII/DR1 and 
C57Bl/6 mice. The PAP-114-128 (15-mer) peptide was shown to elicit CD4+ and 
CD8+ T-cell-specific responses in C57Bl/6 mice. Furthermore, when immunised in a 
DNA vector format (ImmunoBody), PAP-114-128 was able to prevent and reduce 
the growth of TRAMP C1 prostate cancer cell-derived tumours in both prophylactic 
and therapeutic settings. This anti-tumour effect was associated with an enhanced 
infiltration of CD8+ tumour-infiltrating lymphocytes (TILs) and the generation of 
high avidity T cells secreting elevated levels of IFNγ. Importantly, PAP-114-128 
specific IFNγ response was also seen in PBMC isolated from PC patients. Also, 
immunisation of C57Bl/6 and HHDII/DRI mice with the analogue peptide epitope 
(obtained by altering the second amino acid of PAP-114-128) showed significantly 
enhanced IFNγ response compared to PAP-114-128 epitope. Collectively, PAP-114-
128 appears to be a highly relevant peptide on which to base vaccines for the 
treatment of advanced PC.  
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Chapter 1: Introduction 
1.1. Prostate cancer 
1.1.1. Occurrence: Prostate cancer (PC) is the most common form of cancer among males in 
Europe accounting for 25% of all new cases of cancer (Bray et al., 2010). PC 
incidence is strongly related to age, with 75% of cases reported in men above 65 years 
of age. There are remarkable racial differences as well, with the disease being rare in 
Asians and most common in African American men (Siegel et al., 2013). The PSA 
(Prostate Specific Antigen)-based screening that was introduced into the clinic in the 
late 1980s resulted in an increase in the percentage of patients undergoing curative-
intent surgery and radiotherapy. Usually diagnosed by rectal examination, transrectal 
ultrasound or biopsy, an increase in PSA level is one of the major prognostic factors 
for PC (Melia et al., 2012). Normal PSA levels are 3ng/ml or less for under 60 years, 
4ng/ml or less for 60 – 69 years and 5ng/ml or less for >70 years (Melia et al., 2012). 
The extent of PC at the time of diagnosis is a crucial factor to define treatment options 
and also to assess the chance of success. Staging and grading are used to describe PC 
(Gleason et al., 1992). Staging is a system used to describe the size, aggressiveness, 
and spread of the disease while grading shows how different the cells are from normal 
cells (Gleason et al., 1974). (Fig. 1.1). 
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Figure 1.1 Grading and staging used to describe the progression of PC. A. Gleason grade ranges from 1 
to 5 and is based on the degree of differentiation of the cells. PC usually has areas with different grades 
and therefore grades from two areas that make up most of the cancer are added to yield a Gleason score 
between 2 and 10. B. PC evolve on four main stages, with each stage indicating extend of tumour 
spread. The cancer starts manifesting at stage I but can be hardly detected through DRE (Digital Rectal 
examination) but could be detected by the PSA levels. In stage 2, the disease starts evolving into a 
larger growth and could be easily detected. In stage 3 the cancer spreads into the tissues that surround 
the prostate gland, mainly into the pelvic area and in stage 4, the cancer is most advanced (Image 
adapted from pharmaceuticalintelligence.com).  
 
1.1.2. Physiology of normal prostate tissue:The term ‘prostate’ is derived from the Greek 
word ‘prohistani’ which means ‘to stand in front of’. The prostate gland is a small 
organ,located below the bladder and in front of the rectum. The primary function of 
the gland is to produce enzymes that maintain the fluid nature of seminal fluid and 
also to nourish the sperm cells as they pass through (Ross et al., 2010).Normal 
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prostate tissue is composed of three zones:the peripheral, central and transition 
zones(Ross et al., 2010) (Fig. 1.2A). The peripheral zone comprises 70% of the total 
volume of the prostate. It is characterised by simple, round to oval acini and loose 
stroma of muscle(Ross et al., 2010). The central zone forms 25% of the prostate and is 
found towards the base of the prostate and encompasses the ejaculation ducts. This 
zone is characterised by large and complex acini with papillary infoldings, and 
compact stroma with interlacing smooth muscle bundles (Ross et al., 2010). The 
transition zone makes up for 5% of the prostate and is characterised by simple, small 
and round acini with compact stroma (Ross et al., 2010). The normal epithelium of 
prostate is made up of three principle cell types: the secretory cells, basal cells and 
neuroendocrine cells. The secretory cells form 73% of the epithelial volume, express 
PSA, PAP and androgen receptors and has the least proliferative capacity (Ross et al., 
2010). The basal cells are flattened, attenuated cells that are present towards the base 
of the prostate gland. They have the highest proliferative capacity and act as reserve 
cells that repopulate secretory cells (Ross et al., 2010). The third type of cells, 
neuroendocrine cells are the least common and their function is unknown. These do 
express PSA and androgen receptors (Ross et al., 2010).  
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Figure 1.2 The physiology of prostate gland. A. Prostate gland consists of peripheral zone, central zone 
and transitional zone. Most cancer lesions occur in the peripheral zone, fewer in transition zone and 
almost none in central zone. B. Small and large carcinomas in the peripheral zone are often found 
associated with high-grade PIN, whereas carcinoma in the transition zone tends to be of lower grade 
and is more often associated with atypical adenosis (Image adapted from www.signaling-gateway.org).  
 
1.1.3. Pathophysiology of PC: The pathophysiology of PC is poorly understood unlike other 
solid tumours. Although diagnosed in men aged 65 years or older, evidences show that 
the process is initiated much earlier (Merrimen et al., 2013). PC is classified as an 
adenocarcinoma that begins when normal semen-secreting prostate gland cells mutate 
to cancer cells (Merrimen et al., 2013). The process is usually initiated by appearance 
of small ‘clumps’ of cancer cells confined in the prostate gland. The condition termed 
prostatic intraepithelial neoplasia (PIN)is the histologic entity presumed to be the most 
likely precursor lesion for invasive carcinoma and is commonly found in the 
peripheral zone (Merrimen et al.,2013) (Fig. 1.2B). Although not all patients with 
high-grade PIN (HGPIN) develop invasive disease, PIN is characterised by ‘cancer-
like cells’ that multiply and invade nearby organs such as seminal vesicles and 
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rectum(Merrimen et al.,2013). The strong association of PIN with progressive 
abnormalities of PC has led many researchers to propose its use as an intermediate 
marker in PC therapies (Sakr et al.,1999). PC is a malignant tumour and the common 
metastatic sites are the bones, lymph nodes, lungs, liver and sometimes the rectum and 
the bladder (Bubendorf et al., 2013). Recent studies show that the prostate tumour 
metastasis is associated with the recruitment of mesenchymal stem cells (MSC) (Jung 
et al., 2013). Tumours depend on MSC for healing processes which further induce 
their conversion into cancer-associated fibroblasts (CAFs) which further promote 
metastasis (Jung et al., 2013). The recruitment of MSC into the prostate tumours is 
facilitated by CXCL16, a ligand for CXCR6 (Jung et al., 2013). CXCR6 signalling 
stimulates the conversion of MSC into cancer-associated fibroblasts, which secrete 
stromal-derived factor-1 (CXCL12) (Jung et al., 2013). The interaction between 
CXCL12 on CAFs and CXCL4 on tumour cells induce an epithelial-to-mesenchymal 
transition, which ultimately promote metastasis to secondary tumour sites (Jung et al., 
2013).  
 
1.1.4. Current therapies available and their limitations: Traditionally, for localised PC, 
three treatment options are provided: watchful waiting, radical retropubic 
prostatectomy (RRP) and radiotherapy. For men with advanced PC, more advanced 
treatment options such as chemotherapy and hormonal ablation etc have been 
preffered. RRP performed under general or local anaesthesia, is executed to 
meticulously dissect relatively bloodless field, to facilitate optimal cancer control (Fu 
et al., 2011). Recently introduced techniques of laparoscopic and robotic 
prostatectomy are attractive because of reduced surgical trauma and morbidity (Patel 
et al., 2007). Though surgical removal can halt PC progression temporarily and 
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prolong life, it cannot clear the disease completely (if the cancer is advanced) and 
comes at a high price for men affecting their quality of life. The main side effects 
reported so far includes incontinence, sexual dysfunction, bleeding, infection, visceral 
injuries and deep vein thrombosis in some rare cases (Patel et al., 2007). The Nobel 
Prize winning work by Huggins and Hodges 60 years ago identified that PC was an 
androgen independent tumour. Since then a number of methods have been developed 
for achieving castrate testosterone levels such as bilateral orchiectomy, LHRH 
(Leuteinising Hormone Releasing Hormone) agonists, antiandrogens and oestrogens 
(Shahinian et al., 2012). Unfortunately all these techniques come with significant 
adverse side effects. Importantly once the PC metastasizes following hormone 
therapy, the disease will be uncontrollable and no complete curative treatments 
currently exist (Shahinian et al., 2012).  
1.1.5. Rationale for the use of Immunotherapy against PC: Vaccines have long been used in 
a prophylactic setting against infectious disease since they could successfully prevent 
small pox 200 years ago. The underlying mechanism for vaccines is the stimulation of 
protective immune responses directed against the target antigens uniquely expressed 
by the infectious agents (Michael et al., 2013). This approach has been proven to be 
successful for various malignancies. For example vaccination against hepatitis B has 
been found to be effective to reduce the incidence of hepatocellular carcinoma (Lai et 
al., 2013). A human recombinant vaccine developed against HPV (human papilloma 
virus) has shown to be effective in preventing cervical and most vaginal and vulvar 
cancers (Jemal et al., 2013). The application of vaccine as a therapeutic modality is far 
more challenging since they are applied in patients with existing advanced or 
metastatic carcinomas. Also the antigen targeted in this setting is not always cancer 
specific but are either overexpressed or mutated or reactivated in the cancer cell 
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relative to the healthy cells. These antigens have already been exposed to the immune 
system during their ontogeny and hence are not being recognised as a foreign protein 
leading to ‘tolerance’. Also, various other tumour-derived factors mediate the 
proliferation, survival and metastatic potential of tumour cells. All these factors make 
development of therapeutic vaccines against cancer far more challenging than 
preventing tumours. But despite these obstacles, several observations provide the 
rationale for development of therapeutic vaccines especially for treatment of PC. 
Firstly PC is a very slow growing cancer allowing the time for multiple booster 
vaccinations and enough time to develop an effective anti tumour response. Also 
accumulating evidence from multiple clinical trials show that the majority of patients 
can mount a vigorous anti-tumour response despite the advanced age and disease 
progression level (Sheikh et al., 2013, Gulley et al., 2013). Importantly a number of 
highly relevant PC antigens such as PAP, PSA and PSMAhave been identified that 
could serve as authentic targets even at metastatic sites. A good synergy has been 
reported when vaccination strategies where combined with hormone ablation therapy 
in PC patients (Ardiani et al., 2013, Sanchez et al., 2013). This finding was further 
supported by studies which demonstrated that sex steroids such as testosterone and 
oestrogen stimulate tumour cells to secrete factors that promote the expansion of 
regulatory T cells (Tregs) (Prieto et al., 2006).Presence of spontaneous autoantibodies 
indicates that a nascent immune response that could be potentially amplified is 
originally present. Careful selection of patients is very important for immunotherapy 
since patients with an intact immune system and with less tumour burden increase the 
chance of success of immunotherapy by several folds.  
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1.2. Understanding the human immune system for efficient design of 
immunotherapy 
The goal of cancer immunotherapy is to develop potent immune responses against 
target tumour cells. Despite the large number of pre-clinical studies and ongoing 
clinical trials, complete cure for cancer using immunotherapy still remains a distant 
dream. Understanding the key events in the immune response such as the components 
of the immune system and their functions, antigen processing machineries involved is 
crucial. This information allows for the optimal selection of antigenic epitopes, 
identification of adjuvants stimulating the appropriate receptors and designing 
attenuation strategies, and identifying the correct dose/route/timing of vaccines to 
efficiently elicit strong immune memory. 
1.2.1. Cells of the immune system: Lymphocytes bearing antigen receptors constitute 20-
40% of body’s white blood cells (WBC) and are responsible for the signature 
properties of immune system such as diversity, specificity and memory (Picker et 
al.,1999) (Fig. 1.3). The lymphocytes are further classified as B cells, T cells and NK 
cells based on their functions and cell surface markers. T cells and B cells that had not 
encountered an antigen are termed as ‘naive’ and look similar morphologically 
measuring 6µm in size (Picker et al.,1999). Naive cells are maintained in G0 phase 
during their life time (Picker et al.,1999). Once the naive lymphocytes encounter 
antigen, they become activated and enlarge into 15µm diameter cells called 
lymphoblasts (Picker et al.,1999). These cells then progress through the cell cycle 
from G0 to G1 and subsequently into S, G2 and M. Lymphoblasts proliferate and 
differentiate into effector or into the memory cells (Picker et al.,1999). Different 
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lineages/maturational stages of lymphocytes could be distinguished by the presence or 
absence of CD (cluster of differentiation) markers (Picker et al.,1999).  
 
Figure 1.3. Cellular components of the immune system. All cells originate from a hematopoietic stem 
cell (HSC) in the bone marrow, which gives rise to two major lineages, a myeloid progenitor cell and a 
lymphoid progenitor cell.  These two progenitors give rise to the myeloid cells (monocytes, 
macrophages, dendritic cells, meagakaryocytes, granulocytes, RBC and platelets) and lymphoid cells (T 
cells, B cells and natural killer (NK) cells), respectively.  These cells make up the cellular components 
of the innate (non-specific) and adaptive (specific) immune systems.  
 
B lymphocytes (B cells): The B lymphocytes, otherwise called as B cells derive the 
designation from its site of maturation, the bone marrow in mammals (Melkers et 
al.,1999). Matured B cells are distinguished from other cell types by the display of 
immunoglobulin molecules (antibody) which serve as antigen receptors (Melkers et 
al.,1999). A single B cell displays approximately 1.5x105 antibody molecules with 
identical binding site for an antigen (Melkers et al.,1999). Encounter of a naive B cell 
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with an antigen that matches the membrane-bound antibody on its surface, causes 
rapid proliferation and the progeny will differentiate into effector cells called plasma 
cells and memory B cells (Melkers et al.,1999). The plasma cells are end-stage cells 
that do not divide and are short lived. They are highly specialised to produce the 
antibody in a secretory form capable of secreting from a few hundred to more than a 
thousand molecules of antibody per second (Melkers et al.,1999).  
T lymphocytes (T cells): The T lymphocytes, otherwise called as T cells derive the 
designation from their site of maturation, the thymus in mammals (Alberts et 
al.,2002). Matured T cells express a unique membrane-bound antigen-binding 
molecule called the T-cell receptor (TCR) (Alberts et al.,2002). Unlike the antibodies 
in B cells that recognise a native or intact antigen, TCRs can only recognise antigen 
that are bound to cell membrane proteins called as major histocompatability (MHC) 
molecules (Janeway et al.,2001). The MHC molecules are polymorphic glycoproteins 
found on cell membranes and are classified as MHC class I (expressed by all 
nucleated cells) and MHC class II (expressed by only specialised antigen presenting 
cells (APC)) (Janeway et al.,2001). The two well defined subpopulations of T cells are 
T helper cells (Th) and T cytotoxic cells (Tc) distinguished from one another by the 
presence of either CD4 or CD8 membrane glycoproteins respectively on their surface 
(Alberts et al.,2002). The ratio of Th and Tc in normal human peripheral blood is 
approximately 2:1 but could be altered by immunodeficiency diseases and other 
immune disorders (Alberts et al.,2002). Following the activation of Th or Tc cells 
with appropriate MHC molecules (MHC class I interaction activates Tc response and 
MHC class II interaction activates Th response), Th cells differentiate into effector 
cells that help activation of B cells, Tc cells and other cells that participate in immune 
response and Tc cells differentiate into effector cells termed as cytotoxic T 
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lymphocytes (CTLs) that would eliminate any cell that display foreign antigen 
complexed with MHC class I, such as virus-infected cells, tumour cells etc (Alberts et 
al.,2002). Some of the Th or Tc cells differentiate into memory cells that would be 
maintained in the host and on rechallenge with the same antigen would mediate a 
response that is both quicker and greater in magnitude (Alberts et al.,2002).  
Natural killer cells (NK cells):NK cells constitute 5% to 10% of lymphocytes in 
human peripheral blood and display cytotoxic activity against a wide range of cancer 
cells and virus infected cells (Picker et al.,1999). A distinguishing feature of NK cells 
is that they lack TCR and employ specific NK cell receptors to distinguish 
abnormalities, such as reduction in display of MHC molecules or unusual surface 
antigen profile by certain tumour cells (Picker et al., 1999). Also, certain tumour cells 
or virally infected cells display antigens against which the body has raised an antibody 
response. So these altered cells would have the bound antibodies on their surfaces 
which could be recognised by the membrane receptor CD16 of NK cells (Picker et al., 
1999). Such a response is called antibody-dependent cell-mediated cytotoxicity 
(ADCC) (Picker et al., 1999). A new subset of cells termed as NKT cells have been 
identified which share characteristics of T cells and NK cells (Van Kaer et al., 2005). 
These NKT cells have been reported to express CD16 and TCRs which interact with 
MHC-like molecules called CD1 rather than MHC class I and class II molecules (Van 
Kaer et al., 2005).  
Mononuclear phagocytes: This includes blood circulating monocytes and tissue 
resident macrophages (Gordon et al., 2011). During hematopoiesis in the bone 
marrow, HSC differentiate into promonocytes that leave bone marrow, mature and 
circulate in blood as monocytes for approximately 8 hours after which they enlarge 
and migrate into various tissues and differentiate into tissue specific macrophages 
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(Gordon et al., 2011). These macrophages are named according to their tissue location 
for example, intestinal macrophages in the gut, alveolar macrophages in the lung, 
histocytes in connective tissue, kupffer cells in the liver, osteoclasts in the bone etc 
(Gordon et al., 2011). Macrophages are activated by a variety of stimuli such as 
phagocytosis of particulate antigen, contact with receptors that sense antigen and also 
by the cytokines secreted by activated Th cells (Gordon et al., 2011). Activated 
macrophages are reported to express higher levels of MHC class II molecules 
allowing them to function better as antigen presenting cells for Th cells (Gordon et al., 
2011). Thus during an immune response, the macrophages and Th cells facilitate each 
other’s activation. The activated macrophages secrete a number of cytotoxic proteins 
that aid in eliminating infected cells, tumour cells and intracellular bacteria (Gordon et 
al., 2011).  
Granulocytes: Granulocytes are classified as neutrophils, eosinophils and basophils 
based on cellular morphology and cytoplasmic staining characteristics (Geissmann et 
al.,2010). The neutrophils (multilobed nucleus, granulated cytoplasm that stains with 
both acidic and basic dyes) generated in the bone marrow are released into peripheral 
blood and constitute 50-70% of circulating white blood cells (Geissmann et al.,2010). 
These cells circulate in the blood for 7 to 10 hours after which they migrate to tissues 
where they have a life span of few days (Geissmann et al.,2010). During an infection, 
the bone marrow generates abnormally higher number of neutrophils and these are the 
first to arrive at the site of infection (Geissmann et al.,2010). The condition of 
abnormal increase in neutrophil count is termed as leukocytosis and is medically 
considered as an indication of infection (Geissmann et al.,2010). Similar to 
macrophages, neutrophils are phagocytes that secrete lytic enzymes on activation. 
Eosinophils (bilobed nucleus, granulated cytoplasm that stain with acid dye, eosin) 
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constitute 1-3% of circulating WBC, and similar to neutrophils are circulating 
phagocytic cells (Geissmann et al.,2010). These cells are thought to play an important 
role against parasitic organisms by damaging parasite membrane (Geissmann et 
al.,2010). Basophils (lobed nucleus, granulated cytoplasm that stain with basic dye, 
methylene blue) constitute <1% of circulating WBC and are nonphagocytic 
granulocytes (Geissmann et al.,2010). These cells function by releasing 
pharmacologically active substances that play a vital role in allergic responses 
(Geissmann et al.,2010).  
Dendritic cells (DC): Dendritic cells were the first cells identified of the immune 
system by Paul Langerhans in 1868. Atleast four major categories of DC have been 
reported so far: Langerhans DC, interstitial DC, monocyte-derived DC and 
plasmacytoid-derived DC (Collin et al.,2013). All DC arise from HSC and eventually 
follow different pathways and reside in different locations (Collin et al., 2013). All 
DC display class I and class II MHC molecules, and B7 family of costimulatory 
molecules that are vital factors for T cell activations (Collin et al.,2013). DC show 
versatile functions of antigen capture and antigen presentation. DC circulate in the 
blood and on antigen encounter, these cells take up the antigen and migrate to the 
nearest lymph node where they present the antigen to Th cells (Collin et al.,2013). 
After antigen uptake, the expression of MHC class II and co-stimulatory molecules on 
their surface is enhanced many folds for successful T cell activation (Collin et 
al.,2013).  
 
1.2.2. MHC and antigen presentation (exogenous and endogenous pathways):  
Work carried out in the early 1950s by Gorer and George Snell established that every 
mammalian species possess a tightly linked cluster of genes that constitutes the MHC, 
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whose products play important roles in intercellular recognition and in discrimination 
between self and non-self. These genes are arrayed within a continuous stretch of 
DNA and are referred to as the HLA complex in humans (located on chromosome 6) 
and as the H-2 complex in mice (located on chromosome 17) (Trombetta et al., 2005). 
In both the species the genes are classified into class I, class II and class III MHC 
genes (Trombetta et al.,2005). MHC class I and class II function as highly specialised 
antigen presenting molecules that are stabilised by peptide ligands, displaying them on 
their surface for T cell recognition (Trombetta et al.,2005) (Table 1.1). But MHC class 
III is unrelated to class I and class II and encodes various secreted proteins that forms 
the complement system (Trombetta et al.,2005).  
 
Figure 1.4. Structure of MHC class I and MHC class II molecules. They are structurally 
distinct, but homologous proteins. Both are characterised by presence of an extracellular, 
peptide-binding cleft and pair of Ig domains and is anchored to the cell membrane through 
transmembrane segments. 
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Table 1.1. Distinguishing features of class I and class II MHC molecules. 
 
 
MHC class I and peptide interaction: MHC class I is expressed on most nucleated 
cells but the level of expression varies with the highest expressed in lymphocytes 
(5x105 molecules per cell). It was identified that the MHC class I expression 
decreased following viral infections and in tumours but the levels of MHC class I 
expression could be enhanced by cytokines such as interferons (alpha, beta and 
gamma) (Bubenik et al.,2003). MHC class I molecule contains a 45kD α-chain non-
covalently associated to the 12kD β2-microglobulin (Fig. 1.4). The α-chain is encoded 
within A, B and C loci in humans and K and D loci in mice (Table 1.1). Structural 
analysis has shown that the α-chain is organised into α-1, 2 and 3 with the α-3 forming 
the transmembrane domain. The α-1 and 2 interact to form a deep groove or the 
‘peptide-binding cleft’, large enough to bind a peptide of eight to ten amino acid in 
length. The assembly of MHC class I is believed to occur by the initial interaction of 
β2-microglobulin with the α-chain followed by the stabilisation of the structure by 
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binding of an appropriate intracellular peptide (usually derived from endogenous 
processing pathway which is discussed later) and the complete stable complex is 
ultimately transported to the cell surface (Cresswell et al.,2005). MHC class I 
molecule present the bound peptides to CD8+ T cells. Each type of MHC class I 
molecule binds to a unique set of peptides which is primarily determined by the 
presence of specific anchor residues at position 2 (at the amino terminal end) and 
position 9 (at the carboxyl terminus) of the nonameric peptide (Cresswell et al.,2005). 
Therefore any peptide of ideal length (9 amino acid long) that contains the same or 
similar anchor residues will bind to the same MHC class I molecule and this feature 
allows to predict the binding efficiency of different peptides (Cresswell et al.,2005).   
MHC class II and peptide interaction: MHC class II expression is restricted to 
antigen-presenting cells such as macrophages, mature DC, mature B-cells etc. MHC 
class II molecule contains an α and β chain associated by non-covalent interactions 
(Fig. 1.4). The α-2 and β-2 forms the membrane proximal region and α-1 and β-1 
forms the peptide binding cleft. Unlike in MHC class I, the peptide binding cleft in 
MHC class II is open and hence can accommodate slightly longer peptide (13-18 
amino acid long). The structure is only stabilised by a bound peptide and hence most 
of the MHC molecules expressed on the membrane surface will have associated self or 
non self peptide (Colin et al.,1997). MHC class II molecule presents peptides to 
CD4+T cells. Structural analysis have revealed that the binding characteristics of a 
peptide to MHC class II is determined by the central 13 residues that form the major 
contact point between the MHC molecule and the peptide (Colin et al.,1997). Thus 
these peptides often have conserved internal sequence motifs but lack conserved 
anchor residues.  
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Endogenous antigen processing by cytosolic pathway for MHC I binding: Since most 
of the nucleated cells express MHC class I molecule, all of them could act as target 
cells that present endogenous antigens/intracellular proteins for CD8+ T cell activation 
(Cresswell et al.,2005). These cells could also include altered self cells such as cancer 
cells, aging body cells and viral infected cells. The average life span of cellular 
proteins is from 10 minutes to 2 days (Cresswell et al.,2005). Therefore there is a 
steady turn-over of intracellular proteins (both normal and defective) within a cell. 
While most of the proteins are degraded to amino acids, some persist in the cytosol as 
peptides which are sampled and processed for association with MHC class I 
molecules(Cresswell et al.,2005). Initially the proteins are ‘’chopped’’ into peptides 
by a cytosolic proteolytic system called as proteosome (Cresswell et al.,2005). These 
peptides are then transported to the rough endoplasmic reticulum (RER) by transporter 
associated proteins designated as TAPs which are optimised to transport peptides that 
will interact with MHC class I molecules (Cresswell et al.,2005). α and β2 
microglobulin chains that are synthesised on polysomes in RER are loaded with the 
peptides to form a stable MHC class I complex with the help of molecular 
chaperones(Cresswell et al.,2005). The stable peptide-MHC I complex is transported 
to cell surface via the golgi complex for recognition by CD8+ T cells (Cresswell et 
al.,2005) (Fig. 1.5).  
Exogenous antigen processing by the endocytic pathway for MHC II binding: 
Antigens are internalised by APC by endocytosis (either receptor-mediated 
endocytosis or pinocytosis) or phagocytosis or both (Collin et al.,1997).  Since APC 
express both MHC class I and class II molecules (both produced in RER), some 
mechanism should exist to prevent loading of MHC class I peptides into MHC class 
II. Studies has shown that when MHC class II molecule is synthesised in RER, the 
33 
 
peptide binding cleft is associated with a pre-assembled protein called, invariant chain 
(Ii, CD74) (Collin et al.,1997). This bound protein prevents binding of any MHC class 
I peptide to MHC class II within the RER (Collin et al.,1997). Transfection 
experiment with cells that lack genes encoding for MHC class II and invariant chain 
revealed that invariant chain generates signals that direct the transport of the MHC 
class II molecule from RER to the endocytic compartments (Collin et al.,1997). The 
movement happens from early endosomes (pH6-6.5) to late endosomes (pH5-6) and 
finally to lysosomes (pH4.5-5) (Collin et al.,1997). Since the molecule passes from 
higher pH to lower pH (increased proteolytic activity), the invariant chain is digested 
and only a short fragment named as CLIP (Class II associated invariant chain peptide) 
remains in the binding cleft thereby preventing any premature binding of antigenic 
peptide (Collin et al.,1997). It has been reported that a non-classical class II MHC 
molecule called as HLA-DM, found predominantly within the endosomal 
compartment (not in cell membrane), catalyse the exchange of CLIP with the 
antigenic peptide (Collin et al.,1997). Once the peptide is bound, the stable peptide-
MHC II complex is transported to plasma membrane for recognition by CD4+ T cells 
(Collin et al.,1997) (Fig.1.5).  
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Figure 1.5. Exogenous and endogenous antigen processing pathways. Intracellular antigens are 
processed into short peptides by the proteosome. The peptides generated (8-10 amino acid long) are 
then transported to RER by TAP to interact with MHC I molecules. The MHCI-loaded peptide complex 
is then transported to cell surface for recognition by CD8+ T cells. Extracellular antigens are 
internalised by APC and is processed within the hydrolytic compartments of lysosomes. MHC II 
molecule generated at the RER is associated with Ii (Invariant chain) thereby preventing the take up of 
class I peptides by MHC class II in RER. The MHC II-Ii complex is transported to the endosomal 
compartment where it fuses with the endosome. Once in the endosome, Ii degrades and is replaced by 
CLIP which prevents pre-mature binding of peptide to MHC II molecule. The endosomal compartment 
later fuses with the lysosome where CLIP is replaced by the peptide. The peptide-MHC complex is then 
moved to the plasma membrane and the peptide is presented to CD4+ T cell (Image adapted from 
www.qiagen.com).  
Cross-presentation of exogenous antigens by APC: As explained earlier the mode of 
entry of the antigen to the cell (exogenous or endogenous) and the site of processing 
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determine whether a peptide binds to MHC class I or MHC class II molecule. But it 
has been reported that in APC some exogenous antigens could be processed by MHC 
class I and presented to CD8+T cells (Joffre et al.,2012). Several mechanisms have 
been proposed for cross-presentation that induce the processing of endosomal 
compartment of exogenous peptides within the RER but the exact position where the 
two relatively well-defined pathways of antigen presentation overlap still needs to be 
studied and is a highly active area of research (Joffre et al.,2012). Two possible 
mechanisms of cross presentation have been described by Lin and colleagues, the first 
mechanism termed as ‘cytosolic pathway’ involves TAP dependent escape of 
exogenous antigen from the endosome to the cytosol but the site where the peptides 
would be loaded onto MHC class I molecule still remains unclear (Lin et al.,2008). 
The second mechanism termed as ‘vacoular pathway’ is TAP independent and 
suggests the degradation of exogenous proteins by lysosomal proteases within 
endosome followed by the loading of these peptides into the recycling MHC class I 
molecules (Lin et al.,2008). The ‘cytosolic pathway’ is beleived to be the more 
physiologically relevantpathway (Lin et al.,2008).  
1.2.3. TCR, membrane molecules: activators, suppressors: T cells respond to specific 
antigenic peptides that are presented on MHC molecules and the initiation of these 
responses requires three distinct events such as specific antigen and MHC recognition 
by T cells, stable adhesion of T cells to the APC and transduction of signals from the 
cell surface to the nucleus of T cells (Huppa et al.,2003). Each of these events is 
mediated by distinct set of molecules present on T cell surface. The molecule that is 
responsible for the dual specificity (MHC and antigenic peptide restriction) of CD4+T 
cells and CD8+ T cells is termed as T cell receptor or TCR, a heterodimer composed 
of α and β chains (Huppa et al.,2003). The invariant proteins called CD3 and ζwhich 
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are non-covalently linked to the TCR are also required for the transduction of 
biochemical signals and the three are collectively termed as TCR complex (Fig. 1.6) 
(Huppa et al.,2003). When a specific peptide-MHC complex is recognised by a TCR, 
simultaneous binding of CD4 or CD8 molecule with the MHC molecule brings the 
coreceptor close to the TCR complex, leading to phosphorylation of CD3 and ζ chains 
thereby initiating the T cell activation cascade ((Huppa et al.,2003). 
 
 
Figure 1.6. Structure of T cell receptor (TCR). The TCR receptor complex is an octomeric complex of 
variable TCR receptor α and β chains with three dimeric signaling modules CD3 δ/ε, CD3 γ/ε 
and CD247  ζ/ζ. The cytoplasmic tail of the TCR is vital in propagating the signal from the triggered 
TCR into the cell. 
In naive T cells, two distinct signals are required to initiate successful proliferation 
and differentiation into effector cells. Binding of the peptide-MHC to TCR along 
with the CD4/CD8 coreceptors provide signal 1. The signal 2 is provided by 
molecules called as costimulators (Lechner et al.,2011). These antigen-non-specific 
costimulatory signals are primarily provided by interactions between CD28 on the 
surface of T cells and members of the B7 family on the surface of DC, activated 
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macrophages and activated B cells (Lechner et al.,2011). The ligands of the B7 
molecules (B7.1 and B7.2) are CD28 and CTLA-4 expressed on T cell surface 
(Lechner et al.,2011). Though CD28 and CTLA-4 are structurally similar, they are 
antagonistic in function. B7 binding to CD28 delivers a positive costimulatory signal 
to T cell while B7 binding to CTLA4 is inhibitory and prevents or downregulates T 
cell activation (Lechner et al.,2011). While CD28 is expressed by both resting and 
activated T cells, CTLA4 is expressed only on activated T cells (Lechner et 
al.,2011). CTLA4 expression is detected within 24 hours of engagement of TCR 
with maximal expression seen within 2 to 3-days post-stimulation (Lechner et 
al.,2011). Though lower in number, CTLA4 competes with CD28 for B7 binding 
(Lechner et al.,2011). Studies conducted in CTLA4 knock-out mice shows that the 
molecule plays a major role in regulating lymphocyte activation thereby preventing 
lymphadenopathy (enlarged lymph due to massive proliferation of lymphocytes) and 
splenomegaly (enlarged spleen) (Oosterwegel et al.,1999). Studies with cultured 
cells show that T cells on activation by specific peptide-MHC complex in the 
absence of costimulatory signals lead to a state of non-responsiveness termed as 
clonal anergy (Bour-Jordan et al.,2011). This is marked by the inability of T cells to 
proliferate in response to specific peptide-MHC complex (Bour-Jordan et al., 2011). 
It was shown that when T cells were incubated with glutaraldehyde-fixed APC that 
lack B7 molecules, the APC are able to present the peptide-MHC to the TCR thereby 
providing signal 1, but there was minimal activation of T cells or production of 
inflammatory cytokines (Bour-Jordan et al.,2011). Evidence suggests that the anergy 
could be induced in both CD4+ and CD8+ T cells in the absence of costimulatory 
signals (Bour-Jordan et al.,2011).  
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Figure 1.7. Co-stimulatory molecules have been shown to have both positive and negative modulatory 
effects on T activation. For effective stimulation of T cells, signal 1 and signal 2 are required. Signal 1 
is antigen specific and is provided through the interaction between TCR and peptide-MHC molecule on 
the APC. Signal 2 is antigen non-specific and is provided by interaction between the co-stimulatory 
molecules between APC and T cell surface (Image adapted from Hubo et al., 2013).  
 
1.3. Immunotherapy against PC 
1.3.1. Mechanisms of immune evasion in PC: 
PC encourages an immune suppressive environment by activation of several 
mechanisms (Fig.1.8).  
1. Induction of suppressor cells: Studies conducted in humans and mouse have reported 
presence of Tregulatory cells (Treg) (CD4+CD25highFoxp3+) in humans and 
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(CD4+CD25highCD39+) in mouse in tumour microenvironment (Holme et al.,2004). 
These are a small fraction of CD4+ T cells that have suppressive function on effector T 
cells that prevent autoimmunity in healthy individuals (Holme et al.,2004). Tregs have 
been reported to be elevated in cancer patients and is usually associated with poor 
prognosis (Yokokawa et al.,2008). Tregs induce suppressive function either in a 
contact dependent manner or by the release of suppressive molecules such as TGFβ or 
IL-10 that further inhibit T cell, NK cell and DC mediated immune responses (Holme 
et al.,2004). Tregs have been shown to be accumulated in the tumours of mouse model 
of PC (TRAMP) (Degl'innocenti et al.,2008). In vivo antibody-mediated depletion or 
use of cyclophosphamide along with vaccination with Tag pulsed DC was found to 
have no effect on tumour progression in TRAMP mice (Degl'innocenti et al.,2008). In 
an interesting study Gilboa and colleagues showed that vaccination of mice against 
Foxp3 is capable of stimulating a Foxp3-specific CTL response resulting in the 
elimination of Foxp3+ Tregs and enhanced antitumor immunity (Nair et al., 2007). 
CD4+Tregs have been reported to be elevated in the peripheral blood and tumour of 
PC patients but did not correlate with time to disease progression (Rigamonti et 
al.,2012). Therefore further studies are required to better understand the function of 
CD4+Tregs in PC. A subpopulation of CD8+ immunosuppressive cells have been 
reported in TRAMP mice that require priming in prostate-draining lymph nodes by 
tolerogenic Foxo3+ DC (Watkins et al.,2011). Interestingly a similar population of DC 
has been reported in PC patients (Watkins et al.,2011). Analysis of TILs in fresh PC 
tissues showed the presence of CD8+Foxp3+Tregs that could be subverted by use of 
TLR8 ligands (Kiniwa et al.,2007). Therefore strategies silencing Foxo3 in DC or 
targeting TLR8 that would inhibit Tregs as well would be useful for vaccination 
strategies against PC. MDSC (CD34+CD33+Cd13+CD11b+CD15-) are a heterogeneous 
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population of immature myeloid cells that mediate immune suppressionand they 
contain precursors that promote differentiation of macrophages, granulocytes, DC and 
myeloid cells (Ugel et al.,2009). Tumour microenvironment influence immature 
myeloid precursors into suppressive cells that directly or indirectly cause antigen 
specific or non-specific T cell unresponsiveness (Ugel et al.,2009).  The inhibitory 
activity of MDSC could be either by direct cell contact thereby inhibiting NK cell 
cytotoxicity and IFNγ production or by indirect mechanisms such as production of 
ROS, iNOS, arginase 1 etc that block T cells cytotoxicity and polarises the T cell 
response to type 2 (Bronte et al.,2005). MDSC have also been found to influence local 
amino acid availability and angiogenesis thereby favouring tumour development 
(Bronte et al.,2005). Cell cultures of human PC have shown an enhanced 
nitrotyrosinases in TILs suggesting local production of ROS (peroxynitrites) by 
MDSC in PC (Bronte et al.,2005). Studies conducted in transplantable TRAMPC1 
mouse models also showed accumulation of CD11b+GR1high MDSC in tumours 
(Rigamonti et al.,2011).  
2. Survival and proliferation of residual tumours: antigen loss variants:Lowering the 
expression of MHC molecules is a way used by the tumour cells to evade immune 
response (Yael et al.,2012). This could be achieved by total loss, haplotype loss, HLA 
allelic losses or combinations of these (Yael et al.,2012). Lowered MHC expression 
has been shown to be associated with enhanced tumour progression, tumour staging or 
grading, decreased survival in many malignancies and failure to respond to CD8+T 
cell based therapies (Yael et al.,2012). MHC loss was earlier reported in PC cell lines 
and prostate tumour tissues (Banderet al.,1997). Emergence of antigen loss tumour 
variants has also been reported due to immune pressure on tumour cells(Qin et 
al.,2012). Such variants were reported in patients that underwent immunotherapy 
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targeting defined antigens(Qin et al.,2012). Decreased PSA expression has been 
reported in prostate tumour sections of patients with progressive disease(Qin et 
al.,2012). The downregulation of PSA is believed to enhance angiogenesis in prostate 
tumours and a recent study reports that the PSA-low cancer cell population contains 
tumour propagating cancer stem cells that resist castration (Qin et al.,2012). 
3. Upregulation of checkpoint molecules: Tumour cells could induce immune 
suppression by directly affecting T cell activation and function. Co-inhibitory signals 
operate between APC and T cells depending on the ligands that get attached between 
these molecules. Reported co-inhibitory signals include GITRL (APC)-GITR (T cell), 
B7.1 (APC)-CTLA4 (T cell), PDL-1 (APC)-PD-1 (T cell)(Lechner et al.,2011). 
Expression of co-inhibitory ligands are enhanced in tumour microenvironment (Zang 
et al.,2007). Hence the co-stimulation is decreased or lost due to loss of co-stimulatory 
molecules or competition from co-inhibitory ligands (Zang et al.,2007). Elevated 
expression of PD-1 and PDL-1 has been reported in PC (Ebelt et al.,2009). Enhanced 
PD-1 expression is reported in immune cell clusters surrounding PC lesions but not in 
healthy or benign samples (Ebelt et al.,2009). These immune cells were either CD4+ 
or CD8+ T cells that lacked perforin and IFNγ expression and hence in a quiescent 
state (Ebelt et al.,2009). Studies show that a very high percentage (~90%) of CD8+ 
TILs expressed high levels of PD1 (Sfanos et al.,2009). Interestingly these TILs have 
restricted TCR Vb gene usage which shows that only a few dominant tumour antigens 
could induce CD8 T cell clonal expansion, but even these cells may be ineffective due 
to enhanced PD-1, PD-L1 expression (Sfanos et al.,2009). Presence and inhibitory 
effects of B7-H3 and B7x in PC was shown by a large study involving 823 PC 
patients treated with RRP (Chavin et al., 2009, Zang et al.,2007). Intensified B7-H3 
and B7x expression was seen in 93% and 99% (respectively) of prostate PC 
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tumours(Zang et al.,2007). This 7-yearfollow up study showed that the overexpression 
correlated with increased disease spread, cancer recurrence and death from cancer 
(Zang et al.,2007). The enhanced expression of B7-H3 was confirmed in a separate 
study (Gregorio et al.,2008). The pathological feature that seem to be correlated with 
enhanced B7-H3 and B7x expression in PC is metastasis mainly, extracapsular 
extension, seminal vesicle invasion and non-organ confined disease (Gregorio et 
al.,2008). Another interesting observation is the overexpression of indoleamine 2,3-
dioxygenase (IDO) in PC and is currently the focus of study of several groups 
(Rigamonti et al.,2012). It was reported that genetically modified TRAMP mice 
deficient in IDO production showed delay in appearance of palpable tumours 
(Kallberg et al.,2010). But TRAMP mice treated with IDO inhibitors was not found to 
be sufficient to delay tumour progression (Degl’Innnocenti et al.,2008). Therefore 
more studies need to be conducted to understand the multiple effects of IDO on the 
prostate tumour cells before devising techniques to target the molecule.  
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Figure 1.8. Immune evasion mechanisms of PC. Tumours depend on complex immune evasion 
mechanisms to subvert T cell responses. These include FasL-mediated T cell apoptosis, recruitment of 
inhibitory cells (Tregs, MDSC) and molecules (IDO), development of antigen-loss variants, and 
upregulation of checkpoint molecules that cause inactivation of T cell functions.  
 
1.3.2. Tumour associated antigens for specific immunotherapy against PC:  
Several tumour associated antigens (TAA) have been reported in PC that represent 
promising targets for T cell based immunotherapy. The antigens that are preferentially 
expressed in normal and malignant prostate tissues are prostate-specific antigen 
(PSA), prostate-specific membrane antigen (PSMA), prostatic acid phosphatase 
(PAP), prostate stem cell antigen (PSCA), prostatic secretory protein (PSP94), T cell 
receptor gamma alternate reading frameprotein (TARP), transient receptor potential 
(trp)-p8 and six-transmembrane epithelial antigen of theprostate 1 (STEAP1). 
Fig. tumour and TME mediated immune evasion is a hall mark of immune resistant
tumours. + signs indicate a positive influence and - sign indicate a negative influence
on the target. The substances secreted by the tumour such as IL-10, TGF-β, Galectin,
ganglioside, PGE2, has a direct negative effect on CTLs. Whereas the secretion of
VGEF, IL-10 & TGF-β will prevent the maturation of tumour infiltrated dendritic cells
which intern trigger their immune suppressive activity on CTLs by upregulating STAT3,
IDO, Arginase and SOCS1. Another class of DC known as plasmocytoid DC (pDC) can
secrete IDO which leads to the tryptophan degradation an essential aminoacid for T cell
proliferation. Other immune cells such as Treg & IL-13 secreting NKT cells also have a
immune suppressive activity by ditectly inhibiting the proliferation of CTLs.
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1. Prostate-Specific Antigen: PSA is the most widely used serum marker for diagnosis 
and monitoring of cancer progression in PC patients (Balk et al.,2003). It is 
exclusively expressed by prostate epithelial cells and can be detected in the majority 
of PC tissues (Balk et al.,2003). Several HLA-A2 and HLA-DRB1 restricted PSA-
derived epitopes have been identified that were found to be naturally processed and 
elicited tumour reactive CTLs (Freedland et al.,2008, Klyushnenkova et al.,2005). 
The antigen has also been widely studied as part of active immunotherapy such as the 
transduction of DCs with an adeno-associated virus-based vector whichmore 
effectively stimulated PSA-specific CTLs in vitro when compared to protein-pulsed 
DCs (Mahadevan et al.,2007). 
2. PSMA: PSMA represents a marker for normal prostate cells and is expressed in the 
majority of prostate tumors, particularly in undifferentiated, metastatic HRPC (Troyer 
et al.,1995). A very small expression (100-1000 fold lower) was also reported recently 
in other normal tissues such as salivary gland, brain, small intestine, renal tubular 
epithelium andbreast epithelium (Troyer et al.,1995). A number of HLA- class I and 
class II epitopes have been reported that showed efficient T cell responses in human 
HLA class I and class II transgenic mice (Harada et al.,2004). The surface expression 
of PSMA also makes it an attractive target candidate for antibody therapy. Different 
anti-PSMA mAbs coupled to ricin A and bismuth (J591) have shown target-specific 
cytotoxicityagainst PSMA-expressing PC cells and markedly reduced the tumor 
volume in nude mice bearing LNCaP xenografts(Vallabhajosula et al.,2004, McDevitt 
et al.,2000). In another interesting approach, engineered T cells expressing chimeric 
anti-PSMA immunoglobulin-T-cell-receptor constructs were used which specifically 
lysed PSMA expressing PC cells resulting in retarded tumour growth in xenograft 
mouse model (Ma et al., 2004). 
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3.  PAP:PAP represents one of the major proteins secreted by prostate epithelial cells and 
its expression is mainly restricted to benign and malignant prostate tissue (Graddis et 
al.,2011). The highest level of PAP expression was seen in tumours with Gleason 
scores of 6 and 7 (Goldstein et al.,2002). Interestingly, recent reports have shown PAP 
expression in adenocarcinomas of different tissues such as gastric, breast and colon 
cancer (Wang et al.,2005). Naturally processed, immunogenic class I and class II 
epitopes of PAP have been reported that elicited immunogenic response in pre-clinical 
mouse models (Olson et al.,2010, Saif et al.,2013). Immunogenic peptides binding to 
HLA-A2, HLA-A24 and HLA-A3 have been reported which would be highly relevant 
due to their broad applicability for a large proportion of patients (Olson et al., 2010, 
Saif et al.,2013, Wang et al., 2005). Recently a PAP based vaccine, Sipuleucel-T was 
FDA approved for treatment of PC after a phase III trial that showed better response in 
treated patients (Nadeem et al.,2013).  
4. PSCA: PSCA is a cell surface glycoprotein that is expressed in basal and secretory 
epithelial cells of the prostate (Joung et al.,2007). PSCA is expressed in more than 
80% of primary PC and bone metastases and the expression is found to be increased 
with higher stages and Gleason scores (Joung et al.,2007). Recent studies showed 
PSCA expression in other tumours including pancreatic adenocarcinoma, renal cell 
carcinoma and diffuse-type gastric cancer (Raff et al.,2009). HLA- class I and class II 
epitopes of PSCA have been reported that elicited immune response in mouse models 
(Krupa et al.,2011). PSCA has also been studied along with viral and cDNA vectors in 
TRAMP mice and displayed antigen-specific CTL response and increased survival 
rates (Garcia et al.,2008). PSCA mAbs conjugated to a toxin (maytansinoid) showed 
cytotoxicity and tumour regression in xenograft mouse models (Olafsen et al.,2007). 
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Bispecific antibody constructs that target PSCA and CD3 on human T cells also 
showed tumor cell killing (Olafsen et al.,2007).  
5.  Prostein: Prostein is a transmembrane protein, typically expressed in normal and 
malignant prostate tissues and is involved in PC cell metastasis and invasion  
(Musiyenko et al.,2008). The expression (transcript level) was found to be elevated in 
malignant tissues compared to normal tissues (Musiyenko et al.,2008). HLA-A0201, 
HLA-B5101 and HLA-Cw0501 specific epitopes of prostein have been identified to 
be naturally processed and immunogeneic (Musiyenko et al.,2008).  
6. Six-Transmembrane Epithelial Antigen of the Prostate 1: STEAP1 is a transmembrane 
protein predominantly expressed in prostate epithelium and is overexpressed in 
different stages and metastases of PC (Rodeberg et al.,2005). Recent reports show 
STEAP1 expression in a variety ofother tumor types including bladder, colon and 
ovarian cancer (Rodeberg et al.,2005). Several naturally processed HLA restricted 
class I and class II epitopes have been identified (Rodeberg et al.,2005). Studies 
conducted in pre-clinical mouse models show significant reuction in tumour growth 
when STEAP is used along with recombinant cDNA or viral vectors (Challita et 
al.,2007). The antigen is also studied as a target for mAbs and has shown to 
significantly reduce the growth of PCa xenografts inmice (Challita et al.,2007). 
7. T Cell Receptor Gamma Alternate Reading Frame Protein:TARP is derived from a 
unique androgen-regulated transcript found to be expressed in the mitochondria of PC 
cells in males and in breast cancer in females (Epel et al.,2008).Recent studies have 
reported several naturally generated HLA class I and class II binding TARP-peptides 
which stimulated PC and breast cancer cell reactive immune responses(Epel et 
al.,2008). mAbs targeting TARP is also currently studied for diagnostic and 
therapeutic purposes (Epel et al.,2008).  
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8. Trp-p8:The gene trp-p8 encodes a seven-span transmembrane protein, the expression 
of which is mainly restricted to the prostate and detected inthe majority of prostate 
tumors (Kiessling et al.,2003). Recent reports show that expression is more in early 
tmour stages and seem to decrease with higher grades (Kiessling et al.,2003). HLA-
A*0201-binding peptide epitope which was able to stimulate tumor-reactive CTLs in 
vitro has been reported (Kiessling et al., 2003). 
9. PSP94: PSP94 is a secretory protein of 94 amino acids, abundantly found in prostata-
derived constituent of human seminal plasma secreted by prostatic epithelial cells 
(Mbikay et al., 1987). PSP94 has been shown to inhibit follicle stimulating 
hormone secretion by the pituitary and prostate glands and may inhibit prostate cancer 
growth by inhibiting follicle stimulating hormone (Shukeir et al, 2005). Garde et al 
have shown that PSP94 inhibits the growth of androgen-independent human prostate 
cancer PC3 cells, especially in a colony formation assay (Garde et al., 1999). It was 
observed that PSP94 expression is downregulated in different grades of prostate 
cancers (Chan et al., 1999). It has been suggested that that the presence 
of cells expressing PSP94 mRNA may be an indicator of potentially aggressive 
prostate cancer (Whitaker et al., 2010). A recent report also suggests that PSP94 can 
bind to PAP and the PAP-bound PSP94 is present in human seminal plasma 
(Anklesaria et al., 2013). 
1.3.3. Types of immunotherapy and current clinical trials against PC: 
The current understanding of the immune system and tumour immunology has 
equipped cancer immunologists to design specific immunotherapies against various 
forms of cancer. Cancer immunotherapy can be broadly classified into non-specific 
and specific therapies.  
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1.3.3.1.Non-specific immunotherapy:Non-specific immunotherapy aims to stimulate 
or enhance immune response by modes that activate immune system regardless of 
their antigen specificity.  
A) BCG (Bacille Calmette-Guerin) therapy: Studies conducted in the early 1970s 
showed that administration of weakened forms of a mycobacterial strain called 
BCG induced anti-cancer effects. The work conducted by Dr. Alvaro Morales led 
to one of the seminal paper on the use of BCG for the treatment of transitional cell 
carcinoma of the bladder (Morales et al., 2001). BCG was earlier used as an 
effective vaccine against tuberculosis. Extensive clinical studies showed the 
efficacy of BCG against metastatic melanoma and different forms of bladder 
cancer and today, BCG is the treatment choice for early forms of bladder cancer 
(Duda et al., 1995). Whole or attenuated fractions of BCG are also currently 
studied as an adjuvant along other forms of therapy (Uyl-de Groot et al., 2005). 
Though it is speculated that BCG acts by activating the macrophages and 
lymphocytes, the specific mechanism of activation still remains to be elucidated.  
B) Cytokines:The use of cytokines in immunotherapy can lead to a direct or indirect 
anti-tumour immune response. Cytokines such as TNF alpha, IFN alpha, INF beta, 
IL-4 and IL-6 have been shown to induce a direct anti-tumour effect by arresting 
tumour growth (Grivennikov et al., 2010). It has also been established that 
synergistic anti-tumour effects could be attained if combinations of cytokines are 
used rather than single agents (Grivennikov et al., 2010). Cytokines such as IL-2 
induce indirect anti-tumour effect by promoting T cell and NK cell growth (Pouw 
et al., 2010). Clinical trials conducted showed that IL-2 injections induced 
objective tumour regression in 20% of cases in metastatic melanoma and renal cell 
carcinoma and is now FDA approved for the treatment of both these cancer types 
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(Schwartzentruber et al., 2011). Interferons and GM-CSF are shown to enhance 
anti-tumour effect by enhancing B7 expression on the APC surface that are vital 
for T cell activation (Radvanyi et al., 1999). The treatment option with GM-CSF is 
now FDA approved after it was shown to promote the revival of immune system 
following chemo/radiation therapy (Gulley et al., 2005). Advances in 
biotechnology have now allowed the large scale production of these cytokines for 
use in cancer immunotherapy.  
C) Cell Therapy: The transfer of whole cells into cancer patients has also been shown 
to generate non-specific anti-tumour immunity. The PBMC isolated from 
metastatic melanoma patients when treated with IL-2 generates lymphokine-
activated killer cells (LAK cells) (Barkholt et al., 2009).Clinical studies showed 
that when LAK cells were administered along with IL-2 to patients with advanced 
metastatic melanoma or renal cell carcinoma, complete tumour regression was 
achieved in 10% of the cases (Barkholt et al., 2009). A major drawback with the 
passive immunotherapy is that they do not generate immunological memory and 
hence require chronic infusion-based treatments. Currently most forms of passive 
immunotherapy are used along side with specific immunotherapy as adjuvants.  
 
1.3.3.2.Specific Immunotherapy:  
A)Adoptive transfer of T cells:Adoptive transfer of T cells involves isolating anti-
tumour cytolytic T cells from cancer patients and expanding these T cells ex vivo and 
then re-infusing back into the patients to eradicate tumours. These cultured T cells 
are usually re-infused back together with supporting growth factors such as IL-2 
resulting in a broad, patient-specific recognition of tumour cells (Donia et al., 2012). 
Thus the technique requires the production of T cells for each individual patient by 
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employing a standard two step protocol (Donia et al., 2012). Much effort has been 
put to optimise the technique to allow specialised centres to generate clinical grade T 
cell products. Tumour infiltrating lymphocytes (TILs) isolated from the tumour site 
of patients also have been widely used for adoptive transfer particularly for 
melanoma (Ellebaek et al., 2012). This suggests that TILs that are originally present 
in the tumour site failed to eradicate the tumours due to the immunosuppressive 
tumour microenvironment. Ex vivo reactivation of these T cells with factors such as 
IL-2 restores the anti-tumour activity of these lymphocytes (Ellebaek et al., 2012). 
Studies conducted in pre-clinical PC mouse models showed that inhibition of TGF 
beta signaling improved the efficacy of adoptively transferred CD8+ T cells (Zhang 
et al., 2005). Understanding the fate of the injected T cells is crucial to allow better 
optimization of therapies provided. A recent study reports a molecular imaging 
technique that allows non-invasive detection of adoptively transferred cells in 
transgenic HLA-A2/Kb mice (Koya et al., 2010). With the system the authors 
successfully showed that peak accumulation of adoptively transferred cells occur at 
day 5 in the tumour site after which the signals decreased considerably (Koya et al., 
2010). The inability of infused lymphocytes to persist in the tumour site in vivo and 
also the inability to reproducibly isolate high affinity T cells affect the efficacy of 
this technique. In an effort to address the latter issue, scientists have utilised transfer 
of TCR genes to primary T cells to enhance the affinity for a given tumour antigen 
(Morgan et al., 2006, Dossett et al., 2009). The successfulin vitro and pre-clinical 
trials led to clinical trials that demonstrated tumour regression in 2 out of 17 patients 
and further trials are underway (Abad et al., 2008, Morgan et al., 2006). Combining 
adoptive transfer along with pre-treatment regimes such as irradiation or 
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chemotherapy and strategies to deplete immunosuppressive cells could enhance the 
efficacy by creating a favorable tumour microenvironment.   
B)Antibody therapy:The development of hybridoma technology in 1975 by Kohler 
and Milstein lead to the hypothesis that the ‘magic bullet’ for cancer had been 
detected. Initial efforts were marred by the observation that patients treated with first 
generation of murine monoclonal antibodies (mAbs) developed severe human-anti-
mouse antibody responses (HAMA) (Nissim et al., 2008). This led to the 
development of humanised antibodies developed by either grafting CDR 
(complementarity-determining regions) or by transferring murine Fab variable region 
to human portion (Nissim et al.,2008). Many such chimerised or humanised mAbs 
are currently approved such as CD33 (Mylotarg) for the treatment of CD33+ myeloid 
leukaemia, EpCAM (Panorex) for the treatment of colorectal cancer, ErbB2 
(Herceptin) for Her-2/neu overexpressing metastatic breast cancer and , VEGF 
(Avastin) and EGFR (Erbitux, Vectibix) for the treatment of colon 
carcinoma(Nissim et al.,2008).Different mechanisms have been proposed by which 
naked, unconjugated antibodies kill their target tumour cells. The major mechanisms 
that have been described include ADCC, complementdependent cytotoxicity (CDC), 
direct induction of apoptosis via antigen (i.e. Rituximab, CD20) or by death receptor 
targeting (Michael et al.,2005). Antibodies have also been used as vehicles for 
targeted delivery of toxic compounds (chemotherapeutics, radionuclides, apoptosis 
enzymes) to the tumour site (Stavroula et al.,2008). Currently 28 mAbs are 
commercially used in Europe and in USA. The major drawback faced by this form of 
therapy is the short in vivo half-life of antibodies and rapid clearance of antibodies 
from the host body and clinical studies have shown relapse in majority of treated 
patients. Therefore many current studies focus on increasing the therapeutic efficacy 
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by engineering the structure of mAbs. Recent studies showed the design of bispecific 
antibodies with two specificities, which would allow redirecting selected immune 
effector cells such as NK cells (via CD16), DC (via CD64) or T cells (via CD3) to 
target tumour cells (Chames et al.,2009). Recently a bispecific antibody directed 
against prostate-specific membrane antigen (PSMA) and CD3 was shown to 
successfully induce T-cell mediated lysis of PC cells (Buhler et al.,2008). For PC, 
antibodies that target TAAs such as PSA, mucin, PSMA etc or that target cell 
surface receptors such as EGFR, Her2/neu etc have been studied (Joniau et al.,2012). 
Apart from this mAbs has also been used to inhibit regulatory receptors (CTLA-4) or 
to activate immune stimulatory receptors (4-1BB) (Madan et al.,2012). mAb based 
aberrogation of CTLA-4 has shown to produce a systemic but nonspecific activation 
of immune response. Ipilimumab (MDX-010 developed by Bristol-Myers Squibb, 
NY, USA) and tremelimumab (CP-675206 developed by Pfizer, NY, USA) are two 
fully human monoclonal antibodies against CTLA-4 (Madan et al.,2012). 
Ipilimumab has been recently FDA approved for treatment of metastatic melanoma. 
In PC, Ipilimumab has been studied along with chemotherapy, immunotherapy and 
vaccines (Madan et al.,2012). The intravenous administration of ipilimumab has 
been shown to be safe and showed some clinical activity (Madan et al.,2012). 
Currently two phase III trials are underway using Ipilimumab against PC. Another 
inhibitory molecule of interest is PD1 that binds to B7.1 (PDL1) in APC causing T 
cell inhibition. PD-1 is upregulated in PC as mentioned earlier. Hence studies are 
currently underway checking the efficacy of a fully humanised PD-1 antibody 
(MDX-1106, developed by Brostol Mayors Squibb, NY, US) for treatment PC 
(Topalian et al.,2012). Recent studies have shown the importance of B7-H3 and B7x 
in inhibiting T cell response in PC (Zang et al.,2007). Hence mAbs targeting these 
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molecules might be of particular interest for treatment of PC. Another interesting 
way of overcoming inhibition would be to target Tregs using mAbs. A fusion protein 
named Denileukin Diftitox has been designed which consist of full length of IL-2 
fused to the enzymatically active domain of diphtheria toxin (Zinser et al.,2012). 
This protein specifically targets CD25+ Tregs and once internalised the diphtheria 
protein is released into the cytoplasm thereby killing the cell (Zinser et al.,2012). It 
would be interesting to see the effect of such fusion proteins in PC treatment 
especially when combined with other modes of immunotherapy. Another interesting 
strategy using mAbs is targeting agonist molecules such as 4-1BB which is 
expressed in activated CD4 and CD8 T cells. A fully humanised mAb with 
specificity for CD137 (4-1BB) is being investigated in many tumour models 
including castration resistant PC(Vinay et al.,2012). Preliminary results from these 
studies has shown clinical benefit but along with some auto-immune manifestations. 
Thus the use of mAbs hold great promise but the major disadvantage is the 
manifestation of auto-immune responses. Once a way is found to bypass these 
responses mAbs would be highly beneficial for PC treatment along with other modes 
of immunotherapy.  
C)Vaccines: 
i. Tumour cell based vaccines:Pre-clinical studies have confirmed that tumour cells 
could be engineered or administered with adjuvants to improve anti-tumour immune 
response (Drake et al.,2010). The major advantage of using whole cell is that a large 
number of tumour antigens could be simultaneously presented resulting in a more 
generalized T cell response against multiple antigens. Studies have been conducted 
with both autologous and allogeneic tumour cells with the latter being easily available 
(Drake et al., 2010). Successful pre-clinical studies lead to several clinical trials that 
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gave mixed results. The first autologous vaccine for PC used surgically harvested PC 
cells irradiated and engineered to secrete GM-CSF (Drake et al., 2010). Though the 
technique showed interesting immune response and safety in initial phase I study, the 
technical difficulties in the preparation turned out to be a major limitation (Drake et 
al.,2010). Thus the focus of research shifted to allogenic cells, which are easily 
available for large scale distribution. The vaccine named GVAX developed by Cell 
GeneSys consists of irradiated PC cell lines PC3 and LNCaP genetically engineered to 
secrete GM-CSF (Higano et al.,2008). Though the vaccine was found to be well 
tolerated in a phase II clinical trial, phase III trials gave negative results and hence 
were prematurely terminated and its further development is currently uncertain (Vuky 
et al.,2013).  Another phase III trial using a different allogeneic whole cell vaccine, 
Onyvax-P (Onyvax Ltd, London) is currently ongoing (Drake et al.,2010). This 
vaccine consisits of irradiated PC cell lines OnyCap23, LNCaP and P4E6 (Drake et 
al.,2010).  
ii. Virus based vaccines:The strategy of using viruses as vehicles for delivering antigen 
to APC have been shown to be quite promising due to the strong inherent 
immunogenicity of the virus which may inturn lead to an improved immune response 
against the tumour antigens delivered by the virus (Arlen et al.,2005). Virus vectors 
are relatively easier to engineer and also could carry a large amount of genetic 
material. Poxviral vectors are among the commonly used vectors and are composed of 
double stranded DNA that replicate within the cytoplasm of infected cells without 
integrating (Arlen et al.,2005). In virus based vaccines, these vectors are engineered to 
encode tumour specific antigens which are eventually taken up by infiltrating APC 
that present the antigen to CD4+ and CD8+ T cells (Arlen et al.,2005). Poxviral vectors 
are also shown to directly infect the APC present in the skin (Langerhans cells) (Arlen 
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et al.,2005). It has been reported that poxvirus based vectors lead to generation of 
strong neutralizing antibodies against the vector which sometimes render booster 
vaccinations ineffective due to the strong dominating anti-viral-antibody response 
over the intended response against the tumour antigen (Arlen et al.,2005). But this 
issue could be successfully overcome by use of different viral vector such as avipox 
viral vectors for booster vaccination (heterologous prime/boost regime) (Hodge et 
al.,1997). The advantage of using avipox vector is that they do not replicate in 
mammalian cells and do not produce new virions. Thus no neutralizing antibodies 
would be generated against these viruses after mammalian infection, thereby allowing 
them to persist in the cells for a long time to express tumour antigens that would 
eventually mount a significantly enhanced immune response (Kantoff (B) et al., 
2010). Prostvac-VF is a heterologous vaccine (BN Immunotherapeutic Inc) that 
consists of 2 recombinant viral vectors, vaccinia and fowlpox encoding transgenes for 
PSA and co-stimulatory molecules (ICAM-1, B7.1, LFA-3) collectively termed as 
TRICOM (Kantoff et al.,2010). A randomized phase II clinical trial conducted in 
patients with minimally symptomatic metastatic castration resistant PC (CRPC), 
showed no major difference between treated and placebo group and the trial was 
reported to be negative(Kantoff et al.,2010).  However, 3 years post treatment, the 
patients treated with Prostvac-VF showed significantly improved overall survival 
(25.1 vs 16.6), a better 3-year survival (30% vs 17%) and a 44% reduction in death 
rate. Based on these encouraging results, a phase III clinical trial is underway (Kantoff 
et al.,2010). 
iii. Peptide based vaccines:In comparison to other vaccine forms, peptide-based vaccines 
harbor many advantages. Firstly, the peptides could be easily produced, are cost 
effective and is easy for storage and distribution. Secondly, multiple target antigens 
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could be included within a single vaccine formulation allowing treatment of wide 
group of patients. Finally, the immunological responses against the vaccine could be 
monitored exactly against the vaccinated epitope (Drake et al.,2010). This form of 
vaccination also have some disadvantages such as possibility of developing antigen 
loss variants, HLA restricted use, requirement of adjuventation etc. But despite these 
limitations peptide based vaccines hold promise in anti-cancer treatment and many 
clinical trials targeting wide range of HLA alleles and also targeting multiple cancers 
are currently underway (Drake et al.,2010). IMA901 is a peptide vaccine consisting of 
9 HLA class I and 1 HLA class II epitopes that were confirmed to be naturally 
presented and shared between renal colon carcinoma (RCC) tissues (Walter et 
al.,2012). Consecutive phase I and II clinical studies conducted in HLA-A*02+ 
advanced/metastatic RCC patients demonstrated an association between clinical 
benefit and multiple vaccine-induced T-cell responses and an impact of single-dose 
cyclophosphamide on Tregs and overall survival (Walter et al.,2012). The knowledge 
acquired in these trials was used to design a randomised, controlled phase III study 
which is currently ongoing (Walter et al.,2012). MKC1106-PP (MannKind 
Corporation) is another novelDNA-based and peptide-based vaccine co-targeting 2 
tumour associated antigens, PRAME (overexpressed by a variety of cancers of 
epithelial, neuroectodermal, and bone marrow origin) and PSMA (required for 
neovasculature in various solid tumors, overexpressed in hormone refractory PC) 
(Weber et al., 2011). The vaccination involves DNA prime comprising of a 
recombinant plasmid (pPRA-PSM encoding fragments derived from both antigens) 
followed by dual-peptide boost comprising of the peptides derived from PRAME and 
PSMA (Weber et al.,2011). A phase I study conducted in patients with metastatic 
solid tumours showed the vaccine to be well-tolerated and 50% of the immunised 
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patients showed an immune response as assessed by the PRAME-specific and PSMA-
specfic T cells in blood (Weber et al.,2011). A decline in PSA levels were reported in 
7/10 PC patients immunised (Weber et al.,2011). The persistence of antigen specific T 
cells in the blood were also found to be correlated with overall survival and stable 
disease defined over a period of 6 months (Weber et al.,2011).  
iv. DNA based vaccines: DNA based vaccines are composed of naked DNA plasmids 
encoding specific tumour antigens. DNA vaccines have a number of advantages 
compared to other vaccine forms. It is the only recombinant vaccine that does not 
induce any form of vector immunity, thereby allowing repeated administration (Drake 
et al.,2010). Additionally it is safe, rapid, simple and cost effective to manufacture. It 
is also relatively stable at room temperature making cold-chain transport less critical 
compared to other vaccine platforms (Drake et al.,2010). Another attractive feature is 
its flexibility allowing combinations of multiple plasmids encoding a variety of 
antigens (Drake et al.,2010). Despite these advantages, the early DNA vaccine clinical 
trials did not fuel potent anti-tumour responses. But the lessons from these trials have 
encouraged researchers to identify novel methods of delivery allowing administration 
of larger doses, increasing transfection and improving the immune response. 
Conjugates recruiting more efficient T cell help and targeting the DNA gene product 
to activated DC are all just reaching the clinic and are showing not only improved 
immune responses but also clinical responses. Pavlenko et al in phase I trial 
investigated a DNA vaccine (pVAX/PSA) along with GM-CSF and IL-2 as adjuvants 
in patients with castration resistant PC (Pavlenko et al.,2004). The vaccine was found 
to be well tolerated and generated cellular and humoral responses against PSA 
(Pavlenko et al.,2004). Another phase I/II trial was conducted by Low et al using a 
novel DNA vaccine, p.DOM-PSMA (Chudley et al.,2012). This vaccineencodes a 
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domain of fragment C of tetanus toxin to induceCD4+ T cell help, fused to a tumour-
derived HLA-A2+epitope from PSMA (Chudley et al.,2012). In this trial, the DNA 
vaccine was delivered eitherby i.m injection or by i.m. injection followed by 
electroporation (EP) (Chudley et al.,2012). A significantly higher level of humoral 
response was found associated with DNA+EP strategy and this data favoured EP as a 
potent method for stimulating humoral responses induced by DNA vaccines. A phase 
I/II clinical trial using a DNA vaccine encoding human PAP was conducted by 
McNeel et al in PC patients (McNeel et al.,2010). The DNA vaccine was co-
administered with GM-CSF as vaccine adjuvant, six times at 2 week intervals 
(McNeel et al.,2010). The vaccine was found to be safe and 41% of the treated 
patients developed PAP-specific CD4+ and CD8+ responses (McNeel et al.,2010). The 
PSA doubling time was found to be increased from 6.5 months to 9.3 months in the 1-
year post-treatment period (McNeel et al., 2010). However humoral responses 
associated with the DNA vaccine was not detected (McNeel et al.,2010). These 
studies show that DNA vaccines are safe, and can elicit an antigen specific immune 
response in patients. 
v. mRNA based vaccines: The strategy of using mRNA as vaccine vector has several 
advantages such as absence of any risk of insertional mutagenesis, non-requirement of 
promoter, allows repeated administration, absence of vector-induced immunity and 
ease of production (Pascolo et al.,2006). mRNA based vaccines could be administered 
by direct injection of naked mRNA or encapusalated in liposomes. Gene gun delivery 
system or in vitro transfection of cells are also other ways of administration. An 
mRNA based vaccine, CV9103 (CureVac GmbH) has been developed against CRPC 
(Kubler et al.,2011). The vaccine encodes for 4 prostate antigens, PSA, PSCA, PSMA 
and STEAP1. A phase I/II clinical trial conducted in CRPC patients showed the 
59 
 
vaccine to be safe and displayed an unexpectedly high level of cellular 
immunogenicity (Kubler et al.,2011). Immunisations resulted in antigen specific T 
cells in 79% of patients independent of HLA background. 58% of the patients showed 
T cell responses against multiple antigens and 74% of patients showed antigen-non 
specific B cell responses (Kubler et al.,2011). PSA levels were found to be stabilised 
and in one patient 85% drop in PSA level was found which correlated with a stable 
disease (Kubler et al.,2011).  
vi. DC based vaccines:As discussed earlier, DC plays a crucial role in eliciting innate and 
adaptive anti-tumour immune responses. When pulsed with tumour antigens, DC take 
up, process and present both MHC class I and class II associated antigenic epitopes to 
CD8+ and CD4+ T cells respectively. A great amount of work has been done to check 
the efficiency of vaccines that are based on DC pulsed with peptides, fusion proteins, 
mRNA (encoding TAA), tumour lysates etc. Sipuleucel-T (Provenge, Dendreon Corp) 
a vaccine consisiting of autologous APC cultured with a fusion protein (PA2024) was 
FDA approved in 2010 for treatment of CRPC (Nadeem et al., 2013). The fusion 
protein PA2024 is composed of PAP and GM-CSF. The vaccine showed improved 
overall survival with a relative reduction of 22% in the death rate in a phase III 
clinical trial conducted in 512 men with asyptomatic chemotherapy naive metastatic 
CRPC (Nadeem et al.,2013). However the time to objective disease progression was 
similar in treated and placebo groups (Nadeem et al.,2013). Antibody response against 
PA2024 was observed in 66% of patients in the sipuleucel-T group and 3% inthe 
placebo group (Nadeem et al., 2013). It is interesting to note that, although both T cell 
and antibody responses to the vaccine were observed; only antibodyresponses were 
associated with an extension of survival. Several other clinical trials with Sipuleucel-T 
are currently underway. In a recently reported phase II trial in 176 patientswith non-
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metastatic PC, Sipuleucel T was administered after 3 to 4 months of androgen 
deprivation therapy (ADT) (Beer et al.,2011). A 48% increase in PSA doubling time 
was seen in patients that received Sipuleucel-T after testosterone recovery (155 vs 105 
days) (Beer et al.,2011). The patients are currently being followed up for overall 
survival. Another pilot study is currently ongoing testing the efficiency of Sipuleucel-
T along with low-dose cyclophosphamide with or withoutanti-PD-1 monoclonal Ab 
(CT-011) in men with CRPC (http://www/Clinicaltrials.gov, NCT01420965).Another 
DC based vaccine that is currently in clinical trial against PC is BPX-101 which 
consists of intradermal administration of autologous DC pulsed with PSMA and 
transduced with CD40 followed by intravenous infusion of AP1903 24 hours post i.d 
administration (Slawin et al.,2011). AP1903 is a high-affinity dimerizer drug that 
induces CD40 signaling in DC (essential for cross-presentation and overcoming 
peripheral T-cell tolerance) (Slawin et al.,2011). A phase I/II study conducted with 
this vaccine strategy was found to be safe and generated PSA associated response 
(Slawin et al.,2011). All patients immunised showed stable disease and 2 patients 
showed significant PSA responses with 1 patient having undetectable PSA 14 months 
post treatment (Slawin et al.,2011).  
The current study proposes to investigate the therapeutic potential of PAP in a pre-
clinical murine model as a pre-requisite for using the antigen as a potential vaccine for 
PC patients. Firstly, the study aims to identify immunogenic class I and class II PAP 
peptides for immunotherapy and immunomonitoring. Secondly, the study aims to 
develop potent vaccination strategies and evaluate them in prophylactic and 
therapeutic experiments in pre-clinical mouse models.  
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Chapter 2: Materials and methods 
2.1 General laboratory consumables and equipments 
2.1.1 Reagents and list of producers 
Culture media Supplier 
DMEM, RPMI                                                                      Bio Whittaker Europe 
Opti-MEM                                                                         Gibco Life Technologies 
Supplements to culture media Supplier 
Fungizone                                                                                                       Promega 
Geneticin (G418)                                                                                            Promega 
HEPES                                                                                      Bio Whittaker Europe 
Foetal calf serum                                                                      Bio Whittaker Europe 
Glutamine                                                                                 Bio Whittaker Europe 
Penicillin/Streptomycin                                                           Bio Whittaker Europe 
2-mercaptoethanol                                                                                             Sigma 
Other cell culture reagents Supplier 
Dimethyl sulfoxide (DMSO)                                                                             Sigma 
Incomplete Freund’s adjuvant (IFA)                                                                 Sigma 
Lipopolysaccharide (LPS)                                                                                 Sigma 
Phosphate buffer saline (PBS)                                                  BioWhittaker Europe 
Polyinosinicpolycytidylic acid (Poly I.C)                                                         Sigma 
Trypan blue                                                                                                       Sigma 
Trypsin                                                                                    Bio Whittaker Europe 
 
Acetic acid                                                                                      Fischer Scientific 
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Anhydrous ethanol                                                                                           Sigma 
Chemical reagents Supplier 
Bovine serum albumin (BSA)                                                          ICN Biomedicals 
Calcium chloride (CaCl2)                                                                                  Sigma 
Chromium-51                                                                                          Biosciences 
Dextran sulphate                                                                                                Sigma 
Ethyldiaminetetraacetic acid (EDTA)                                                               Sigma 
Fluorescent mounting media                                                                   Vectashield 
Goat serum                                                                                                       Sigma 
Gold microcarriers (1.0mm)                                                                          BioRad 
Isopropanol                                                                                                      Sigma 
Isoton                                                                                            Beckman-Coulter 
Magnesium chloride (MgCl2)                                    Fischer Scientific or Promega 
Methanol                                                                                          Acros Organics 
Murine GM-CSF                                                                                       Biosource 
Murine IL-2                                                                                               Biosource 
1.5M Tris-HCl, pH 6.8 or pH 8.8                                                              Geneflow 
Paraformaldehyde                                                                                            Sigma 
Phenol/Chloroform/Isoamyl alcohol                                                               Sigma 
Phosphate buffer saline (PBS)(1X)                                        Bio Whittaker Europe 
Poly vinyl pyrrolidone (PVP)                                                                         Sigma 
Potassium acetate (KOAc)                                                                              Sigma 
Propidium iodide                                                                                             Sigma 
Sodium azide (NaN3)                                                                                  Sigma 
Sodium chloride (NaCl)                                                             Fischer Scientific 
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Sodium dodecyl sulphate (SDS)                                                Fischer Scientific 
Spermidine                                                                                                  Sigma 
Tris                                                                                              Fischer Scientific 
Tween 20                                                                                                  Sigma 
2-methylbutane (Isopentane)                                                       Acros Organics 
Vitamin E                                                                                                   Sigma 
Xylene                                                                                          Acros Organics 
Immunochemical reagents Supplier 
Goat anti-mouse-FITC                                                                                 Sigma 
Goat anti-rat-FITC                                                                                       Sigma 
Streptavidin-HRP                                                                                       Zymed 
Plasmid 
pcDNA3.1                                                                                              Invitrogen 
Kits Supplier 
Lymphocyte depletion: 
Mouse CD4                                                                               Stemcell Technologies 
Mouse CD8                                                                                Stemcell Technologies 
ELISA: 
Mouse IFNγ                                                                                          R&D Systems 
2.1.2 Equipment 
Disposable equipment and plastic-ware Supplier 
BD microlance 3 needles (0.5ml, 1ml)                                        Becton Dickenson 
Bijou tubes (5ml)                                                                                Sterilin 
Cryovials (1.2ml)                                                                                    TPP 
8-chamber slides                                                                              Sarstedt 
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ELISA plates (96-well)                                                                       Costar 
Eppendorf tubes (0.5ml, 1.5ml)                                                      Sarstedt 
FACS tubes                                                                                          Elkay 
Filter tips (10ml, 200ml, 1ml)                                                          Sarstedt 
Flat bottom culture dishes (6-, 24-, 96-well)                                    Sarstedt 
Pasteur pipettes                                                                                Sarstedt 
Petri dishes                                                                                        Sarstedt 
Round bottom culture dishes (96-well)                                             Sarstedt 
Scalpels                                                                          Harward Technology 
Screw top tubes (15ml, 50ml)                                                           Sarstedt 
Serologicalpipettes (5ml, 10ml, 25ml)                                              Sarstedt 
Syringes (10ml)                                                                   BectonDickenson 
Tefzeltubing                                                                                      BioRad 
Tips (20ml, 200ml, 1ml)                                                                  Sarstedt 
T25, T75, T175 tissue culture flasks                                              Sarstedt 
Universal tubes (20ml)                                                                   Sterilin 
0.2mmfilters                                                                                    Sartorius 
Equipment Supplier 
Centrifuge, microcentrifuge                                                                MSE 
Class II safety cabinets                                                                   Walker 
Confocal microscope                                                                        Leica 
Cryostore                                                                              Forma Scientific 
Drying cabinet                                                          Scientific Laboratory Supplies 
Flow cytometer                                                                             Beckman-Coulter 
Helios genegun                                                                                              BioRad 
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Microscope                                                                                                      Nikon 
-80°C freezer                                                                                                   Revco 
96-well plate reader                                                                                         Tecan 
96-well plate harvester                                                                                  Packard 
37°C, 5% CO2 incubator                                                                Forma Scientific 
Top count scintillation counter                                                                     Packard 
Tubing prep station                                                                                        BioRad 
Water baths                                                                                    Grant instruments 
2.1.3 Buffers 
(i) Buffers for tissue cultures 
Trypan Blue: White cell counting solution: 0.1% (v/v) solution of Trypan blue in 
PBS 0.6% (v/v) acetic acid in PBS 
(ii) Buffers for flow cytometry 
Permeabilisation &Fixation solution: 1% (v/v) paraformaldehyde in PBS 70% (v/v) 
ethanol in PBS 
FACS buffer: 0.1% (w/v) BSA, 0.02% (w/v) NaN3, 1X PBS 
(iii) Buffers for ELISA 
Wash buffer: Stop solution: 0.05% (v/v) Tween 20 in PBS 2N H2SO4 
Block buffer: Substrate solution: 1% (w/v) BSA 1 volume colour reagent A (R&D 
Systems), 5% (w/v) sucrose 1 volume colour reagent B (R&D Systems) ,0.05% 
(w/v) NaN3, Completed to final volume with PBS 
Reagent diluent for IFNγ:  1% (w/v) BSA 0.1% (w/v) BSA, Completed to final 
volume with PBS 0.05% (v/v) Tween 20, Completed to final volume with PBS 
T cell media: RPMI,10% (v/v) FCS,2mM L-glutamine,20mM HEPES,50mM 2-
mercaptoethanol, 50U/ml Penicillin/Streptomycin+0.25mg/ml Fungizone 
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BM-DC media: RPMI,5% (v/v) FCS, 2mM L-glutamine,10mM HEPES,50mM 2-
mercaptoethanol, 25U/ml Penicillin/Streptomycin, 0.25mg/ml Fungizone, 1ng/ml 
mGM-CSF 
2.2. Methods:  
2.2.1. Human and mouse PAP DNA sequence:  
Human PAP DNA sequence (Variant 1, secretory form): Accession number 
(NM_001099.4)  
ATGAGAGCTGCACCCCTCCTCCTGGCCAGGGCAGCAAGCCTTAGCCTTGGCTTCTTGTTTCTGCTTTTTTTCTG
GCTAGACCGAAGTGTACTAGCCAAGGAGTTGAAGTTTGTGACTTTGGTGTTTCGGCATGGAGACCGAAGTCCC
ATTGACACCTTTCCCACTGACCCCATAAAGGAATCCTCATGGCCACAAGGATTTGGCCAACTCACCCAGCTGG
GCATGGAGCAGCATTATGAACTTGGAGAGTATATAAGAAAGAGATATAGAAAATTCTTGAATGAGTCCTATAAA
CATGAACAGGTTTATATTCGAAGCACAGACGTTGACCGGACTTTGATGAGTGCTATGACAAACCTGGCAGCCC
TGTTTCCCCCAGAAGGTGTCAGCATCTGGAATCCTATCCTACTCTGGCAGCCCATCCCGGTGCACACAGTTCC
TCTTTCTGAAGATCAGTTGCTATACCTGCCTTTCAGGAACTGCCCTCGTTTTCAAGAACTTGAGAGTGAGACTTT
GAAATCAGAGGAATTCCAGAAGAGGCTGCACCCTTATAAGGATTTTATAGCTACCTTGGGAAAACTTTCAGGAT
TACATGGCCAGGACCTTTTTGGAATTTGGAGTAAAGTCTACGACCCTTTATATTGTGAGAGTGTTCACAATTTCA
CTTTACCCTCCTGGGCCACTGAGGACACCATGACTAAGTTGAGAGAATTGTCAGAATTGTCCCTCCTGTCCCTC
TATGGAATTCACAAGCAGAAAGAGAAATCTAGGCTCCAAGGGGGTGTCCTGGTCAATGAAATCCTCAATCACAT
GAAGAGAGCAACTCAGATACCAAGCTACAAAAAACTCATCATGTATTCTGCGCATGACACTACTGTGAGTGGCC
TACAGATGGCGCTAGATGTTTACAACGGACTCCTTCCTCCCTATGCTTCTTGCCACTTGACGGAATTGTACTTT
GAGAAGGGGGAGTACTTTGTGGAGATGTACTATCGGAATGAGACGCAGCACGAGCCGTATCCCCTCATGCTA
CCTGGCTGCAGCCCCAGCTGTCCTCTGGAGAGGTTTGCTGAGCTGGTTGGCCCTGTGATCCCTCAAGACTGG
TCCACGGAGTGTATGACCACAAACAGCCATCAAGGTACTGAAGACAGTACAGATTAG 
Mouse PAP DNA sequence (Variant 1, secretory form): Accession number 
(NM_207668) 
ATGCGAGCCGTTCCTCTGCCCCTGAGCCGGACAGCAAGCCTCAGCCTTGGCTTCTTGCTCCTGCTTTCTCTCT
GCCTGGACCCAGGCCAAGCCAAGGAGTTGAAGTTTGTGACATTGGTGTTTCGGCATGGAGACCGAGGTCCCA
TCGAGACCTTTCCTACCGACCCCATTACAGAATCCTCGTGGCCACAAGGATTTGGCCAACTCACCCAGTGGGG
CATGGAACAGCACTACGAACTTGGAAGTTATATAAGGAAAAGATACGGAAGATTCTTGAACGACACCTATAAGC
ATGATCAGATTTATATCCGGAGCACAGATGTGGACAGGACTTTGATGAGTGCTATGACAAACCTTGCAGCCCTG
TTTCCTCCAGAGGGGATCAGCATCTGGAATCCTAGACTGCTCTGGCAGCCCATCCCAGTGCACACCGTGTCTC
TCTCTGAGGATCGGTTGCTGTACCTGCCTTTCAGAGACTGCCCTCGTTTTGAAGAACTCAAGAGTGAGACTTTA
GAATCTGAGGAATTCTTGAAGAGGCTTCATCCATATAAAAGCTTCCTGGACACCTTGTCGTCGCTGTCGGGATT
CGATGACCAGGATCTTTTTGGAATCTGGAGTAAAGTTTATGACCCTTTATTCTGCGAGAGTGTTCACAATTTCAC
CTTGCCCTCCTGGGCCACCGAGGACGCCATGATTAAGTTGAAAGAGCTATCAGAATTATCTCTGCTATCACTTT
ATGGAATTCACAAGCAGAAAGAGAAATCTCGACTCCAAGGGGGCGTCCTGGTCAATGAAATCCTCAAGAATAT
GAAGCTTGCAACTCAGCCACAGAAGTATAAAAAGCTGGTCATGTATTCCGCACACGACACTACCGTGAGTGGC
CTGCAGATGGCGCTAGATGTTTATAATGGAGTTCTGCCTCCCTACGCTTCTTGCCACATGATGGAATTGTACCA
TGATAAGGGGGGGCACTTTGTGGAGATGTACTATCGGAATGAGACCCAGAACGAGCCCTACCCACTCACGCT
GCCAGGCTGCACCCACAGCTGCCCTCTGGAGAAGTTTGCGGAGCTACTGGACCCGGTGATCTCCCAGGACTG
GGCCACGGAGTGTATGGCCACAAGCAGCCACCAAGTGCTGAGGGTTATCCTTGCCACTACATTTTGCCTGGTA
ACCGGGATCCTGGTGATACTTCTGCTTGTCCTCATCCGCCATGGGCCCTGCTGGCAGAGAGATGTGTATCGGA
ACATCTGA 
2.2.2. Human and mouse PAP peptide sequences aligned: 
Humanvariant1 MRAAPLLLARAASLSLGFLFLLFFWLDRSVLAKELKFVTLVFRHGDRSPIDTFPTDPIKE 
Mousevariant1 MRAVPLPLSRTASLSLGFLLLLSLCLD-PGQAKELKFVTLVFRHGDRGPIETFPTDPITE 
              ***.** *:*:********:** : ** .  ****************.**:*******.* 
  
Humanvariant1 SSWPQGFGQLTQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNL 
Mousevariant1 SSWPQGFGQLTQWGMEQHYELGSYIRKRYGRFLNDTYKHDQIYIRSTDVDRTLMSAMTNL 
              ************ *********.****** :***::***:*:****************** 
  
Humanvariant1 AALFPPEGVSIWNPILLWQPIPVHTVPLSEDQLLYLPFRNCPRFQELESETLKSEEFQKR 
Mousevariant1 AALFPPEGISIWNPRLLWQPIPVHTVSLSEDRLLYLPFRDCPRFEELKSETLESEEFLKR 
              ********:***** ***********.****:*******:****:**:****:**** ** 
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Humanvariant1 LHPYKDFIATLGKLSGLHGQDLFGIWSKVYDPLYCESVHNFTLPSWATEDTMTKLRELSE 
Mousevariant1 LHPYKSFLDTLSSLSGFDDQDLFGIWSKVYDPLFCESVHNFTLPSWATEDAMIKLKELSE 
              *****.*: **..***:..**************:****************:* **:**** 
  
Humanvariant1 LSLLSLYGIHKQKEKSRLQGGVLVNEILNHMKRATQIPSYKKLIMYSAHDTTVSGLQMAL 
Mousevariant1 LSLLSLYGIHKQKEKSRLQGGVLVNEILKNMKLATQPQKYKKLVMYSAHDTTVSGLQMAL 
              ****************************::** ***  .****:**************** 
  
Humanvariant1 DVYNGLLPPYASCHLTELYFEKGEYFVEMYYRNETQHEPYPLMLPGCSPSCPLERFAELV 
Mousevariant1 DVYNGVLPPYASCHMMELYHDKGGHFVEMYYRNETQNEPYPLTLPGCTHSCPLEKFAELL 
              *****:********: ***.:** :***********:***** ****: *****:****: 
  
Humanvariant1 GPVIPQDWSTECMTTNSHQGTEDSTD-------------------------------- 
Mousevariant1 DPVISQDWATECMATSSHQVLRVILATTFCLVTGILVILLLVLIRHGPCWQRDVYRNI 
              .***.***:****:*.***  .                                     
  
2.2.3. Peptide synthesis: The PAP protein sequence was screened for predicted 
MHC class I (HLA-A2) and MHC class II (HLA-DR1) binding peptides using the 
SYFPEITHI (www.syfpeithi.de) algorithm. Peptide epitopes with high binding 
scores were shortlisted. Peptides PAP-299-307 (ALDVYNGLL), PAP-299-313 
(ALDVYNGLLPPYASC), PAP-230-244 (DTMTKLRELSELSLL), PAP-230-238 
(DTMTKLREL), PAP-114-128 (MSAMTNLAALFPPEG) and PAP-115-123 
(SAMTNLAAL) were synthesized, purified to >90% by HPLC, and their identity 
and purity confirmed by mass spectrum analysis (Mocell Biotec). Control peptides 
included class I (ISIWNPRL) and class II (ISIWNPRLLWQPIPV) epitopes from 
influenza. 
2.2.4. Animals: HLA-A2.1/DR1-transgenic H-2 class I-/class II-knockout transgenic 
C57Bl/6 mice (HHDII/DR1) were obtained from Dr. Lone [via CNRS, France]. 
C57Bl/6 colonies (colonies supplied by Charles River) were bred at Nottingham 
Trent University facilities in accordance with the UK Home Office Codes of Practice 
for the housing and care of animals. Male mice aged 6-7 weeks were used for all the 
experiments. Transgene expression in mice used for this study were checked prior to 
use.  
2.2.5. Cell lines: Tumerogenic TRAMP C1 cells derived from transgenic TRAMP 
(Transgenic Adenocarcinoma of Mouse Prostate) mice (a kind gift from Professor 
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Matteo Bellone, Fondazione Centro San Raffaele, Italy) were cultured with DMEM 
supplemented with 10% v/v FCS (BioWhittaker) and 5mM L-glutamine 
(BioWhittaker). PAP expression in TRAMP C1 cells were confirmed by 
immunofluorescence. EL-4 cells (non-tumerogenic) (generous gift from Prof. Eric 
Tartour, Université Paris Descartes) and MC38 cells (generous gift from Prof. Albert 
DeLeo, University of Pittsburgh) were cultured with RPMI supplemented with 10% 
v/v FCS and 5mM L-glutamine (BioWhittaker). 
2.2.6. Plasmid (IB-PAP-114-128): CDRs (Complementarity Determining Regions) 
within ImmunoBody single heavy and light chain vectors had been replaced with 
unique restriction sites in order to enable the rapid insertion of epitope sequences. To 
generate the PAP ImmunoBody human IgG1 construct, complimentary 
oligonucleotides encoding the HLA-A2 restricted epitope of PAP-115-123 
(SAMTNLAAL) were annealed and incorporated into the CDRH2 site of the vector. 
Into the same construct, the CD4 DR1 114-128 (MSAMTNLAALFPPEG) restricted 
helper epitope was inserted into the CDRL1 of the kappa chain. On sequence 
confirmation the plasmid was amplified and isolated using a Qiagen EndoFree Maxi 
Prep kit according to manufacturer’s instructions. To generate the OVA-
ImmunoBody construct, complimentary oligonucleotides encoding the H2-Kb 
restricted epitope of OVA-258-265 (SIINFEKL) were annealed and incorporated 
into the CDRH2 site of the vector. All immunobody constructs were prepared by Dr. 
Rachael Metheringham, Scancell Ltd. 
2.2.7. Peptide immunisation procedure: Mice were immunised with the peptides 
(100µg of class II peptide and boosted with 75 µg of class I peptide) emulsified in 
incomplete Freund’s adjuvant (IFA) (Sigma-Aldrich) at a ratio of 1:1 via an injection 
into the base of the tail. Immunisations were given on day 1 and boost on day 14 
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unless otherwise mentioned. Spleens were harvested a week after the final 
immunisation.  
2.2.8 DNA bullet synthesis and gene gun immunisation procedure: For cDNA 
immunisation, pcDNA 3.1(-) expression vectors encoding human or murine PAP 
molecules (from Scancell Ltd.) were coated onto 1.0mm gold microcarriers. Briefly, 
36μg of DNA was mixed with 200μl of 0.05M spermidine containing 16.6mg of 
gold. After sonication, 200μl of 1M CaCl2 were added dropwise to the mix whilst 
sonicating and the mixture was incubated for 10 minutes at RT. The DNA-gold 
mixture was then washed three times in anhydrous ethanol and re-suspended in 2ml 
of 0.025mg/ml PVP. Whilst the tube was sonicating, the sample was loaded into a 
dried Tefzel tubing and left to stand for 30 minutes in a Tubing Prep Station. The 
dry ethanol was gently removed using a syringe leaving the gold undisturbed. 
Nitrogen was turned on and the tubing was left spinning for five minutes. Once 
totally dried, the tubing was removed from the station and cut using a guillotine. 
DNA bullets were stored at 4°C until used for immunisation. Each mouse was 
immunised with one bullet containing 1 µg of DNA using a Helios gene gun (Bio-
Rad). Two rounds of immunisations were undertaken at 14-day intervals unless 
otherwise mentioned. Spleens were harvested a week after the final immunisations. 
2.2.9. Murine IFNγ elispot assay: Murine IFN elispot assays were performed 
according to manufacturer’s protocol (Mabtec) on the day of splenectomy using 96-
well elispot plates (Millipore). For each experiment (1x106 per well), triplicate wells 
received 0.1 µg of class I peptide and a second triplicate received 10 µg of class II 
peptide. Triplicate control wells included irrelevant/no peptides at the same 
concentrations. The plates were developed after 48 h with BCIP/NBT (BioRad) for 
30-45 min and plates were rinsed with tap water. Spots were quantitated with an 
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elispot reader (Cellular Technology Limited). An animal was scored as positive 
when the response in the peptide containing well was at least twice that of control 
wells.  
2.2.10. In vitro re-stimulation of murine splenocytes with LPS blasts: Spleens 
were harvested from naïve mice and cells were flushed out. LPS blasts were set up in 
a T75 flask by culturing 60x106 spleen cells in T cell medium supplemented with 
1mg of LPS, 7mg/ml of dextran sulphate and 40mg/ml of Vitamin E. After 48 hours, 
cells from LPS blasts were harvested, washed, re-suspended in 5ml of T cell medium 
and irradiated with caesium for 8 minutes at the University of Nottingham. These 
LPS blasts were washed again and pulsed with 100mg/ml of the relevant or 
irrelevant peptide for 1 hour at 37°C. After washing, these cells were used for in 
vitro re-stimulation of the splenocytes harvested from immunised mice. One week 
after the last immunisation, spleens were harvested, counted, re-suspended and set up 
in a T25 flask at 25x106 cells/5ml. Finally, 5x106 irradiated and peptide-pulsed LPS 
blasts per 5ml were added to the splenocytes to make a final volume of 10ml in each 
T25 flask. 
2.2.11. Chromium Release Assay: Splenocytes from immunised mice were 
depleted of CD4+ T cells after 7 days of in vitro culture using a mouse CD4+ T cell 
depletion kit (Stem Cell Technologies) according to the manufacturer’s protocol. 
The 51Cr-release assays were performed 7 days after in vitro re-stimulation of murine 
splenocytes. Briefly, 5x104 target cells (EL4) labelled with 51Cr for 1 h at 37C were 
co-incubated with decreasing numbers of CD4 depleted splenocytes (effector cells) 
in round bottom 96-well plate (200 μl per well). After 4 h, 50 μl of supernatant was 
collected and transferred to a luma-plate. The radioactivity was then measured using 
a Microbeta counter (TopCount Scintillation Counter). Specific lysis was calculated 
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according to the formula: percent specific lysis=((cpm of sample-spontaneous 
release)/(total release-spontaneous release))x100. An assay was scored positive if the 
specific lysis of the sample was twice the background and the spontaneous release no 
more than 20%. 
2.2.12. Isolation and in vitro culture of bone marrow-derived dendritic cells 
(BMDCs): Mouse hind limbs were harvested and bone marrow was flushed out with 
BMDC media (RPMI+5% (v/v) FCS+ 2 mM L-glutamine+ 10 mM HEPES+ 50 mM 
2-mercaptoethanol+ 25 U/ml Penicillin/Streptomycin 0.25 mg/ml Fungizone+ 1 
ng/ml mGM-CSF) after removing muscles and knuckles. Cells were washed, 
counted and plated out in 24-well plates at 1x106 cells per ml per well of BMDC 
media containing 1ng/ml of murine GM-CSF. Cells were washed with fresh media 
every 2 days for 7 days. The day before proliferation assay, BMDCs were harvested 
and pulsed with 10μg/ml of peptide of interest for 4 h. LPS was added at 1 μg/ml 
overnight in order to mature the cells. The following day, BMDCs were washed 
twice in T cell media (RPMI+10% (v/v) FCS+ 2 mM L-glutamine+ 10mM HEPES+ 
50 mM 2-mercaptoethanol+ 25 U/ml Penicillin/Streptomycin 0.25 mg/ml 
Fungizone) and re-suspended in 1ml BMDC media containing poly-IC (12.5µg) to 
complete maturation for 2 h at 37C. The peptide-loaded, matured DCs were used 
for proliferation assays.  
2.2.13. 3H-Thymidine incorporation assay: Spleens of immunised animals were 
harvested seven days after the last immunisation. The cell suspension was then 
washed, counted and and set up in a T25 flask at 30x106 cells/8ml of T cell media 
containing 10μg/ml of the relevant peptide or irrelevant peptide (control) and 1U/ml 
Vit.E. 20U/ml of IL-2 were added to the culture on day 3 and day 7. Splenocytes 
were cultured for 10 days at 37°C, 5% CO2 prior to CD8+ T cell depletion using a 
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mouse CD8+ T cell depletion kit (Stem Cell Technologies) according to the 
manufacturer’s protocol and used as responder cells in proliferation assays 
(5x104cells/well). Preparations were shown to be typically 90% free of CD8+ T cells 
by flow cytometry using a Beckman Coulter Gallios® flow cytometer (data not 
shown). For the assay, cells were co-cultured with 5x103 BMDCs either pulsed with 
the immunogenic or control peptide in quadruplicates in round-bottom 96-well 
plates. Cultures were incubated for approximately 60 h at 37C, and (3H)-thymidine 
was added at 37 kBq/well for the final 18 h. Plates were harvested onto 96 Uni/Filter 
plates (Packard Instrument), scintillation liquid (Microscint 0, Packard) added and 
the plates were counted using a Top-Count counter (Packard). Results are expressed 
as counts per minute (cpm) as means of quadruplicates. Statistical analysis was 
performed using unpaired Student’s t-test. 
2.2.14. Flow cytometry: For alle xperiments, flow cytometry was undertaken using 
2-5x105 cells were used per polystyrene tube (Elkay). Cells were washed and 
incubated for 30 minutes with conjugated primary antibody. Rat anti-mouse H2-Db 
(BioLegend), rat anti-mouse CD4 (AbD Serotec), rat anti-mouse CD8 (AbD Serotec) 
antibodies were used in these experiments. Appropriate isotype controls were used in 
each experiment. Dilutions of antibodies were used as per manufacturer’s 
instructions. Following incubation with the primary antibody, cells were washed and 
re-suspended in 400 μl of Isoton prior to acquisition and analysis using a Beckman 
Coulter Gallios® flow cytometer and Kaluza® software.  
2.2.15 Dextramer staining of PAP-115-123 specific splenocytes: The presence of 
CD8+ lymphocytes specific for the PAP-115-123 epitope was detected using H2-Db 
specific PAP-115-123 dextramers (Immudex, Denmark). For this, C57BL/6 mice 
were immunized with PAP-114-128 peptide, IB-PAP-114-128 or the empty vector as 
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described above. Mice were sacrificed 7 days after the final immunization, at which 
time splenocytes were isolated. After depletion of erythrocytes, the splenocytes were 
washed twice with PBS (supplemented with 2% v/v FCS). Dextramer staining was 
performed according to the manufacturer’s protocol (www.immudex.com). PAP-
115-123-specific splenocytes were detected using a Beckman Coulter Gallios® flow 
cytometer. 
2.2.16. Immunofluorescence: OCT embedded tumour tissues were sectioned, fixed 
with 4% paraformaldehyde for 5 min at room temperature and blocked with 10% rat 
serum in 0.25% Triton-X100 in PBS for 30 min at room temperature. Rat anti-mouse 
CD8 (AbD Serotec) was used (diluted as per manufacturer’s instructions in blocking 
buffer) for 2 h at room temperature. Appropriate isotype controls were used in each 
experiment. Slides were mounted with fluorescent mounting media containing DAPI 
and studied under using a confocal microscope. 
2.2.17. In vitro stimulation of PBMCs: A 10-day ELISPOT assay was performed to 
determine the precursor frequencies of peptide specific T cells. On day 1 PBMCs 
were plated (2x106 cells/ml) into 24 well plates in quadruplicates in 2ml of RPMI-
1640 medium containing L-glutamine, penicillin, streptomycin and 10% AB serum 
(T-cell medium).  The cells were incubated at 370C, 5% CO2. On day 2, the media 
was replenished with IL-2 (20U/ml) and IL-7 (5ng/ml). On day 3, 10µg/ ml peptide 
antigen or Flu antigen was added to respective wells. On day 7, 500ul of 
supernatants were collected for ELISA. The cells were then washed and replenished 
with fresh IL2 (20U/ml). IFNγ elispot assay was performed on day 8 according to 
manufacturer’s protocol (R&D Systems) 
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Chapter 3: Validation of PAP as a potential antigen for immunotherapy 
3.1. Introduction: Development of effective cancer vaccines remains to be a major 
challenge due to the lack of optimal tumour antigens to target, appropriate strategies 
to offset regulatory mechanisms that inhibit immunotherapy and predictive markers 
that allow us to predict a patient’s response to therapy. This study aims to identify 
relevant MHC-restricted PAP (Prostate Acid Phosphatase) peptides that could be 
applied in clinical trials for immunotherapeutic interventions in prostate cancer (PC) 
patients.  
Improved methodologies developed over a number of years have significantly 
contributed to tumour antigen/epitope discovery and evaluation of functionality.  The 
most commonly used techniques can be broadly divided into two, namely the direct 
immunology approach and the reverse immunology approach (Fig.3.1). Direct 
immunology approaches involve the direct isolation of T-cell epitopes from tumour 
cells (isolated from solid tumour, blood or cell lines) (Muller et al., 2006). 
Biochemical techniques such as immune-affinity chromatography (used for frozen 
tissue, blood cells or cell lines), acid elution (used for cells from dissociated tissue, 
adherent or suspension cell lines) are used for isolation of MHC-associated peptides 
from the tumour cell source (Storkus et al., 1993, Clark et al., 2001). Once the 
peptide-MHC complex is isolated, it is analysed and sequenced by mass 
spectrometry. SEREX (serological analysis of recombinantly expressed clones) has 
been a widely used technique that relies on the use of cancer patient’s sera to screen 
selected tumour cDNA epression libraries (Miles et al., 2007, Geng et al., 2008).The 
first tumour antigen, MAGE-1 was discovered through autologous typing and 
application of a newly developed DNA-cloning technique for defining the targets of 
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T-cell recognition (van der Bruggen et al., 1991). Research on MAGE-1 showed for 
the first time that the human immune system can respond to tumour antigen, and the 
findings transformed the field which resulted in a dynamic effort to discover tumour 
antigens, which has resulted in a long and ever increasing number of antigens from a 
variety of tumours that could serve as targets for immunotherapy.Though the direct 
immunology approach gives high purity isolates, it suffers disadvantages such as 
high cost, complexity of protocols involved and time consumed (Liu et al., 2006). In 
reverse immunology approach the candidate genes are identified/selected based on 
tumour-restricted expression. Gene expression assays (cDNA microarrays, 
oligonucleotide chips, cDNA library sequencing) can be used to determine gene 
expression levels or antibody staining (immunofluorescence, flow cytometry, 
western blotting) of cancer tissues can determine protein expression levels of 
differentially expressed antigens (Princiotta et al., 2003).  
In functional terms, tumour antigens can be broadly divided into antigens that are 
required for tumour development and maintenance of malignant potential 
(indispensable antigens) and those that are non-essential. It is preferable that the 
selected antigen is indispensable for tumour development otherwise this may 
eventually result in the development of antigen-loss variants leading to tumour 
escape. The National Cancer Institute recently established a list of ‘’well-vetted’’, 
priority ranked tumour antigens based on predefined, unprejudiced criteria (Cheever 
et al., 2009). The criteria weighting for antigens, in descending order, was as 
follows: (a) therapeutic function, (b) immunogenicity, (c) role of the antigen in 
oncogenicity, (d) specificity, (e) expression level and percent of antigen-positive 
cells, (f) stem cell expression, (g) number of patients with antigen-positive cancers, 
(h) number of antigenic epitopes, and (i) cellular location of antigen expression 
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(Cheever et al., 2009). Once candidate antigens are selected, immunogenic peptide 
epitopes are predicted by in silico analysis using several different computer based 
algorithms. These algorithms are based on the natural processing (proteosomal 
degradation) and presentation (peptide-MHC interactions) of proteins (Rammensee 
et al.,1999). It is based on the fact that MHC molecules would bind with peptides 
with similar ‘motifs’ (Sturniolo et al.,1999). It considers every amino acid within a 
peptide and assigns each amino acid a positive or negative value, depending on the 
characteristics of the MHC groove with which it will interact (Rammensee et al., 
1999). 
Fig. 3.1. Steps involved in direct and reverse immunology approach. Direct immunology 
approach involves isolation/identification of potential antigen from tumour source. The 
immunogenicity of the antigen is assessed in vitro and immunogenic epitopes purified and isolated. 
These epitopes are then checked in pre-clinical animal models and on succesful testing are then 
passed to clinical trials. Reverse immunology approach starts by selecting the candidate tumour 
antigen and using computer prediction softwares to predict the immunogenicity of epitopes. Selected 
epitopes are tested in vitro and in pre-clinical animal models and then passed to clinical trials. The 
time span required for direct immunology approach is usually 8-10 year and for reverse approach is 2-
3 years.  
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SYFPEITHI (www.syfpeithi.de) is one of the widely used evidence based motif 
matrix, as the data used within the algorithm are derived from knowledge of actual 
natural ligands and can predict both class I and class II epitopes (Mathieu et al., 
2007). The predicted epitopes are then taken to the validation phase, where the 
natural presentation and immunogenicity of the epitopes are corroborated. The 
expression of HLA bound epitopes can be evaluated by biochemical methods 
followed by mass spectrometry analysis and sequencing. Immunogenicity 
assessment of predicted peptides relies on establishing their ability to stimulate MHC 
class I or class II restricted T cell responses. This could be achieved by generating a 
primary response, where naïve T cells respond to antigen in culture or a secondary 
response, where patient T cells are used which had already been exposed to antigen 
in vivo. Immunospot assay (Elispot) is widely used to detect antigen specific T cell 
responses and is based on detection of cytokine secretion in response to antigen. T-
cell cytotoxicity assays that are currently used include Chromium release assays, 
lactate dehydrogenase assays etc that are based on alterations in plasma membrane 
permeability and subsequent release (leakage) of components into the supernatant. 
Assessment of uptake of dyes such as CFSE which are normally excluded by viable 
cells is another method and can be used in combination with flow cytometry. Some 
studies have used flow cytometry to detect the expression of CD107 in the 
membrane, which is transiently expressed during the process of cell killing (Rubio et 
al., 2003).Cytokine-secretion assays, intracellular cytokine assays, etc are a few of 
the techniques that have been carefully validated and established recently (Welters et 
al., 2012). Further validation of peptide specificity can be obtained using multimer 
(tetramer,pentamer, dextramer) staining to identify antigen specific T cells. This has 
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proved to be especially successful for the identification of peptide specific CD8+ T 
cells.  
Though the probability of identifying a peptide that is naturally processed, presented, 
and sufficient to induce CTL activity and tumour lysis with reverse immunology 
approach is low, it has been successfully used for identification of several epitopes 
from antigens such as MAGE-1, MAGE-2, MAGE-3, TRP2, gp100, Her-2/neu, 
SSX-2 etc.   
PC cells express several tumour-associated antigens (TAA) namely prostate-specific 
membrane antigen (PSMA), prostate specific antigen (PSA), and prostate acidic 
phosphatase (PAP) (O'Keefe et al., 2004). The prostate restricted expression and 
overexpression of PAP inPC makes this antigen an ideal candidate for PC vaccines 
(Cunha et al., 2006). Moreover a PAP based vaccine has recently been FDA 
approved for the treatment of patients with advanced PC. The vaccine named 
Provenge/Sipuleucel-T, takes advantage of the properties of dendritic cells (DC) to 
present peptide to T-cells, making PAP an attractive target for immunotherapy 
(Gupta et al., 2011). This vaccination strategy involves collection of DC from PC 
patients and activation ex vivo with PA2024. PA2024 is a recombinant fusion protein 
which consists of PAP linked to GM-CSF (Gupta et al., 2011). Though the treatment 
model could increase the overall survival of the patients treated, the exact region of 
the PAP protein responsible for the outcome observed remain unknown. Also 
production of entire protein is time consuming and costly due to the process involved 
in eliminating possible contamination from bacterial components. In addition, 
vaccinations using long peptides are proved to be more beneficial and to provide an 
efficient immune response than whole proteins (Speetjens et al., 2009).  
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The protein sequence homology between the murine and human sequence in PAP is 
high (89%) allowing the results obtained using mouse model to be translated with 
more confidence into human clinical trials. Here the PAP protein was screened for 
HLA-A2 specific immunogenic epitopes using Syfpeithi database. The 
immunogenicity and natural processing of the selected epitopes in HHDII/DRI and 
C57Bl/6 mice were investigated and the identified immunogenic epitopes were 
selected for vaccine design.  
3.2. Results:  
3.2.1. Screening for PAP epitopes for vaccine design:  
To identify potential PAP epitopes, the whole PAP sequence was screened 
through the Syfpeithi database. Three PAP epitopes with high binding score to 
human HLA class I (HLA-A2) and class II (HLA-DR1) molecules were 
shortlisted (Table3.1). The immunogenicity and natural processing of the selected 
peptides were first assessed using HHDII/DR1 mice after gene gun immunisation 
with hPAP encoding plasmid (pcDNA3.1) coated with gold particles. Mice were 
immunised on day 1 and day 7 and the spleens were harvested a week following 
the second immunisation. Splenocytes were pulsed with 1µg/ml of class I 
peptides and 10µg/ml of class II peptides for 48 hours in elispot plates. The 
number of peptide restricted IFNγ producing cells was recorded for all six 
peptides PAP-299-306 [ALDVYNGL], PAP-299-313 [ALDVYNGLLPPYASC], 
PAP-230-244 [DTMTKLRELSELSLL], PAP-230-238 [DTMTKLREL], PAP-
114-128 [MSAMTNLAALFPPEG] and PAP-115-123 [SAMTNLAAL]. All the 
peptides were able to induce significantly higher (unpaired student’s t-test, 
p<0.05) IFNγ response, both against the 15-mer and the 9-mer peptides 
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compared to control (Fig. 3.2). Splenocytes with no added peptides were used as 
control. Irrelevant controls were not used in this study due to shortage of 
splenocytes. The experiments were repeated in two separate occasions with three 
mice per group. Interestingly, the PAP-114-128 epitope shortlisted gave a high 
binding score for mouse MHC class I (H2Db, Syfpeithi score: 28) and class II 
(H2-IA-b: http://tools.immuneepitope.org/analyze/html/mhc_II_binding-.html, 
score: 21) molecules. This epitope is also identical for both mouse and human. 
Hence to determine the immunogenicity of the epitope in the mouse, syngeneic 
C57Bl/6 mice were immunised with murine PAP cDNA on day 1 and day 7. Ex 
vivo elispot assays were performed on spleens isolated 7 days after the final 
immunisation and PAP-114-128 and PAP-115-123 generated a significant 
(unpaired student’s t-test, p<0.05) IFNγ response from C57Bl/6 immune T-cells 
compared to control. Splenocytes with no added peptides were used as control 
(Fig.3.3).  The experiment was repeated twice with three mice per group. Thus 
this epitope was selected for further study since it demonstrated immunogenicity 
in syngeneic C57Bl/6 and in transgenic HHDII/DRI mouse models. 
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Table 3.1. PAP-derived epitopes and their binding scores predicted from 
syfpeithi database
 
Fig.3.2. IFNγ response of PAP-restricted epitopes identified on ex vivo elispot assay. Male 
HHDII/DRI mice were immunised with 1µg of human PAP cDNA by gene gun on day 1 and day 
7. 7 days after the final immunisation splenocytes were harvested and ex vivo elispot performed. 
The frequency of IFNγ sfu per 106 splenocytes is shown here. From the three 15-mer sequences 
screened, a 9 mer specific and 15 mer specific response was obtained. Naïve splenocytes with no 
added peptides were used as control. Comparisons of means(+/- SEM) between groups (T cells 
299-306    299-313                    230-238      230-244                 115-123    114-128                   Control 
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pulsed with the peptide or control) are made with an unpaired t test. The experiments were 
repeated twice with 3 mice per group. 
 
3.2.2. Enhanced IFNγ response seen for the selected PAP epitopes after 
optimised immunisation regime: 
The importance of selecting the optimum timing and mode of boosting strategy 
has been the focus of many current studies. To optimise the immunisation 
regime, mice were divided into two groups of three. The first group received PAP 
cDNA immunisation on day 1 and day 7, while the second group received PAP 
cDNA immunisation on day 1 and day 14. Spleens were harvested from both 
groups 7 days after the final immunisation and cells were processed for elispot 
assay. Ex vivo elispot performed on isolated splenocytes showed a significantly 
enhanced IFNγ response (unpaired student’s t-test, p<0.05) in the second group 
of mice where the immunisations were given 14 days apart (Fig.3.4). This 
enhanced IFNγ response was seen in class I (PAP-115-123, PAP-230-238) and 
class II (PAP-114-128, PAP-230-244) epitopes that were tested. Hence this mode 
of immunisation was followed for the rest of the study. Interestingly, overall CD4 
and CD8 population in lymph and spleen of the two groups remained similar 
(Fig.3.5).  
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Fig.3.3. PAP-114-128 epitope elicit IFNγ response in C57Bl/6 and HHDII/DRI mice. Mice 
(C57Bl/6 or HHDII/DRI) were immunised with PAP cDNA by gene gun on day 1 and day 7. A 
week after the final immunisation the splenocytes were harvested and ex vivo elispot performed. 
A 9 mer specific and 15 mer specific IFNγ response was seen in C57Bl/6 and HHDII/DR1 mice. 
Comparisons of means between groups (T cells pulsed with peptide or control) are made with an 
unpaired t test. Splenocytes with no added peptide was used as control. A response was 
considered positive if the number of spots in the wells stimulated with specific peptides was 2 
fold higher, than the number of spots in the wells without peptide (control). The experiments 
were repeated twice with 3 mice per group. 
The experiment was repeated with an OVA-Immunobody and similar results 
were obtained, thus confirming the advantage of sequential immunisation 14 
days apart. 
 115-123            114-128          Control        115-123              114-128           Control 
                                        HHDII/DRI                                                                        C57Bl/6 
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Figure 3.4.Comparison of IFNγ response obtained from two immunisation regimes. 
HHDII/DRI mice were immunised with PAP cDNA on day 1 and day 7 or on day 1 and day 14. 
A week after the final immunisation splenocytes were harvested and ex vivo elispot performed. 
The modified immunisation regime (with 14 day interval) gave a significantly higher IFNγ 
response compared to the normal immunisation regime (with 7 day interval). Splenocytes pulsed 
with Flu peptide was used as control. The experiment was performed with three mice per group. 
Comparisons between the groups (+/-SEM) were performed using an unpaired t-test.  
 
3.2.3. Assessment of optimum peptide concentration for PAP-114-128 epitope: 
The PAP114-128 epitope was selected for further vaccination studies due to the fact 
that it has 100% homology between human and mouse. To assess the optimum range 
of peptide concentration for ex vivo elispot, C57Bl/6 mice were immunised with 
100µg of PAP-114-128 peptide (admixed with IFA) on day 1 and 75µg of PAP-115-
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123 (admixed with IFA) on day 14.  A week after the final immunisation, splenocytes 
were isolated for ex vivo elispot assay. Splenocytes were co-cultured with varying 
concentrations of PAP-114-128 and PAP-115-123 peptides. The results obtained 
show that 0.1µg of PAP-115-123 peptide and 10µg of PAP-114-128 peptide gave 
significantly higher (unpaired student’s t-test, p<0.05) IFNγ response compared to 
other peptide concentrations (Fig. 3.6). Splenocytes pulsed with irrelevant Flu 
peptides were used as control. The experiment was performed using three mice per 
group and were similar to the results obtained using HHDII/DRI mice. Comparisons 
of means (+/- SEM) between groups (splenocytes pulsed with relevant peptide or 
Flu) were made using an unpaired t test. 
             
                  
 
Figure 3.5. Comparison of CD4 and CD8 T cells obtained from two immunisation regimes. 
HHDII/DRI mice were immunised with PAP cDNA on day 1 and day 7 or on day 1 and day 14. A 
week after the final immunisation, spleen and lymph nodes were harvested and stained with CD4 and 
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CD8 antibodies and analysed using flow cytometry. No significant difference was seen in the 
percentage of CD4 and CD8 population between the two immunisation regimes in spleen and lymph. 
The experiment was performed with three mice per group.  
              
      
 
Figure 3.6. Optimum concentration of PAP-114-128 and PAP-115-123 epitopes for ex vivo 
elispot is shown. C57Bl/6 mice were immunised with PAP-114-128 peptide. A week after the 
final boost spleens were harvested and ex vivo elispot performed with varying concentrations of 
PAP114-128 and PAP-115-123 epitope. Splenocytes pulsed with Flu peptide was used as control. 
Comparisons between groups (+/-SEM) are made by unpaired t-test. The experiment was 
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performed with three mice per group. 0.1µg of PAP-115-123 and 10µg of PAP-114-128 gave 
significantly higher IFNγ response compared to other peptide concentrations monitored.  
 
 
 
3.2.4. ELISA confirms PAP-114-128 peptide specific IFNγ production by 
C57Bl/6 mouse splenocytes post- immunisation:  
To confirm the IFNγ response from elispot, ELISA was performed to detect secretion 
of IFNγ in T cell cultures after PAP-114-128 peptide immunisation. For this, 
C57Bl/6 mice were immunised with 100µg of PAP-114-128 peptide on day 1 and 
75µg of PAP-115-123 on day 14. A week after the final immunisation spleens were 
harvested and cultured in vitro in presence of PAP-114-128 and PAP-115-123 
peptide epitopes. Supernatants from the culture wells were collected on day 3 and 
day 5 and an ELISA was performed for determining IFNγ secretion levels. Wells 
supplemented with Flu class I and class II peptides were used as control. Both PAP-
114-128 specific and PAP-115-123 specific IFNγ secretions were detected especially 
on day 5 supernatants isolated (Fig.3.7). The IFNγ secretion for PAP-115-123 
epitope on day 3 was 60pg/ml and on day 5 was 125pg/ml whereas for PAP-114-128 
epitopes was 20pg/ml on day 3 and 135pg/ml on day 5.  
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Fig. 3.7. IFNγ secretion analysis by ELISA following in vitro stimulation with PAP-114-128 and 
PAP-115-123 peptides. Cytokine analysis was carried out on supernatants harvested on day 3 and 
day 5 after in vitro restimulation with the PAP-114-128 and PAP-115-123 epitopes. Statistical 
differences between PAP peptides and Irrelevant Flu peptides are determined by unpaired student’s T 
test. The experiment was repeated twice with three mice per group.  
3.2.5. PAP-114-128 elicits a CD8 specific cytotoxic response and CD4 specific 
proliferative response in C57Bl/6 mice:  
To determine whether the 15-mer PAP-114-128 could elicit a CD4 and/or a CD8 
T-cell response, C57Bl/6 mice were immunised with 100µg of PAP-114-128 on 
day 1 and 75µg of PAP-115-123 on day 14 admixed with IFA in a 1:1 ratio. A 
week after the final immunisation, isolated splenocytes were restimulated for 7 
days with the PAP-114-128 peptide. CD8 and CD4 T cells were then separated 
using the Stemcell Technology isolation kit. A chromium release assay performed 
on CD4 depleted cells showed significant PAP-115-123 peptide specific killing 
(24% killing) of target cells (Fig.3.8). EL-4 cells pulsed with PAP-115-123 was 
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used as target cells. EL-4 pulsed with Flu peptide was used as control. 
Comparisons of means (+/- SEM) between groups (EL-4 pulsed with PAP115-
123 or Flu) were performed using an unpaired t test. Thymidine incorporation 
assay was performed on CD8 depleted T-cells to show CD4 specific proliferative 
response. PAP-114-128 did indeed elicit a significant (two-fold increase) CD4 
specific proliferative response compared to control (BMDC pulsed with Flu 
peptide) (Fig. 3.8). Results are expressed as counts per minute [cpm] as means of 
quadruplicates. Comparisons of means (+/- SEM) between groups (BMDC 
pulsed with PAP114-128 or Flu) are made with an unpaired t test. The 
experiment was repeated twice with three mice per group and similar results 
were obtained on both occasions.  
3.2.6. Generation of dextramer positive peptide specific CD8+ T-cells by PAP-
114-128 peptide immunisation:  
The number of PAP-115-123-specific CD8+ T-cells was assessed using H2-Db 
specific PAP-115-123 dextramers (Immudex, Denmark). C57Bl/6 mice were 
immunised with PAP-114-128 peptide, on day 1 and day 14 and spleens and 
lymph nodes were harvested 7 days after the second immunisation. The cells 
were stained with the dextramer along with CD3+ and CD8+ antibodies 
according to the manufacturer’s protocol. PAP-115-123 specific T-cells were 
detected using a 10-color Beckman-Coulter Gallios instrument. 0.74% of PAP-
115-123 dextramer positive cells were detected in spleen, 0.38% of PAP-115-
123 dextramer positive cells were detected in the lymph nodes (inguinal) of 
immunised mice (Fig.3.9) and 0.12% was detected in spleens of naive mice. 
Similar numbers were obtained when the experiment was repeated.  
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Fig.3.8. CD8 specific cytotoxic response and CD4 specific proliferative response shown after 
PAP-114-128 peptide immunisation. Splenocytes from PAP-114-128 peptide immunised mice 
were restimulated for a week and CD8 and CD4 T cells were separated. For Chromium release 
cytotoxicity assay, EL-4 cells pulsed with PAP-115-123 were used as target cells. EL-4 pulsed 
with Flu peptide was used as control. Comparisons of means(+/- SEM) between groups (EL-4 
pulsed with relevant peptide or Flu) are performed using an unpaired t test. For thymidine 
incorporation proliferative assay BMDC pulsed with PAP-114-128 was used and BMDC pulsed 
with Flu peptide was used as control.  Results are expressed as counts per minute [cpm] as means 
of quadruplicates. Comparisons of means(+/- SEM) between groups (BMDC pulsed with relevant 
peptide or Flu) are performed using an unpaired t test. The experiments were repeated twice with 
three mice per group.  
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Fig. 3.9. PAP-115-123 dextramer positive cells shown after PAP-114-128 peptide 
immunisation. Spleens and lymphs were harvested a week after the boost and RBC depleted. 
The cells were washed and stained for PAP-115-123 dextramer, CD3 and CD8 antibodies 
according to manufacturer’s instructions. PAP-115-123 specific dextramer positive cells were 
detected in spleen and lymph. The percentage of dextramer positive cells in spleen was found to 
be higher compared to lymph nodes. No significant dextramer positive cells were observed in 
spleen and lymph of naive mice. The experiment was repeated twice with three mice per group.  
 
3.3. Discussion:  
Earlier pre-clinical and clinical stuides conducted have shown PAP specific benefits 
in pre-clinical models and in patients respectively (Burch et al.,2004, McNeel et al., 
2009,Zlotocha et al.,2005). The use of short MHC peptide epitopes (8-10 amino acid 
in length) long were used initially. The first peptide vaccine with the ability to 
induce a T cell response in mice was incorporated into LCMV (lymphocytic 
choriomeningitis virus) vector (Aichele et al., 1990). However, subsequent studies 
reported that vaccination with short peptides could lead to immunological tolerance 
to the immunising antigen (Knutson et al.,2005) and that immunisations with short 
peptides lead to exogenous loading of all cells (including T cells and B cells) 
expressing class I MHC molecules (Bijker et al., 2008). These cells, unlike DC, lack 
those co-stimulatory molecules required to mount an immune response and hence 
they circulate to lymph nodes thereby inducing immunological tolerance.  
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The first successful LCMV vaccine incorporated a helper CD4+ T cell epitope that 
induced a prolonged T helper response for CD8+ T cells by fully activating DC 
through the CD40-CD40L pathway along with the secretion of interleukin 2 (IL2) 
(Fayolle et al.,1991). Subsequently, co-injection of CD4 and CD8 peptide epitopes, 
not only prevented immune tolerance but also increased the magnitude of T cell 
response, resulting in better tumour protection in pre-clinical mouse models 
(Valmori et al., 1994). Recent studies in mice confirmed that injection of short CTL 
epitopes in IFA failed to induce CD8+ memory T cells (Bijker et al.,2007). Another 
significant improvement in the field was achieved by producing ‘hybrid peptides’ 
conjugating minimal Th and Tc epitopes that produced a better response than when 
the epitopes were delivered as a mix (Shirai et al., 1994). Finally, head to head 
comparisons proved that the length of the peptide used for vaccination significantly 
infuences the magnitude of the immune response (Zwaveling et al.,2002). Preclinical 
studies conducted using long peptides (20 amino acids and longer) embedding the 
short CD8 epitope in their sequence and prolongated by the natural sequence found 
in the protein demonstrated that these long peptides are superior in inducing CD8+ T 
cell responses (Zwaveling et al., 2002). Taken together, optimal immunisation will 
require the recruitment of both CD4+ and CD8+ T cells, in order to generate a long-
lasting anti-tumour immune response. 
In this study high scoring peptides for HLA-A0201 and HLA-DR0101 molecules 
were selected and evaluated for their immunogenicity in HHDII/DRI mice. 
HHDII/DRI mice, which combines the classic HLA transgene (HLA-A2.1/Db-h2m 
single chain, DRI) with selective knockdown of murine H-2 that restricts the whole 
MHC class I- derived T-cell repertoire to HLA-A2.1 and MHC class II repertoire to 
HLA-DR1 (Anthony et al., 2004). The selected three 15-mer epitopes, PAP-230-
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244, PAP-299-313 and PAP-114-128, also showed high binding HLA-A2 specific 9-
mer epitopes incorporated within the sequence. It is important to determine whether 
the epitopes are naturally processed and presented by APC or tumour cells. If not, 
they would not be recognised by CD4+ and CD8+ T cells. One way to assess the 
processing of an immunogenic epitope is to immunise the mice with a plasmid 
encoding the gene of interest using gene gun technology (Tuting et al., 1999). Here 
HHDII/DRI mice were immunised with pcDNA3.1(-) plasmid encoding human PAP 
cDNA using gene gun. Splenocytes of the immunised mice showed significant  
response against all the selected epitopes showing that all of them are naturally 
processed. It is interesting to note that the predicted syfpeithi scores correlated with 
the immunogenicity of the epitopes. PAP-114-128 was shortlisted for further study 
due to the fact that it shares identical amino acid sequence in human and mouse and 
hence in vivo results obtained using mouse model can be translated with more 
confidence into human for clinical trials. Splenocytes isolated from immunised 
C57Bl/6 mice and HHDII/DRI mice showed a significant  response against the 
PAP-114-128 epitope. This allowed study of the epitope further in C57Bl/6 mice 
which are less expensive and easier to breed. The novel 15-mer epitope 114-128 
incorporates a 9-mer epitope (115-123) capable of eliciting a CD8+ T-cell response. 
Importantly, mice immunised with PAP-114-128 and boosted with PAP-115-123 did 
elicit significant IFNγ response as confirmed by elispot and ELISA and also elicited 
CD8 specific cytotoxic T-cell response confirmed by chromium release assay and 
CD4 specific proliferative T-cell response by thymidine incorporation assay.  Hence 
the use of PAP-114-128 allows us to harness CD4+ and CD8+ response from 
immunisation with a 15-mer peptide. Also, spleens isolated from peptide immunised 
mice showed PAP-115-123 specific dextramer positive cells in both spleen and 
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lymph nodes compared to naive mice. Interestingly, an overlapping epitope, PAP-
112-120 has been reported to be immunogenic in human studies (Olson et al., 2010), 
but unlike PAP-114-128 this epitope showed very weak binding to mouse MHC 
molecules (syfpethi score: 13).  
Apart from the antigen/peptide selected, the timing and mode of immunisation plays 
an important role in mounting a ‘balanced’ immune response. Various pre-clinical 
studies have confirmed that vaccination-induced immunity in mice and boosting a 
sustained pool of memory cells, which associated with potent protection provided a 
therapeutic benefit. Appropriate timing of booster vaccination was shown to be 
crucial, as a short duration between immunisations hindered with persistence of 
memory T cell population thereby affecting survival in a prophylactic setting (Nolz 
et al., 2011). In this study an increased timing of booster vaccination (from 7 days to 
14 days) resulted in a significantly enhanced IFNγ response. There was no 
significant increase in the total number of CD8+ and CD4+ T cells in spleen and 
lymph. Since the second immunisation was given after a prolonged interval, the 
boost might have activated the memory pool instead of the effector population. It has 
also been established that re-activating the memory subset could give a far higher 
immune response compared to the naïve T cells. (Kaech et al., 2002). The 
importance of selecting optimal timing and vaccination schedule has been the focus 
of many recent studies. It was recently shown that the high avidity T cells can be 
selected in the memory and effectively recalled by a single DNA boost without any 
significant reduction in avidity (Brentville et al., 2012). However in contrast a boost 
with peptide vaccine lead to the killing or conversion of high avidity T cells in to 
low avidity in both in vivo and ex vivo model systems suggesting  supra-optimal 
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stimulations lead to the loss of functional avidity of T cells in vaccination strategies 
(Brentville et al., 2012). 
It has also been reported that multiple booster vaccinations actually have negative 
effects on immune response (Sallusto et al., 2010). Thus it can be inferred that 
booster vaccinations impact on anti-tumour immunity and this represents prime 
consideration when conducting clinical trials where the ‘immune status’ of the 
patients will vary. 
In this study we have used peptide admixed with IFA as antigen source. IFA in a 
variety of forms is widely used in pre-clinical and clinical studies for administration 
of antigenic peptides (Bonhoure et al.,2006) and is thought to act by inducing local 
inflammation and form a depot that prevent antigen degradation and allows the slow 
release of antigen to antigen presenting cells (Reinhardt et al., 2003). Interestingly a 
recent study has reported that the use of IFA for peptide delivery could lead to the 
accumulation of antigen specific CD8+ T cells at the site of vaccination rather than in 
the tumours (Yared et al.,2013).  This scenario requires further investigation and 
represents a potential mechanism abrogating effective therapy. 
Overall, the findings shown here demonstrate that PAP-114-128 is a promising 
candidate for PAP-based anti-cancer vaccine strategies. The use of appropriate pre-
clinical tumour models will allow optimum immunisation protocols to be 
established. 
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Chapter 4: Assessment of vaccination strategies in pre-clinical mouse model 
using PAP as target antigen 
4.1. Introduction: 
Prostate cancer(PC) is a heterogenous disease where malignant cells arise from the 
epithelial layers comprising luminal cells, basal cells and neuroendocrine cells. 
Different studies show that PC initiating cells are potentially either basal (Goldstein 
et al., 2010) or luminal stem cells (Wang et al.,2009) or both (Garber et al.,2010). A 
thorough understanding of where the malignant cells arise in the prostate would be 
highly important for the develpment of effective therapies. Pre-clinical mouse 
models have helped researchers to study the aetiology, prevention and treatment of 
PC. Naturally occuring PC is absent in mice and hence a great deal of work has been 
done to engineer mice to develop spontanouse PC. It should be noted that the mouse 
and human prostate have anatomical dissimilarities (Fig. 4.1). The mouse prostate is 
lobular with four lobes where as human prostate has one lobe divided into central, 
transitional and peripheral zones (De Jong et al.,2010). The difference in 
histopathology and time frame for disease progression between human and mouse is 
another concern. But despite the various hurdles, mice is still widely used to model 
human PC. Firstly the human and mouse genome are 95% identical and hence mice 
share many structurally similar genes and genomic alterations implicated in cancer 
(Maser et al.,2007). Also, it is relatively easier to induce genetic alterations in mice. 
Finally, mice have a short gestation time and hence it is cost effective to house and 
breed to generate large populations.  
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Figure 4.1. Anatomical dissimilarities between human and mouse prostate. The mouse prostate is 
lobular with four lobes where as human prostate has one lobe divided into central, transitional and 
peripheral zones (Image adapted from kenneth et al., 2011) 
One of the most well characterisedmouse models established recently (1995-97) is 
the TRAMP (Transgenic Adenocarcnoma of the Mouse Prostate) model (Greenberg 
et al.,1995). TRAMP is a spontaneous autochthonous transplantable mouse tumour 
model developed in C57Bl/6 strain, where SV-40 large and small T antigens are 
expressed under androgen-dependent control of the rat probasin promoter (Gingrich 
et al., 1996). This results in the inhibition of p53 and Rb tumour suppressor activity 
in mouse prostatic epithelia. Development and progression of PC in TRAMP closely 
mimics the human disease, that progresses from mild to severe intraepithelial 
neoplasm in 6-12 weeks old TRAMP mice (Gingrich et al., 1999) (Fig.4.2). This 
further develops into focal adenocarcinoma and metastasize to lymph, lungs and 
rarely to bone, kidney and adrenal glands by the age of 24-30 weeks (Gingrich et al., 
1999). As seen in human PC, the neoplasm in TRAMP developes from an initial 
androgen dependent stage to androgen independent and then toa castration resistant 
phase (Gingrich et al., 1999). Similar to human prostatic carcinomas, decreased 
cytokeratin 8 and E-cadherin expression is seen associated with poorly differentiated 
adinocarcinomas as compared to PINs and differential adinocarcinoma (Bonkhoffet 
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al.,2001). Interestingly, poorly differentiated adenocarcinomas of TRAMP show a 
neuroendocrine phenotype (Bonkhoffet al.,2001). Approximately 10% of human 
prostate carcinoma also show a neuroendocrine phenotype associated with 
aggressive disease(Bonkhoffet al.,2001).  
 
Figure 4.2. Development and progression of PC in TRAMP mice (MRI images) (Carpinelli et al., 
2007). The progression closely mimics human PC progressing from mild to severe intraepithelial 
neoplasm in 6-12 weeks old TRAMP mice. 
Three cell lines have been succesfully characterised and established from the 
prostatic tumour of 32 week old TRAMP mice (Foster et al., 1997). These cell lines, 
named as TRAMP-C1, C2 and C3, represent different stages in tumour progression 
in TRAMP mice. Since the cell lines were isolated from a syngeneic strain of mouse, 
these cells could be grafted into immune competant, intact animals and thereby 
facilitate studies for immunotherapy against PC. Studies have shown that all three 
cell lines express cytokeratin, E-cadherin and androgen receptors and do not have a 
mutated p53 (Barbara et al.,1997). Interestingly, TRAMP-C1 and TRAMP-C2 are 
tumerogenic in C57Bl/6 hosts, while TRAMP-C3 is not (Barbara et al.,1997).  This 
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allows the testing of both tumour suppressing and tumour promoting activities using 
these cell lines, none of which have been reported to express the T antigen 
oncoprotein in vitro or in vivo (Barbara et al.,1997). Thus the cells represent various 
stages of cellular transformation and progression into androgen independent 
metastatic disease and hence are valuable tools to develop and test candidate immune 
therapeutics. In this study the TRAMP-C1 cellswereused to establish subcutaneous 
tumours in C57Bl/6 mice.  
It is well accepted that presence of class II molecules and co-stimulators are required 
for a long lasting helper CD4+ response which in turnis required in some 
circumstances for differentiation of cytotoxic CD8+ responses (Devon et al.,2003). 
Induction of tumour specific responsesvia cross priming by DC will provide the 
required co-stimulatory signals and class II molecules for T –cell activation. The 
major reason for failure of many current cancer vaccines is that they cannot 
specifically target DCin vivo. To overcome this, several groups have devised 
strategies to grow DC ex vivo, pulsing them with tumour antigens and re-infusing 
back into the patient (Tart et al.,1999). However, this technique is expensive, time 
consuming and patient specific. The only FDA approved therapeutic vaccine 
Provenge is a DC based vaccine, and a major drawback with the Provenge design is 
that each patient’s DC is produced from blood processed in vitro and then re-infused 
back into the the same patient; this makes product development expensive.   
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Figure 4.3.ImmunoBody double expression vector pDCOrigframework.Once epitopes have been 
incorporated into the VH and VL sites within the single vectors they are transferred intothe double 
expression vector utilizing (as highlighted)HindIII/AfeI and BamHI/BsiWI in frame with their 
respective human constant regions. High-level expression of both the heavy and light chains in 
mammaliancells is driven from the CMV immediate early promoter. The CDR regions of the vector 
are designed to contain unique restriction endonuclease sites which can be easily opened, and 
oligonucleotides (encoding the T cell epitopes)inserted(Image adapted from Metheringham et al., 
2009). 
 
Earlier studies have shown that antigen/antibody complexes caneffectively target DC 
to mount an efficient immune response (Desjarlaiset al.,2007). But the technique was 
proved inefficient due to difficulty of manufacture of these inherently unstable 
complexes. However, the discovery that anti-idiotypic antibodies mimick antigens 
and can stimulate both antibody and T cell responses was a major breakthrough (de 
Cerioet al.,2007). Incorporation of T cell epitopes/mimotopes within the 
complementarity determining regions (CDRs) of antibodies also showed that 
antigens can be efficiently presented to DC in vivo(Pudneyet al.,2010). This 
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observation lead to the development of a DNA vaccine platform, known as 
ImmunoBody by Scancell Ltd. ImmunoBody is a delivery system that can encode 
antigen epitopes within an antibody (human IgG1/mouse IgG2a) framework 
(Pudneyet al.,2010). The variable regions of the antibody are replaced with DNA 
encoding the antigenic epitopes without affecting the integrity or stability of the 
vector system (Pudneyet al.,2010) (Fig. 4.3). The major advantage of the vector 
system is that it incorporates various design features that allow rapid production of a 
wide range of vaccines. The CDR regions of the vector are designed to contain 
unique restriction endonuclease sites which can be easily opened and 
oligonucleotides (encoding the T cell epitopes) inserted into the region 
(Metheringhamet al., 2009). Importantly, the variable and constant regions of the 
vector are also designed to have restriction sites, which allow easy exchange of other 
IgG subtypes (Metheringhamet al.,2009).  It has been reported that it is possible to 
use the DNA that encodes CTL antigens from a variety of viral (Hep B), foreign 
(ovalbumin), self (Tie-2) and tumour associated antigens (Trp-2, gp-100) within the 
variable region of the antibody to elicit immune responses in different strains of mice 
such as C57Bl/6, Balb/c, HLA-A2 and DR4 transgenic mice (Metheringhamet 
al.,2009). These responses were mediated by CD8+T cell subsets and not NK cells 
since the depletion of CD8+ T cellsabrogated epitope specific responses 
(Metheringhamet al.,2009). A helper T cell specific response was also shown for 
epitopes from viral (Hep B) or melanoma associated antigens such as gp100 and 
tyrosinase (Metheringhamet al.,2009). 
In this study, the PAP epitopes that were identified in the previous chapter (PAP-
115-123 9-mer and PAP-114-128 15-mer) were inserted into theImmunoBody vector 
to determine if the immunogenicity of the epitope could be enhanced by the delivery 
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system. To investigate the efficacy of the vaccine, a subcutaneous transplantable 
tumour model using TRAMP-C1 cells in C57Bl/6 transgenic mice was established. 
The efficacy of the epitope to elicit a PAP specific immune response against PAP 
expressing TRAMP tumours wasconfirmed in a therapeutic and prophylactic setting.  
 
4.2. Results:  
4.2.1. Establishment of transplantable TRAMP-C1 tumour model 
A subcutaneous transplantable TRAMP-C1 tumour model was established in 
syngeneic C57Bl/6 mice. TRAMP-C1 cells (passage 13) were received as a kind gift 
from Prof. M. Belloni, Italy. TRAMP-C1 cells were cultured in DMEM 
supplemented with 10% v/v FCS (BioWhittaker) and 5mM L-glutamine. The cells 
were first assessed for PAP expression using immunofluorescence (Fig. 4.4). For 
this, cells were seeded onto 8-well chamber slides for 24 hours and washed with 
FACS buffer, fixed with 1% paraformaldehyde and blocked for 30 minutes in 
blocking buffer (0.1% tween+10%BSA in PBS). All cells uniformly showed PAP 
expression as shown in Fig. 4.4. Cells stained with theisotypeantibody were used as 
control. To optimise the number of TRAMP-C1 cells to be injected in mice for 
tumour growth, male C57Bl/6 mice were injected subcutaneously in the right flank 
with 5x106 TRAMP cells as described previously (Wang et al., 2011). Tumours were 
measured twice weekly using calipers. 5/6 mice injected successfully developed 
tumours and reached 1cm2 size by the end of three-four weeks (Fig. 4.5). The 
experiment was repeated twice and all mice injected with TRAMP-C1 cells 
developed tumours.  
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Figure 4.4.Immunofluorescence showing PAP expression in passage 13 TRAMP-C1 cells. Cells were 
washed and stained with rabbit anti-mouse PAP (Santa Cruz Biotechnology) antibody as described in 
the methods. 2x104 P13 cells were seeded onto 8-well chamber slides for 24 hours, washed with 
FACS buffer, fixed with 1% paraformaldehyde and blocked for 30 minutes in blocking buffer (0.1% 
tween+10%BSA in PBS). Appropriate isotype controls were used in each experiment. Following 
incubation with the conjugated primary antibody, cells were washed twice in FACS buffer. Slides 
were mounted with fluorescent mounting media with DAPI and studied under immunofluorescent 
microscope. Objective magnification: x20 
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Figure 4.5. Tumour growth pattern of TRAMP-C1 cells in C57Bl/6 mice is shown. 5x106 TRAMP-
C1 cells were injected subcutaneously at right flank. Tumour growth was monitored twice weekly 
using calipers to assess the area of tumours. Animals were sacrificed according to Home Office 
regulations once the tumour reached 1cm2 size. 5/6 animals gave uniform tumour growth. 1cm2 
tumours were obtained at the end of third week. The experiment was repeated twice with n=5 mice 
and all injected mice developed tumours.  
 
4.2.2. The ImmunoBody vector significantly enhances the IFN response, CD8+ 
specific cytotoxicity and CD4+ specific proliferation induced by the PAP-
114-128 epitope in C57Bl/6 mice 
The PAP-114-128 epitope was incorporated in ImmunoBody vector (IB-PAP-114-
128). Briefly, Complementarity determining Regions (CDRs) withinthe 
ImmunoBody single heavy and light chain vectors had been replaced with a unique 
restriction sites in order to enable the rapid insertion of epitope sequences. To 
generate the PAP ImmunoBody human IgG1 construct, complimentary 
oligonucleotides encoding the HLA-A2 restricted epitope of PAP-115-123 
(SAMTNLAAL) were annealed and incorporated into the CDRH2 site of the vector 
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as described. Into the same construct, the CD4+ DR1 114-128 
(MSAMTNLAALFPPEG) restricted helper epitope was inserted into the CDRL1 of 
the kappa chain. On sequence confirmation the plasmid was amplified and isolated 
using a QiagenEndoFree Maxi Prep kit according to manufacturer’s instructions.The 
IB-PAP-114-128 vector was prepared by Dr. Rachel Metheringham from Scancell 
Ltd. 
Male C57Bl/6 mice were immunised on day 1 with either PAP-114-128 peptide or 
IB-PAP-114-128 and boosted with the same vaccine preparation on day 14. Spleens 
were harvested a week after the final immunisation and ex vivo elispot performed 
according to manufacturer’s protocol (Mabtec) on the day of splenectomy using 96-
well elispot plates (Millipore). For each experiment (1x106 per well), triplicate wells 
received 0.1µg of PAP-115-123 peptide and a second triplicate received 10µg of 
PAP-114-128 peptide. Triplicate control wells included irrelevant (flu) at the same 
concentrationsor no peptide. The plates were developed after 48 h with BCIP/NBT 
(BioRad) for 30-45 min and then rinsedwith tap water. Spots were quantitated with 
an ELISpot reader (Cellular Technology Limited). Wells were scored as positive 
when the response in the peptide containing well was at least twice that of control 
wells, as described previously (Pere et al., 2011). Ex vivo elispot assays 
demonstrated a significantly higher IFN response for splenocytes from IB-PAP-
114-128 immunised mice compared to splenocytes from animals receiving the PAP-
114-128 peptide (unpaired student t-test)(Fig. 4.6). Splenocytes pulsed with class I 
and class II peptides from influenzavirus antigen were used as control. The number 
of IFN spots obtained after PAP-114-128 peptide immunisation (250 spots) was 
significantly higher compared to the irrelevant Flu peptide (25 spots). After IB-PAP-
114-128 immunisation the number of IFN spots were almost double (450 spots) 
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compared to PAP-114-128 peptide and almost 8-fold compared with irrelevant 
peptides (50 spots).  
Figure 4.6.Comparison of IFN  response by ex vivo elispot after PAP-114-128 peptide and 
IB-PAP-114-128 immunisation. C57Bl/6 mice were immunised with either IB-PAP-114-128 
or PAP-114-128 peptide on day 1 and day 14. A week after the final immunisation spleens 
were isolated for ex vivo elispot assay. IB-PAP-114-128 immunisation gave a significantly 
higher IFN  response compared to PAP-114-128 peptide immunisation. T cells pulsed with 
irrelevant (Flu) peptide was used as control.  Comparisons of means(+/- SEM) of T cells 
pulsed with relevant peptide or Flu are made with an unpaired t test. 
To determine if this enhanced response was mediated by CD8+ specific, splenocytes 
from immunised mice, spenocytes were depleted of CD4+ T cells after 7 days of in 
vitro culture using a mouse CD4+ T cell depletion kit (Stem Cell Technologies) 
according to the manufacturer’s protocol as described in materials and methods 
(section 2.7). The 51Cr-release assays were performed 7 days after in vitro re-
stimulation of murine splenocytes. Briefly, 5x104 target cells (EL4) pulsed with 
PAP-115-123 were labelled with 51Cr for 1 h at 37C and were co-incubated with 
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decreasing numbers of CD4+ depleted splenocytes (effector cells) in round bottom 
96-well plate. After 4 h, 50μl of supernatant was collected and transferred to a luma-
plate. The radioactivity was then measured using a Microbeta counter (TopCount 
Scintillation Counter). Specific lysis was calculated according to the formula: 
percent specific lysis=[[cpm of sample-spontaneous release]/[total release-
spontaneous release]]x100. An assay was scored positive if the specific lysis of the 
sample was twice the background and the spontaneous release no more than 20%. 
Both immunisation strategies resulted in a significant increase in killing of EL-4 
target cells pulsed with the 9-mer PAP-115-123 peptide compared to the control 
(EL-4 cells pulsed with class I peptide from influenza) (unpaired student t-test)(Fig. 
4.7). However, IB-PAP-114-128 immunisation resulted in 40% target cellsbeing 
killed, whereas only 20% of the target cells were killed by cells isolated from the 
PAP-114-128 peptide group (Fig. 4.7). The percentage of killing decreased as the 
effector:target ratio decreased, thereby demonstrating the specificity of killing by the 
CD8++ T cells. The experiment was repeated three times with three mice per group 
and similar results were obtained.  
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Figure 4.7.CD8+ specific cytotoxicity seen after PAP-114-128 peptide and IB-PAP-114-128 
immunisations. Splenocytes from immunised mice were restimulated for a week and CD8+ and CD4+ 
T cells were seperated using Stem cell isolation kit according to manufacturer’s protocol. EL-4 cells 
pulsed with PAP-115-123 were used as target cells. EL-4 pulsed with Flu peptide was used as control. 
Comparisons of means(+/- SEM) between groups (EL-4 pulsed with relevant peptide or Flu) are made 
with an unpaired t test. The experiment was repeated three times with three mice per group.  
The ability of the 15-mer PAP-114-128 peptide to elicit a CD4+ T cell-specific 
proliferative response was confirmed using a [3H]thymidine incorporation assay. 
Splenocytes from spleens andinguinal lymph nodes of immunised mice were 
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depleted of CD8+ T cells after 7 days of in vitro culture using a mouse CD8+ T cell 
depletion kit (Stem Cell Technologies) according to the manufacturer’s protocol and 
used as responder cells in proliferation assays (5x104cells/well). Preparations were 
shown to be typically 90% free of CD8+ T cells by flow cytometry using a Beckman 
Coulter Gallios® flow cytometer (data not shown). For the assay, responder cells 
were co-cultured with 5x103 BMDCs either pulsed with the PAP-114-128 or control 
peptide (Flu) in quadruplicates in round-bottom 96-well plates. Cultures were 
incubated for approximately 60 h at 37C, and [3H]-thymidine was added at 37 
kBq/well for the final 18 h. Plates were harvested onto 96 Uni/Filter plates (Packard 
Instrument), scintillation liquid (Microscint 0, Packard) added and the plates were 
counted using a Top-Count counter (Packard). Results are expressed as counts per 
minute (cpm) as means of quadruplicates. Statistical analysis was performed using 
unpaired Student’s t-test.PAP-114-128 specific proliferative response was seen in 
spleen and lymph nodes after peptide and ImmunoBody immunisations (Fig.4.8). IB-
PAP-114-128 immunisation resulted in a significantly higher CD4+ T cell-specific 
proliferative response than did immunisation with the PAP-114-128 peptide (Fig. 
4.8). PAP-114-128 immunisation gave a proliferative response of 3400 cpm (1500 
cpm for Flu) for spleen and 1800 cpm (1000 cpm for Flu) for lymph node cells. On 
the other hand IB-PAP-114-128immunisation gave a proliferative response of 4500 
cpm (1000 cpm for Flu) for spleen and 4000 cpm (1500 cpm for Flu) for lymphnode 
cells. The experiments were repeated three times with 3 mice per group. 
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Figure 4.8.CD4+ specific proliferative response is compared using thymidine incorporation assay 
after PAP-114-128 peptide and IB-PAP-114-128 immunisations.Spleens and lymph node cells from 
immunised mice were isolated, restimulated for a week and CD4+ cells were separated using Stemcell 
isolation kit according to manufacturer’s instructions. BMDC pulsed with PAP-114-128 were used as 
target cells. Results are expressed as counts per minute (cpm) as means of quadruplicates. 
Comparisons of means(+/- SEM) between groups (BMDC pulsed with PAP-114-128 or Flu class II 
peptide) are made with an unpaired t test. The experiments were repeated three times with three mice 
per group.  
 
4.2.3. Immunisation with PAP-114-128 and IB-PAP-114-128 induces PAP-115-
123 specific CD8+ dextramer positive cells  
The presence of CD8+ lymphocytes specific for the PAP-115-123 epitope was 
detected using H2-Db specific PAP-115-123 dextramers (Immudex, Denmark). For 
this, C57Bl/6 male mice were immunised with PAP-114-128 peptide, IB-PAP-114-
128 or empty ImmunoBody vector (control) on day 1 and day 14 and spleens were 
harvested 7 days after final immunisation. After depletion of erythrocytes, the 
splenocytes were washed twice with PBS (supplemented with 2% v/v FCS). 
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Dextramer staining was performed according to the manufacturer’s protocol 
(www.immudex.com). PAP-115-123-specific splenocytes were detected using a 
Beckman Coulter Gallios® flow cytometer. A similar number of CD8+/peptide-
specific T cells was detected in both settings (0.50% PAP-115-123specific CD8+ 
lymphocytes following PAP-114-128 peptide immunisation; 0.59% specific 
lymphocytes following immunisation with IB-PAP-114-128; 0.12% following 
immunisation with the empty vector) (Fig.4.9).  The experiment was repeated three 
times with 3 mice per group and similar results were obtained.  
 
 
 
Figure 4.9. PAP-115-123 dextramer positive cells as assessed by flow cytometry after PAP-114-128 
peptide and IB-PAP-114-128 immunisations. Splenocytes from immunised mice were isolated 7 days 
after the final immunisations. The cells were depleted of RBC and stained with PAP-115-123-
dextramer, CD3+ and CD8+ antibodies according to manufacturer’s instructions. Animals immunised 
with empty vector was used as control. Similar percentage of PAP-115-123 dextramer positive cells 
were found in PAP-114-128 peptide (0.50%) and IB-PAP-114-128 (0.59%) immunised mice. The 
experiment was repeated three times with 3 mice per group. 
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4.2.4. Immunisation with PAP-114-128 inhibits the development and growth of 
TRAMP-derived tumours in C57Bl/6 mice 
The ability of different immunisation strategies to protect against the growth of 
TRAMP-C1 tumour cells in C57Bl/6 mice was studied. For this, C57Bl/6 mice were 
immunised with PAP-114-128 peptide, IB-PAP-114-128 or empty ImmunoBody 
vector (as control) on day 1 and day 14. The mice were injected subcutaneously 
(right flank) with 5x106 TRAMP cells 7 days after the final immunisation. Tumours 
were monitored twice weekly using calipers.IB-PAP-114-128 inhibited tumour 
growth in 11/12 mice, whereas PAP-114-128 peptide inhibited tumours in 8/12 mice 
(Fig. 4.10A). The differences in tumour growth between the groups at day 27 was 
highly significant (unpaired student t-test). By the end of day 36, the survival in IB-
PAP-114-128 immunised animals was 91.67% compared to 66.67% and 8.3% in the 
peptide and empty vector groups respectively (Fig.4.10B). The experiment was 
repeated four times with 3 mice per group. All data are presented as (means ± SEM).  
Next, the ability of the immunisation strategies to inhibit established tumourswas 
compared. Four days post tumour injection, tumour bearing mice were immunised 
with PAP-114-128 peptide, IB-PAP-114-128 or empty ImmunoBody vector. Booster 
immunisations were given on day 10. There was a significant difference in tumour 
growth pattern in immunised mice compared to control group (empty vector) 
(unpaired student t-test). IB-PAP-114-128 inhibited tumour growth in 10/12 mice, 
whereas PAP-114-128 peptide immunisation inhibited tumour growth in 7/12 mice 
(Fig. 4.11A). By the end of day 40, survival in the IB-PAP-114-128 immunised 
group was 86% compared to 62% and 8% for the peptide and empty vector groups 
respectively (Fig. 4.11B). Experiments were repeated four times with three mice per 
group. All data are presented as (means ± SEM).  
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Figure 4.10. PAP-114-128 suppresses the growth of TRAMP tumours in a prophylactic setting.  
C57Bl/6 mice were immunised with PAP-114-128 peptide, IB-PAP-114-128 or empty ImmunoBody 
vector (as control) on day 1 and day 14. The mice were injected with 5x106 TRAMP cells seven days 
after the final immunisation. Tumours were monitored twice weekly using calipers. IB-PAP-114-128 
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immunisation inhibited tumours in 11/12 mice and PAP-114-128 peptide immunisation inhibited 
tumors in 8/12 mice (A). The percentage survival of animals immunised with IB-PAP-114-128, PAP-
114-128 and empty immunobody vector is shown using Kaplan Meier plots. The survival benefit of 
treatments was tested (IB-PAP-114-128 immunisation and control, ***p=0.0001; PAP-114-128 
immunisation and control, *p=0.024) using log rank tests. (B). The experiment was repeated four 
times with three mice per group. 
4.2.5. The increased anti-tumour effects of vaccination with IB-PAP-114-128 is 
associated with an enhanced infiltration of CD8+ TILs 
To determine whether the increased efficacy of the IB-PAP-114-128 vaccine was 
associated with an effect on the number of CD8+ lymphocytes infiltrating tumours 
[TILs], tumour bearing C57Bl/6 mice were immunised with PAP-114-128 peptide, 
IB-PAP-114-128 or empty vector and tumours were collected on day 24 and the 
presence of CD8+ TILs determined by flow cytometry. For this, tumors were 
chopped into small pieces using a scalpel and incubatedwith collagenase D (0.1%; 
Sigma-Aldrich) in HBSS for 30 min at37°C. The cells were then passed through a 
nylon mesh, washed and stained with rat anti-mouse CD8+ (AbDSerotec)antibody 
(diluted as per manufacturer’s instructions in blocking buffer) for 1 h at room 
temperature. The infiltration of tumours by CD8+ T cells in animals treated with IB-
PAP-114-128 was more pronounced (18%) than that in animals immunised with 
PAP-114-128 peptide (4.59%) and empty ImmunoBody® vector (control) (0.07%) 
(Fig. 4.12A).The CD8+ TILs were assessed in six mice per group and all mice 
showed similar level of CD8+ TILs (Fig. 4.12B). In addition, CD8+ TILs were 
checked in OCT embedded tumour tissues. For this, OCT embedded tumour tissues 
were sectioned, fixed with 4% paraformaldehyde for 5 min at room temperature and 
blocked with 10% rat serum in 0.25% Triton-X100 in PBS for 30 min at room 
temperature. Rat anti-mouse CD8+ (AbDSerotec) was used (diluted as per 
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manufacturer’s instructions in blocking buffer) for 2 h at room temperature. 
Appropriate isotype controls were used in each experiment. Slides were mounted 
with fluorescent mounting media containing DAPI and studied under using a 
confocal microscope.Immunofluorescence staining in OCT embedded tumour tissues 
also confirmed that more CD8+ T cells were present in tumour tissue of animals 
treated with IB-PAP-114-128 compared to PAP-114-128 peptide and negative 
controls (Fig. 4.13). The experiments were repeated twice with 3 mice per group.  
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Figure 4.11.PAP-114-128 suppresses the growth of established TRAMP tumours. Four days post 
tumour injection, tumour bearing mice were immunised with PAP-114-128 peptide, IB-PAP-114-128 
or empty ImmunoBody® vector. Booster doses were given on day 10. There was a significant 
difference in tumour growth pattern in immunised mice compared to control group (empty vector) 
(unpaired student t-test (means(+/- SEM). IB-PAP-114-128 inhibited tumour growth in 10/12 mice. 
PAP-114-128 peptide inhibited tumour growth in 7/12 mice (A). The percentage survival of animals 
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immunised with IB-PAP-114-128, PAP-114-128 and empty immunobody vector is shown using 
Kaplan Meier plots. The survival benefit of treatments was tested (IB-PAP-114-128 immunisation 
and control, ***p=0.0002; PAP-114-128 immunisation and control, **p=0.0018) using log rank tests. 
(B). The experiment was repeated four times with three mice per group. 
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Figure 4.12.CD8+ TILs assessed in tumours isolated from different immunisation strategies. Tumour 
bearing C57Bl/6 mice were immunised with PAP-114-128 peptide, IB-PAP-114-128 or empty vector 
and tumours were isolated on day 24. Isolated tumours were stained for CD8+ TILs. An enhanced 
CD8+ TIL population was seen after flow cytometry in IB-PAP-114-128 immunised group compared 
to PAP-114-128 peptide and empty vector group [A, B]. This experiment was repeated twice with 
three mice per group. 
 
Figure 4.13.CD8+ TILs assessed in tumours isolated from different immunisation strategies. Tumour 
bearing C57Bl/6 mice were immunised with PAP-114-128 peptide, IB-PAP-114-128 or empty vector 
and tumours were isolated on day 24. Isolated tumours were frozen embedded in OCT, sectioned and 
stained for CD8+ TILs. An enhanced CD8+ TIL population was seen in tumour sections ofIB-PAP-
114-128 immunised group compared to PAP-114-128 peptide and empty vector group. Sections from 
six mice per group were analysed and similar results were seen.  
 
4.2.6. Enhanced tumour regression following IB-PAP-114-128 immunisation is 
associated with the induction of higher avidity IFN -secreting T cells  
To determine the influence of different immunisation strategies on the frequency of 
IFN  secretingsplenocytes in tumour-bearing mice, splenocytes were isolated from 
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mice bearing established tumours that had been immunised (‘therapy’ group) on day 
30, and IFN  secretion in response to varying concentrations of PAP-114-128 
peptide determined using an ex vivoelispot assay. Splenocytes with no added 
peptides were used as control. The frequency of IFN sfu per 106 (means ± SEM) 
was determined. There was a greater proportion of IFN  secreting splenocytes in the 
IB-PAP-114-128 group compared to mice immunised with peptide in IFA, and these 
were capable of recognizing lower concentrationsof peptides (Fig. 4.14). The 
number of IFN  spots obtained after PAP-114-128 immunisation was 120 compared 
to 200 spots after IB-PAP-114-128. The log EC50 value of PAP-114-128 
immunisations were much higher (-3.5) compared to IB-PAP-114-128 (-7.35) (Fig. 
4.14B). These findings demonstrate that the increased efficacy of the IB-PAP-114-
128vaccine involves the generation of higher avidity T cells.The experiment was 
repeated twice with 5 mice per group. 
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Figure 4.14 Splenocytes isolated from tumour bearing mice (n=6) after different immunisation 
strategies are compared for their efficiency in secreting IFN (A). Splenocytes were co-cultured 
overnight with 0.1µg of PAP-115-123 9 mer epitope or 10µg of PAP-114-128 15-mer epitope in an 
elispot plate. Splenocytes with no added peptides were used as control. The frequency of IFN  sfu per 
106 (means(+/- SEM)) is shown here. Ex vivo ELISpot assay performed show an enhanced IFN  
response in T cells isolated from IB-PAP-114-128 treated tumour bearing mice. IB-PAP-114-128 
immunised animals produced T cells with better avidity (B). The experiment was repeated twice with 
five mice per group. 
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4.3. Discussion:  
It is a well-established fact that use of long or synthetic peptides is superiorfor 
inducing anti-tumour immunity, sincethe sequence incorporates multiple epitopes 
allowing both HLA class I and II responses to be generated from a single peptide 
(Chauvin et al., 2012, Meliefet al., 2008). Herein, we have identified two PAP 
epitopes, PAP-114-128 and PAP-115-123, which are naturally processed and 
presented. The identified 15-mer sequence embeds a 9-mer sequence within it. Pre-
clinical studies conducted using long peptides embedding a short CD8+ epitope 
indicated that such peptides are superior in inducing CD8+ T cell responses 
(Zwavelinget al., 2002). However for this to be effective, cross-presentation of the 
long peptide by the APC/DC is required in contrast to direct loading of HLA 
molecules (Meliefet al., 2008). Also, the inability to specifically target DC in vivo is 
one of the major reasons for failure of many current cancer vaccines.  
Here, it has been demonstrated that self-tolerance to PAP can be broken using an 
effective targeting / delivery vector which possesses characteristics that induce 
strong, long-lasting protective cellular immunity (ImmunoBody).The Fc receptors 
integrated into the ImmunoBody have high affinity for CD64 expressed on DC, 
thereby allowing the proficient stimulation of both CD4+ (helper) and CD8+ 
(cytotoxic) responses (Pudneyet al., 2010). Earlier studies conducted using the 
ImmunoBody vector have shown that preferential targeting of DC is highly 
important, since removal of the Fc region reduces the efficiency of T cell stimulation 
by almost 1000 fold (Pudney et al., 2010) 
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Inthis study, IB-PAP-114-128induced asignificantly enhanced IFN  responsein 
C57Bl/6 mice compared to PAP-114-128 peptide immunisation. This increased 
response correlated well with an enhanced in vitro cytotoxicity and proliferative 
responses, and was mirrored by a better protection against established subcutaneous 
TRAMP-derived tumours in vivo. Though it was believed initially that gene gun 
immunisation worked by direct transfection of APC that travel to lymph nodes and 
activate T cells (Porgadoret al., 1998), it was later proved that cross presentation is 
the major route for CTL induction following gene gun immunisation (Cho et al., 
2001). The apparent difference between gene gun ImmunoBody immunisation (IB-
PAP-114-128) and the protein equivalent (PAP-114-128) suggests that direct 
transfection of APC might also play a unique role in mounting immune responses. It 
has been documented that peptide epitopes could be generated from defective 
polypeptides (with misfoldings, defective translational errors etc) collectively known 
as defective ribosomal products (DRiPs) (Yewdellet al., 2006). Insertion of peptide 
epitopes into the CDRs of the ImmunoBody prevents antibody folding and therefore 
could result in enhanced processing of peptide epitopes (Metheringhamet al., 2009). 
But it has been shown that secreted protein is also necessary as abrogation of protein 
secretion via removal of leader sequences leads to reduced responses 
(Metheringhamet al., 2009). Thus it could be suggested that the high frequency 
responses obtained followingIB-PAP-114-128 immunisations could be a result of 
both direct and cross presentation. Interestingly, the number of peptide-specific 
CD8+/dextramer positive cells remained the same in both immunisation groups. This 
shows that with PAP-114-128 peptide in IFA immunisation, antigen-specific T cell 
responses were induced but objective anti-tumour responses have been rare. IFA 
used as an adjuvant here, is thought to induce local inflammation along with acting 
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as a depot that protects peptide from rapid degradation thereby allowing slow release 
to APC (Redmond et al., 2005). A recent study by Yared et al. shows that 
peptide/IFA vaccination sites contain high amounts of antigen that may outcompete 
tumour sites for T cell recognition, chemokine production, T cell accumulation and 
tissue destruction (Yaredet al., 2013). The study suggests that persistent antigen at 
the vaccination site induces strong sequestration and subsequent dysfunction and 
deletion of T cells and this might explain in part, the reason for low performance by 
PAP-114-128 peptide vaccination in this study. Thus it would be more desirable to 
use non-persistant and rapidly biodegradable vaccine adjuvants for peptide 
vaccination strategies.  
Apart from the high frequency, T cells derived from mice immunised with IB-PAP-
114-128 showed higher avidity as these T cells were able to recognise significantly 
lower concentrations of peptide than cells derived from animals immunised with 
PAP-114-128 peptide in IFA. Eliciting high avidity T cells is highly advantageous as 
it promotes the recognition of tumour cells that express very low antigen levels 
(Brentvilleet al., 2012). Earlier studies have shown that unlike low avidity T cells, 
high avidity T cells are effectivein eradicating tumours, mediating viral clearance 
and importantly are also recruiting into the memory pool (Brentvilleet al., 2012). 
The study also reported that the recruited high avidity T cells in the memory 
poolcould be effectively recalled by a single DNA boost without any significant 
reduction in avidity (Brentvilleet al., 2012). It is important to note that only low 
levels of peptides are required to stimulate high avidity T cell responses. The lack of 
requirement of large amounts of peptide has a significant advantage in vaccine 
design as it allows more flexibility in terms of the number and length of peptide 
epitopes that could be incorporated (Brentvilleet al., 2012). Thus it allows 
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incorporation of several epitopes binding to a range of MHC alleles, targeting wide 
range of patients.  
In another interesting study comparing ImmunoBody DNA vaccine encoding the 
melanoma TRP-2 epitope to TRP-2 peptide, an enhanced responseto ImmunoBody 
immunisation was shown (Metheringhamet al., 2009). A similar enhanced response 
was also seen when compared to whole murine TRP2 antigen DNA immunisation 
(Metheringhamet al., 2009).  When whole PAP cDNA immunisation was compared 
with IB-PAP114-128 immunisation, a significantly enhanced IFN  response, CD8+ 
specific cytotoxicity and CD4+ specific proliferation associated with IB-PAP-114-
128 immunisationwas observed (data not shown). Though previous studies have 
shown that PAP xeno-antigen can break tolerance, anti-tumour response to the whole 
syngeneic PAP self-antigen could only be enhanced by adjuvants and in the absence 
of regulatory T cells (Lawrence et al., 2001, Spies et al., 2012). This would suggest 
that the presence of regulatory determinants within the whole antigen might be 
responsible for preventing efficient T cell responses. So, the removal of 
immunogenic epitope sequences from the whole antigen and its insertion into an 
inert carrier such as ImmunoBody might ward off the regulatory environment, 
thereby resulting in an enhanced immune response (Metheringhamet al., 2009).  
Recent studies have shown that the quantity, quality and location of CD8+ TILs helps 
to predict patient survival in several cancer types (Karja et al., 2006, Mlecnik et al., 
2011). In PC, CD4+ and CD8+ TILs have been reported as an independent predictor 
of recurrence free survival in patients (Vesaet al., 2005). Studies in animal models 
have providedsufficient evidence to allow us to conclude that infiltration of tumours 
by tumour-reactive T cells is essential for efficient tumour regression. Here we have 
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observed a 67% and 62% tumour-free survival in mice treated with PAP-114-128 
peptide in a prophylactic and therapeutic setting respectively. The percentage of 
tumour-free survival was significantly enhanced by use of IB-PAP-114-128 (92% for 
prophylactic and 86% for therapeutic) in both the settings. We have identified that 
this enhanced tumour clearance was associated with better infiltration of the tumours 
by CD8+ T cells. A significantly higher CD8+ TIL infiltration was seen in tumour 
sections and tumour tissues isolated from mice immunised with IB-PAP-114-128 
(18%) compared to the control peptide (5%). Interestingly ‘islands’ of TILs were 
also seen in a small proportion of mice (2/12) that showed a complete tumour 
regression (Data not shown). Earlier studies have shown that the intra-tumoral 
location (formation of TIL ‘islands’) and density of CD8+ TILs together with 
CD45RO+ memory T cells showed good correlation with disease-free, overall 
survival in humans(Leishaet al., 2012). Since this prediction was superior to the 
standard TNM imaging system, a major initiative is underway to measure and 
incorporate CD8+ and CD45RO+ tumour infiltrates into standard clinical practice as 
a tumour immune score (Galonet al.,2012). Interestingly no CD4+ TIL infiltration 
was seen in the TRAMP tumours. Also there have been conflicting reports on the 
role of CD4+ TILs in PC progression. Mercaderet al showed that androgen depletion 
therapy was associated with a profuse CD4+ T cell infiltration into the tumour 
microenvironment (Mercaderet al., 2001). Agreeing with this observation Vesaet al 
showed that enhanced CD4+ and CD8+ TILs represented a good prognostic factor for 
PSA-free survival in patients with local prostate carcinoma following radical 
prostatectomy (Vesaet al., 2005). In contrast, Mc Ardle et al and Iraniet al reported 
that tumours with dense CD4+ infiltration associated with an increased risk of 
tumour recurrence (Mc Ardle et al., 2004, Iraniet al.,1999). This disparity might 
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have arisen due to the wide variety of CD4+ T cell subsets such as Th1, Th17 and 
regulatory T cellswith opposing effects that are found inthe tumour 
microenvironment. Understanding the activation, memory states and antigen 
specificity ofCD8+ TILs would be important to assess the role of these infiltrates 
within the prostate tumour. 
In summary, these findings demonstrate that PAP-114-128 encompassing PAP-115-
123 is a promising candidate for further development of PAP-based anti-cancer 
vaccine strategies as it encompasses a number of features that are consistent with the 
generation of functional, anti-tumour protection. The specific finding that this cDNA 
vaccine encoding PAP can augment PAP-specific T cell responses is highly relevant 
given that sipuleucel T, a vaccine based on PAP has recently been approved by the 
Federal Drug Administration (FDA) and has shown clinical benefit in terms of 
overall survival. Work is ongoing using the established murine model to define more 
robust PAP-114-128 based immunisation strategies, and the induction of protective 
anti-tumour immunity in the clinical setting.  
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Chapter 5: Immunogenicity of wild and analogue PAP peptide epitopes in 
prostate cancer PBMC  
5.1. Introduction: 
A number of cancer immunotherapy strategies are currently being tested in clinical 
trials (Johnson et al., 2006, Small et al., 2006, Higano et al., 2009). Although 
clinical efficacy would be the final test, evaluating immunological responses as 
intermediate markers is necessary due to the complicated developmental pathway 
involved for these candidates. To promote a candidate to a clinical trial, it is 
necessary to demonstrate that the treatment has a significant impact on an 
intermediate predictive of clinical outcome. In case of cancer immunotherapy such a 
predictive would be generation of tumour antigen specific T-cell response detectable 
by immunological assays (Timothy et al., 2001). It would be vital to use assays that 
evaluate the number and function of CD8+ CTLs and CD4+ T helper cells, 
particularly T helper type 1 responses that eventually result in required CTL 
generation. In vitro immune analyses require an adequate source of T cells to assess 
the immune response generated to the immunisation. Clearly, peripheral blood 
mononuclear cells (PBMC) are the most convenient source of T cells that would 
reflect the true frequency and functional activity of immune response generated in 
patients (Arthur et al., 2005). But it would be important to consider the time of 
collection before and after immunisation and also to be consistent on the use of 
either fresh specimens or cryopreserved cells.  
It is also vital to consider the performance characteristics of the immunological assay 
selected such as the magnitude of immune response that should be considered as 
positive response etc (Fadi et al., 2012). An ideal immunological assay would have 
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adequate sensitivity, specificity, reliability and reproducibility. Also, the assay 
should be simple and rapid and be able to measure T cell activity without introducing 
significant distortions. Assays such as the elispot have been shown to reliably detect 
the number of antigen specific T cells in PBMC preparations (Mathieu et al., 2007). 
There have also been efforts to determine whether such elispot data correlates with 
survival. In an analysis of melanoma patients treated with a polyvalent vaccine, 
presence of antigen specific, IFNγ secreting T cells correlated with longer recurrence 
free survival (12 months) than non-responders (3 months) (Reynold et al.,1997). The 
use of elispot has been recently simplified with the development of computerised 
plate readers using digital cameras that provide superlative discrimination of antigen-
specific T cell responses from background (Fadi et al., 2012). Thus elispot assay is 
an excellent choice for immune monitoring in small scale and large scale studies. 
The elispot assay has been further improved recently to include a dual colour to 
evaluate two different cytokine release patterns simultaneously (Okamoto et al., 
1998). Also, some studies have used PBMC loaded with poxvirus vectors encoding 
the antigen of interest that allowed patients of any HLA type to be included in the 
analyses (Larsson et al., 1999).  
In the current study, PAP-114-128 epitope was found to be immunogenic and 
naturally processed in transgenic HHDII/DRI mice and in syngeneic C57Bl/6 mice. 
Hence it was hypothesised that PAP-114-128 would be naturally processed and 
should be identifiable within the T cell repertoire of HLA-A2 patients with prostate 
cancer (PC). Furthermore, vaccines based on PAP are more likely to be effective if 
they are administered to PC patients that already demonstrate a detectable immune 
response against the antigen. Elispot assay was performed in cryopreserved PBMC 
samples of HLA-A2 PC patients and benign individuals. PAP-114-128 specific T 
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cell response was seen in PC patients but not in benign samples. Furthermore, PAP-
114-128 specific T cell response was seen in PBMC samples isolated from PC 
patients that responded to an mRNA-based vaccine treatment. These studies 
confirmed that patients with PC can have pre-existing T cells specific for the PAP-
114-128 peptide.  
 
5.2. Results:  
5.2.1. PAP-115-123 specific IFNγ response seen in PC PBMC samples 
To determine the presence of circulating T cells specific for PAP-115-123 in 
humans, PBMC samples from HLA-A2 positive PC patients and benign candidates 
were used. The cryopreserved PBMC samples were thawed, washed and 
restimulated for 7 days with PAP-114-129 epitope. The cells were then washed and 
rested overnight and 4x104 cells were plated per well of the elispot plate. 1µg of 
PAP-115-123 epitope was added per well and cultured for 48 hours. The plates were 
developed as per the manufacturer’s instructions (please refer materials and 
methods). PBMC cultured with no peptide were used as control. PAP-115-123 
specific IFNγ response was seen in 7/10 PC patient PBMC tested (Fig.5.1). 
Interestingly, no PAP-115-123 specific IFNγ response was seen in any of the benign 
samples tested. The PAP-115-123 specific IFNγ response was significantly higher in 
7/10 patients (unpaired t-test, p<0.05) compared to control (splenocytes pulsed with 
no peptide). The number of IFNγ spots in one of the patients was as high as 220 
spots compared to the control (60 spots). The number of spots in the other 6 PC 
patients ranged between 50-100 compared to 10-20 in control wells. Though some of 
the benign samples showed 50-100 spots, the number of spots in the control wells 
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was also high. Hence no PAP-115-123 specific IFNγ response was seen in benign 
samples.  
Figure 5.1. IFNγ response seen in PBMC samples isolated from PC and benign candidates after 
restimulation with PAP-115-123 epitope in elispot assay. Cryopreserved PBMC samples from ten 
HLA-A2 positive PC patients and ten benign candidates were compared. The PBMC were cultured in 
vitro with 5µg of PAP-114-128 epitope for 7 days. The cells were then washed and rested overnight 
and 4x104 cells were plated per well of the elispot plate. 1µg of PAP-115-123 epitope was added per 
well and cultured for 48 hours. The plates were then washed according to manufacturer’s protocol. 
PBMC with no added peptide was used as control. Comparisons of means (+/- SEM) between groups 
(T cells pulsed with PAP-115-123 or no peptide) are made with an unpaired t test. 
5.2.2. PAP-115-123 specific IFNγ response seen post vaccination in PBMC 
samples isolated from PC patients  
The presence of circulating PAP-115-123 specific T cells were assessed in PBMC 
samples isolated from PC patients that received immunisation in the Norway Clinical 
Trial performed by Prof. Gustav Gaudernack (Oslo University Hospital, Norway). In 
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the trial, DC (dendritic cell) were isolated from PC patients and cultured in vitro. The 
cultured DC were transfected with mRNA isolated from the PC cell lines (DU145, 
LNCAP and PC3). The matured DC were re-infused back into the patients (Fig.5.2). 
PBMC samples isolated a week before the immunisation (pre-vaccination) and 12 
weeks after the immunisation (post-vaccination) was used in this study. The patients 
post immunisation were categorised as responders and non-responders based on the 
PSA levels and also on the extent of metastasis identified by bone scans.  PAP-115-
123 specific IFNγ response was assessed in 8 PBMC pre-vaccination samples and 8 
PBMC post vaccination samples. Cryopreserved PBMC were thawed, washed and 
rested overnight. 4x104 cells were plated per well of the elispot plate. 10µg of PAP-
115-123 epitope was added per well and cultured for 48 hours. The plates were 
developed according to manufacturer’s protocol (please refer materials and 
methods). PBMC cultured with HIV or no peptide was used as control. Out of the 8 
samples tested, 6 post vaccination samples showed a significantly higher PAP-115-
123 specific IFNγ response compared to their respective pre-vaccination samples 
(unpaired t-test, p<0.05) (Fig. 5.3). The patients that showed significantly higher 
PAP-115-123 specific IFNγ post vaccination were p12, p15, p19, p102, p107 and 
p108. The number of spots obtained in the post vaccination samples of these patients 
ranged from 60-160 spots compared to 10-30 spots in the pre-vaccination samples.  
To assess if the PAP-115-123 specific T cells in these PBMC samples could be 
stimulated by a lower concentration of peptide, 1µg of PAP-115-123 epitope was 
added per well and cultured for 48 hours. PBMC cultured with HIV or no peptide 
was used as control. Out of the 8 samples tested, 6 post vaccination samples showed 
a significantly higher PAP-115-123 specific IFNγ response compared to their 
respective pre-vaccination samples (unpaired t-test, p<0.05) (Fig. 5.4). The patients 
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that showed significantly higher PAP-115-123 specific IFNγ post vaccination were 
p12, p19, p101, p102, p107 and p108. The number of spots obtained in the post 
vaccination samples of these patients ranged from 60-140 spots compared to 10-30 
spots in the pre-vaccination samples. Patient p15 that showed a significant response 
with 10µg of PAP-115-123 did not show a similar response with 1µg of PAP-115-
123. On the other hand, patient p101 showed significant IFNγ response when 
restimulated with 1µg of PAP-115-123 and failed to respond when restimulated with 
10µg of PAP-115-123. The number of background spots was slightly higher when 
PBMC were restimulated with 1µg of PAP-115-123. 
 
Figure 5.2. The flow chart of Norway clinical trial. Monocytes were isolated from PC patients and 
cultured in vitro. mRNA isolated from the PC cell lines DU145, LNCAP and PC3 were transfected 
into immature DC. The DC were then allowed to mature and were re-infused back into the patient. 
PBMC isolated a week before (pre-vaccination) and 12 weeks after immunisations (post-vaccination) 
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were used in this study. The patients post immunisation were categorised as responders and non-
responders based on the PSA levels and also metastatic state of the disease based on bone scans.  
 
Figure 5.3. IFNγ response seen in PBMC samples isolated from PC responder patients (Norway 
Clinical Trial) after restimulation with 10µg of PAP-115-123 epitope in Elispot assay. PBMC isolated 
pre-vaccination (black bars) and post vaccination (red bars) are compared here. Patient samples are 
represented as p10, p12, p15 etc. The cryopreserved PBMC were washed and rested overnight and 
4x104 cells were plated per well of the elispot plate. 10µg of PAP-115-123 epitope was added per 
well and cultured for 48 hours. The plates were then washed according to manufacturer’s protocol. 
PBMC cultured with HIV or no added peptide was used as control. Comparisons of means (+/- SEM) 
between groups (PBMC pre-vaccination or post-vaccination) are made with an unpaired t test. 
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Figure 5.4. IFNγ response seen in PBMC samples isolated from PC responder patients (Norway 
Clinical Trial) after restimulation with 1µg of PAP-115-123 epitope in Elispot assay. PBMC isolated 
pre-vaccination (black bars) and post vaccination (red bars) are compared here. Patient samples are 
represented as p10, p12, p15 etc. The cryopreserved PBMC were washed and rested overnight and 
4x104 cells were plated per well of the elispot plate. 1µg of PAP-115-123 epitope was added per well 
and cultured for 48 hours. The plates were then washed according to manufacturer’s protocol. PBMC 
cultured with HIV or no added peptide was used as control. Comparisons of means (+/- SEM) 
between groups (PBMC pre-vaccination or post-vaccination) are made with an unpaired t test. 
5.2.3. PAP-115-123 specific IFNγ response seen in PBMC samples isolated from 
PC patients that positively responded to vaccination  
PAP-115-123 specific IFNγ response was assessed in 8 patients that positively 
responded to the vaccination module (responders) in the Norway Clinical Trial and 4 
patients that failed to show a clinical response (non-responders). Cryopreserved 
PBMC were thawed, washed and rested overnight. 4x104 cells were plated per well 
of the elispot plate. 10µg of PAP-115-123 epitope was added per well and cultured 
for 48 hours. The plates were developed according to manufacturer’s protocol 
(please refer materials and methods). PBMC cultured with HIV or no peptide was 
used as control. A 2-4 fold increase in PAP-115-123 specific IFNγ response was 
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seen in 8 of the responder patients assessed and 2-12 fold decrease in IFNγ response 
was seen in 4 of the non-responder patients (Fig. 5.5). The IFNγ secretion in these 
PBMC samples was also confirmed by ELISA (Fig.5.6). The cryopreserved PBMC 
were washed and rested overnight and 4x104 cells were plated per well. 10µg of 
PAP-115-123 epitope was added per well and cultured for 48 hours. Supernatants 
were harvested and analysed for IFNγ secretion using ELISA kit (R&D Systems) 
according to manufacturer’s instructions (please refer materials and methods). 1-1.5 
fold increase in IFNγ response was seen in all responders (except in p19) and a 2-2.5 
fold decrease was seen in non-responders.  
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Figure 5.5. Fold change in IFNγ response seen in PBMC samples isolated from PC responder 
patients (Norway Clinical Trial) after restimulation with 10µg of PAP-115-123 epitope in Elispot 
assay is shown. Patient samples are represented as p10, p12, p15 etc. The patients that was reported to 
have responded to the treatment (p10,p12,p15,p19,p101, pa102,p107 and p108) are indicated by red 
bars. The patients that was reported to have failed to respond to the treatment (p103,p104,p105 and 
p109) are indicated by white bars. The cryopreserved PBMC were washed and rested overnight and 
4x104 cells were plated per well of the elispot plate. 10µg of PAP-115-123 epitope was added per 
well and cultured for 48 hours. The plates were then washed according to manufacturer’s protocol. 
PBMC cultured with HIV or no added peptide was used as control.  
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Figure 5.6. Fold change in IFNγ response seen in PBMC samples isolated from PC responder patients 
(Norway Clinical Trial) after restimulation with 10µg of PAP-115-123 epitope in ELISA is shown. 
Patient samples are represented as p10, p12, p15 etc. The patients that was reported to have responded 
to the treatment (p10,p12,p15,p19,p101, p102,p107 and p108) are indicated by red bars. The patients 
that was reported to have failed to respond to the treatment (p103,p104,p105 and p109) are indicated 
by white bars. The cryopreserved PBMC were washed and rested overnight and 4x104 cells were 
plated per well. 10µg of PAP-115-123 epitope was added per well and cultured for 48 hours. 
Supernatants were harvested and analysed for IFNγ secretion. 
5.2.4. PAP-115-123 analogue peptide showed enhanced immune response in 
syngeneic C57Bl/6 mice and transgenic HHDII/DRI mice compared to PAP-
115-123 peptide 
The analogue epitope of PAP-115-123 obtained by altering the second amino acid of 
the sequence from alanine to lysine was found to have a higher binding score as 
predicted by syfpeithi database. The binding score of PAP-115-123 epitope 
(SAMTNLAAL) to HLA-A2.1 was 24 and that of the analogue peptide 
(SLMTNLAAL) was found to be 30. To compare the immunogenicity of PAP-115-
123 epitope and its analogue epitope, syngeneic C57Bl/6 mice were immunised with 
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the epitopes (Fig.5.7). C57Bl/6 mice in the PAP-114-128 peptide immunisation 
group was immunised with 100µg of PAP-114-128 on day 1 and 75µg of PAP-115-
123 on day 14. C57Bl/6 mice in the PAP-114-128 analogue peptide immunisation 
group was immunised with 100µg of PAP-114-128 analogue peptide on day 1 and 
75µg of PAP-115-123 on day 14. A week after the final immunisation spleens were 
isolated for ex vivo elispot assay. 1x106 splenocytes were co-cultured with 1µg of 
PAP-115-123 peptide or PAP-115-123 analogue peptide. Splenocytes with no added 
peptide were used as control. A 2-fold increase in IFNγ response was seen in PAP-
114-128 analogue peptide immunised group (Fig.5.8A). The number of spots in 
PAP-114-128 immunised group was 280 whereas the number of spots in PAP-114-
128 analogue peptide group was 590. Comparisons of means (+/- SEM) between 
groups (T cells pulsed with PAP-114-128 peptide or PAP-114-128 analogue peptide) 
are made with an unpaired t test. The experiment was performed with three mice per 
group. Peptide specific IFNγ response was also assessed with splenocytes pulsed 
with varying concentrations (10, 1, 0.1, 0.01, 0.001 and 0.0001mg/ml) of PAP-115-
123 epitope or analogue epitope. A significantly enhanced  response was seen 
in analogue peptide immunised group with peptide concentrations 1, 0.1, 0.01 and 
0.001mg/ml (unpaired t-test, p<0.05) (Fig.5.8B). 
To assess whether the T cells generated following PAP-114-128 analogue peptide 
immunisation could recognise naturally processed PAP-115-123 epitopes, 
splenocytes from the immunised mice were co-cultured with TRAMP-C1 cells (that 
naturally express PAP) and IFNγ response assessed by elispot assay. 1x106 
splenocytes were co-cultured with 1x105 TRAMP-C1 cells as target cells. Control 
wells received 1x105 MC38 (that do not express PAP) cells as target cells. 
Significantly high IFNγ response was seen in splenocytes isolated from PAP-114-
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128 analogue peptide immunised mice co-cultured with TRAMP cells (unpaired t-
test, p<0.05) (Fig.5.9). The number of spots obtained from co-culture with TRAMP 
cells was 650 and number of spots obtained from co-culture with MC38 cells was 
100. The experiment was performed with three mice per group. 
 
 
Fig.5.7. Experimental plan for comparison of peptide and analogue (mutated) peptide immunisation.  
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Figure 5.8. Comparison of IFNγ response by ex vivo elispot after PAP-115-123 peptide and PAP-115-123 analogue peptide 
immunisation (A) and to varying PAP-115-123 peptide/analogue peptide concentrations (B). C57Bl/6 mice in the PAP-115-123 
peptide immunisation group was immunised with 100µg of PAP-114-128 on day 1 and 75µg of PAP-115-123 on day 14. 
C57Bl/6 mice in the PAP-115-123 analogue peptide immunisation group was immunised with 100µg of PAP-114-128 
analogue peptide on day 1 and 75µg of PAP-115-123  on day 14. A week after the final immunisation spleens were isolated for 
ex vivo elispot assay. 1x106 splenocytes were co-cultured with 1µg of PAP-115-123 peptide or PAP-115-123 analogue peptide. 
Splenocytes with no added peptide were used as control. Comparisons of means(+/- SEM) between groups (T cells pulsed with 
PAP-115-123 peptide or PAP-115-123 analogue peptide) are made with an unpaired t test. The experiment was performed with 
three mice per group. 
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Figure 5.9. Comparison of IFNγ response by ex vivo elispot from PAP-115-123 analogue peptide 
immunised splenocytes co-cultured with TRAMP-C1 cells and MC38 cells. C57Bl/6 mice were 
immunised with 100µg of PAP-114-128 analogue peptide on day 1 and 75µg of PAP-115-123  on day 
14. A week after the final immunisation spleens were isolated for ex vivo elispot assay. 1x106 
splenocytes were co-cultured with 1x105 TRAMP-C1 cells as target cells. Control wells received 
1x105 MC38 cells as target cells. Comparisons of means(+/- SEM) between groups (T cells pulsed 
with TRAMP-C1 or MC38) are made with an unpaired t test. The experiment was performed with 
three mice per group. 
The immunogenic efficiency of PAP-115-123 epitope and PAP-115-123 analogue 
peptide was further compared in transgenic HHDII/DRI mice. For this, HHDII/DRI 
mice in the PAP-114-128 peptide immunisation group was immunised with 100µg of 
PAP-114-128 on day 1 and 75µg of PAP-115-123 on day 14. HHDII/DRI mice in 
the PAP-114-128 analogue peptide immunisation group was immunised with 100µg 
of PAP-114-128 analogue peptide on day 1 and 75µg of PAP-115-123 on day 14. A 
week after the final immunisation spleens were isolated for ex vivo elispot assay. 
1x106 splenocytes were co-cultured with 1µg of class I PAP-115-123 peptide or 
PAP-115-123 analogue peptide or 10µg of class II PAP-114-128 peptide or PAP-
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114-128 analogue peptide. Splenocytes with no added peptide were used as control. 
Splenocytes isolated from PAP-115-123 analogue peptide immunised group showed 
significantly higher IFNγ response when co-cultured with class I PAP115-123 and 
PAP-115-123 analogue peptide epitopes (unpaired t-test, p<0.05) (Fig. 5.10). No 
significant increase in IFNγ response was seen when splenocytes were co-cultured 
with PAP-114-128 class II epitope. The experiment was performed with three mice 
per group. 
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Figure 5.10. Comparison of IFNγ response by ex vivo elispot after PAP-114-128 peptide and PAP-
114-128 analogue peptide immunisation in HHDII/DRI mice is shown. HHDII/DRI mice in the PAP-
114-128 peptide immunisation group was immunised with 100µg of PAP-114-128 on day 1 and 75µg 
of PAP-115-123 on day 14. HHDII/DRI mice in the PAP-114-128 analogue peptide immunisation 
group was immunised with 100µg of PAP-114-128 analogue peptide on day 1 and 75µg of PAP-115-
123  on day 14. A week after the final immunisation spleens were isolated for ex vivo elispot assay. 
1x106 splenocytes were co-cultured with 1µg of class I PAP-115-123 peptide or PAP-115-123 
analogue peptide or 10µg of class II PAP-114-128 peptide or PAP-114-128 analogue peptide. 
Splenocytes with no added peptide were used as control. Comparisons of means(+/- SEM) between 
groups (T cells pulsed with class I/class II peptide or class I/class II analogue peptide) are made with 
an unpaired t test. The experiment was performed with three mice per group. 
5.2.5. PAP-115-123 specific IFNγ response seen in PC PBMC samples 
To determine the presence of circulating T cells specific for PAP-115-123 analogue 
peptide in humans, PBMC samples from HLA-A2 positive PC patients and benign 
candidates were used. The cryopreserved PBMC samples were thawed, washed and 
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restimulated for 7 days with PAP-114-129 analogue epitope. The cells were then 
washed and rested overnight and 4x104 cells were plated per well of the elispot plate. 
1µg of PAP-115-123 analogue epitope was added per well and cultured for 48 hours. 
The plates were developed as per the manufacturer’s instructions (please refer 
materials and methods). PBMC cultured with no peptide were used as control. PAP-
115-123 analogue specific IFNγ response was seen in 7/10 PC patient PBMC tested 
(Fig.5.11). Interestingly, no PAP-115-123 analogue specific IFNγ response was seen 
in any of the benign samples tested. The PAP-115-123 analogue peptide specific 
IFNγ response was significantly higher in 7/10 patients (unpaired t-test, p<0.05) 
compared to control (splenocytes pulsed with no peptide). The number of IFNγ spots 
in one of the patients was as high as 180 spots compared to control (54 spots). 
Similar response was also obtained when PBMC samples were co-cultured with 
PAP-115-123 epitope (Fig. 5.1). The number of spots in the other 6 PC patients 
ranged between 50-100 compared to 10-20 in control wells. Though some of the 
benign samples showed 50-100 spots the number of spots in the control wells was 
also high. Hence no PAP-115-123 analogue peptide specific IFNγ response was seen 
in benign samples.  
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Figure 5.11. IFNγ response seen in PBMC samples isolated from PC and benign candidates after 
restimulation with PAP-115-123 analogue epitope in elispot assay. Cryopreserved PBMC samples 
from ten HLA-A2 PC patients and ten benign candidates were compared. The PBMC were cultured in 
vitro with 5µg of PAP-114-128 analogue epitope for 7 days. The cells were then washed and rested 
overnight and 4x104 cells were plated per well of the elispot plate. 1µg of PAP-115-123 analogue 
epitope was added per well and cultured for 48 hours. The plates were then washed according to 
manufacturer’s protocol. PBMC with no added peptide was used as control. Comparisons of means 
(+/- SEM) between groups (T cells pulsed with PAP-115-123 analogue or no peptide) are made with 
an unpaired t test. 
5.3. Discussion: 
PAP has emerged as a widely studied target antigen against PC in particular after 
clinical trials showing clinical benefits in patients treated with vaccines targeting 
PAP by different modes of antigen presentation (Higano et al., 2009, Johnson et al., 
2006). In the previous chapters an immunogenic class II PAP epitope PAP-114-128 
was identified that incorporates class I PAP-115-123. In this chapter we evaluate 
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pre-existing T cells specific for these epitopes in HLA-A2 positive PC patients and 
benign individuals. Benign growth of the prostate gland is accompanied by a 
significant increase in the proliferation rate of epithelial cells, but do not frequently 
progress to malignancy (Cole et al., 1999). Hence comparing malignant and benign 
PBMC samples might give vital information relating to malignant transformation in 
PC. Significant PAP-115-123 specific IFNγ response was seen in 7/10 PC patients 
PBMC tested. Interestingly, none of the benign samples tested showed a PAP 
specific IFNγ response. PAP-115-123 specific IFNγ response in PBMC samples 
from PC patients that underwent phase I/II clinical study of a vaccine based on 
allogeneic tumour mRNA transfected autologous DC was also assessed. In the 
clinical trial, mRNA isolated from three PC cell lines (DU145, LNCAP and PC3) 
were used. It should be noted that DU145 and LNCAP are PAP expressing cell lines. 
Out of the 8 PBMC samples tested, 6 post vaccination samples showed significant 
PAP-115-123 specific IFNγ response compared to pre-vaccination. This response 
could clearly be vaccine dependent since very little/no response was observed in pre-
vaccination samples from the same patients. Similar response was seen when 
different concentrations (10µg and 1µg) of PAP-115-123 epitope was used to 
stimulate the PBMC. The patients in the clinical trial has been categorised as 
responders and non-responders using PSA as a surrogate marker for clinical 
response. The patients that showed a decrease in the PSA log slope has been 
categorised as responders and those who showed an increase in the PSA log slope 
has been categorised as non-responders. In the current study, a correlation between 
PAP-115-123 specific T cell response and a favourable early clinical outcome is 
seen. A 2-4 fold increase in PAP-115-123 specific IFNγ response was seen in 
responders and on the other hand a 2-10 fold decrease in response was found 
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associated with the non-responders. ELISA performed on the supernatants isolated 
from these samples also confirmed a fold increase in PAP-115-123 specific IFNγ 
response in responders and decrease in non-responders.  
It was earlier reported that modification of single anchor residues could improve 
MHC class I binding and could extend the time period available for T cells to 
recognise the presented peptide (Hardwick et al., 2013). Similar modifications have 
been reported to induce effective immune response against a range of tumour types 
such as leukemias and solid tumours and have now shown promise in phase I clinical 
trials (Christensen et al.,2009, Fourcade et al.,2008). In the current study it was 
observed that when alanine in the second position is replaced with lysine, the 
binding coefficient as predicted by syfpeithi database (against HLA-A2.1) increased 
from 25 to 33. The binding co-efficient to the H2Kb of mice remained unchanged. 
Immunisations in C57Bl/6 mice and HHDII/DRI mice showed that PAP-114-128 
analogue peptide immunisations generated significantly higher IFNγ response 
compared to PAP-114-128 immunisation. The T cells generated in C57Bl/6 mice 
were able to lyse TRAMP cells that express PAP, showing that it could be naturally 
processed. The enhanced IFNγ response was seen over a range of PAP-115-123 
peptide epitope concentrations used for stimulating the splenocytes. Interestingly, 
PAP115-123 analogue peptide was also able to produce significant high IFNγ 
response in PC patient PBMC. No specific response was seen in benign samples 
tested and hence the response generated by PAP-115-123 analogue peptide was very 
similar to that of PAP-115-123 epitope. This demonstrates that there is a potential 
PAP repertoire available in humans. The ability to detect effector T cells in blood 
samples of patients is highly relevant since it could be used as a biomarker to 
determine whether patients achieved therapeutic immune response to a vaccination 
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strategy. This would also allow evaluation of optimal booster immunisation 
schedules. This is particularly relevant in case of PAP given the recent FDA 
approval of Sipuleucel-T, a PAP based vaccine against PC. The current data continue 
our development and characterisation of PAP based vaccines and provides the first 
modified PAP antigen immunogenic peptide for inclusion in a PAP-based vaccine 
with a potential use in clinical trials.  
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Chapter 6: Discussion 
The scope of this project was to identify immunogenic PAP peptide epitopes that 
could be further shortlisted and included in clinical trials for PC. The study also 
focused on strategies to enhance the immunogenicity of the identified epitopes and a 
mouse tumour model was established to study the effect of vaccine strategies 
focusing on PAP as a target antigen for the induction of anti-tumour immunity. 
6.1. PAP as target antigen for PC: 
In 1938, 85 years after the identification of PC, it was discovered that the activity of 
PAP was increased in the circulation of PC patients, especially those with bone 
metastasis (Gutman et al., 1938). This later led to the use of PAP as a biochemical 
indicator for PC progression until the establishment and introduction of PSA as the 
new marker associated with PC progression (Veeramani et al., 2005). But a renewed 
interest in PAP began after an increasing number of studies have identified PAP as a 
significant prognostic factor for patients with intermediate to high risk PC (Small et 
al., 2006; Sheridan et al., 2007). The prostate restricted expression and over 
expression in more than 90% of PC makes PAP an attractive target for 
immunotherapy. In humans, PAP is one of the major proteins secreted by secretory 
epithelial cells in the prostate which constitutes about 0.5mg/g wet weight of prostate 
tissue and nearly 1mg/ml in seminal fluid (Graddis et al., 2011). The molecular 
structure and active site of PAP has been extensively studied in different species and 
multiple sequence analysis has revealed close cross-species resemblance between the 
different mammalian PAP proteins (Hassan et al., 2010). Interestingly, human PAP 
showed approximately 99% sequence homology with the panther, 94% with the 
monkey and 83% with the mouse (Hassan et al., 2010). Hence PAP is one of the 
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very few prostate specific antigens were rodent homologue is observed and allows 
easier clinical translation of pre-clinical studies conducted in mice.  
PAP was established as a potent therapeutic target for immunotherapy against PC 
following the FDA approval of Sipuleucel-T, a cellular vaccine targeting PAP. 
Sipuleucel-T elicited PAP-specific T cell responses in 27.3% of patients and PAP-
specific antibody responses in 28.5% of patients (Kantoff et al., 2010); the vaccine 
also significantly enhanced the survival rates in treated patients (Kantoff et al., 
2010). In a separate phase I/II clinical trial, a DNA vaccine encoding human PAP 
was used and after six immunisations, 10 out of 22 patients developed PAP-specific 
T cells and some patients showed long term PAP-specific IFNγ responses (Mc Neel 
et al., 2009). These re-assuring studies show that at least in the case of PAP, 
tolerance to self antigen could be overcome by adopting strategies to enhance the 
immunogenicity. Though these studies show PAP to be a potential target for 
immunotherapy against PC, immune responses were not elicited in all of the 
immunised patients, calling for the development of improved immunisation 
strategies. Another interesting report showed that a considerable percentage of colon, 
gastric and breast cancer cell lines were positive for PAP at both the mRNA and 
protein levels (Wang et al., 2005). In addition, the group reported that cancer 
reactive CTLs could be induced from peripheral blood of colon and gastric cancer 
patients by in vitro stimulation with a PAP peptide. These findings strongly suggest 
that PAP could be a target antigen in immunotherapy for patients with non-prostate 
adenocarcinomas as well. 
6.2. Immunogenic regions of PAP for immunotherapy against PC: 
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Naturally occurring, immunological ‘hot spot’ regions in antigens have been 
suggested as regions of interest as immunotherapeutic targets (Olson et al.,2010). 
This study reports a region in the PAP protein (114-128) as containing nested HLA-
A2 and HLA-DR1 binding sites. Such epitope rich regions would be of special 
interest in cancer vaccine studies since they could generate both antigen-specific 
CD4+ and CD8+ T cell responses and is 100% similar in human and mouse. The 
epitope showed high binding score to human (HLA-A2.1) and mouse (H2-Db) MHC 
molecules. Ex vivo elispot assays performed using spleen cells from PAP immunised 
mice showed PAP-114-128 specific and PAP-115-123 specific IFNγ response in 
HHDII/DRI (transgenic) and C57Bl/6 (syngeneic) mice. Importantly, the mice also 
elicited a CD8+ specific cytotoxic T-cell response, confirmed by chromium release 
assay and a CD4+ specific proliferative T-cell response by thymidine incorporation 
assay.  Hence the use of PAP-114-128 allows us to harness CD4+ and CD8+ response 
from immunisation with a 15-mer peptide. Also, presence of PAP-115-123 specific 
dextramer positive cells was seen in both spleen and lymph nodes of immunised 
mice. Though many studies have previously reported different immunogenic PAP 
epitopes (Olson et al., 2010), the PAP-114-128 epitope reported here represents a 
novel 15-mer MHC class II epitope incorporating a 9-mer class I epitope (Saif et al., 
2013).  
6.3. PAP-115-123 specific IFNγ response in PC patients: 
Previous reports have demonstrated the presence of PAP specific Th1 responses in 
PC patients (Olson et al.,2010, Johnson et al.,2012). The presence of PAP-115-123 
peptide specific T cells in the blood of PC patients was assessed in the present study. 
The results showed PAP-115-123 specific IFNγ responses in PBMC isolated from 
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6/10 HLA-A2+ PC patients. Interestingly no response was observed in any of the 
samples assessed from patients with benign disease. The presence of PAP-115-123 
specific IFNγ secreting Th1-type cells in patient blood leukocytes is quite 
encouraging, as it suggests the presence of an ‘immune environment’ capable of 
supporting PAP specific immune responses. PAP-115-123 specific IFNγ responses 
were also observed in PC patients that received immunisations with a DC based 
vaccine pulsed with mRNA isolated from PAP+ PC cell lines. PAP specific IFNγ 
responses were assessed in pre-vaccination and post-vaccination using PBMC 
samples and a significantly enhanced IFNγ response post-vaccination was 
demonstrated. Interestingly these patients were previously reported as responders to 
vaccination based on a fall in serum PSA levels and on bone scans to assess the 
levels of skeletal metastasis. Patients that did not respond to the therapy 
demonstrated a decreased IFNγ response post-vaccination. These IFNγ responses 
were further confirmed using ELISA assays. The decrease in IFNγ secretion post-
vaccination in non-responder patients demonstrates the presence of an attenuated T 
cell repertoire which appears to be associated with non-responsiveness. To confirm 
whether this is due to T cell exhaustion/anergy requires further investigations.  
6.4. Use of transplantable subcutaneous TRAMP-C57Bl/6 mice as tumour 
model: 
The identification of PAP-115-123 specific IFNγ responses in PC patients 
encouraged further studies using this epitope in pre-clinical models and to 
investigate ways to enhance the immunogenicity of the epitope. Further studies were 
performed in C57Bl/6 mice, since a subcutaneous tumour model had been 
established in these mice with TRAMP C1 cells. 5x106 PAP+ TRAMP cells injected 
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subcutaneously into C57Bl/6 mice produced tumours of 1cm2 size in all mice by day 
36 following implantation. The availability of C57Bl/6 mice and relatively short 
time span for tumour generation allowed an extensive investigation to be conducted. 
Autochthonous TRAMP mice were not used in this stage of study due to the 
following reasons. Firstly, TRAMP mice are notoriously difficult to maintain and 
secondly, future work may focus on developing vaccine strategies in older mice for 
which the spontaneous TRAMP model is unsuited. PC is a disease that affects the 
older population hence it would be vital to assess the effect of vaccination in older 
mice to provide a more appropriate setting for clinical translation. TRAMP mice 
invariably and progressively developed mouse PIN (mPIN), adenocarcinoma, and 
visceral metastases by the end of 24-30 weeks when the mice are still quite young 
(Shappell et al., 2004).  
6.5. Immunogenicity of PAP-114-128 enhanced by the Immunobody vector 
platform: 
Through studies conducted in the transplantable TRAMP mouse model it was 
identified that the immunogenicity of PAP-114-128 epitope could be significantly 
enhanced by the use of the Immunobody vector (Scancell’s DC vaccine platform). It 
is now well accepted that the best way to stimulate the immune system is via DC as 
the natural pathway for T cell activation (Small et al.,2006).  The only FDA 
approved vaccine against PC, Sipuleucel-T is a DC based vaccine (Small et 
al.,2006). However one flaw with this vaccine strategy is the need to extract each 
patient’s DC for in vitro programming, making it extremely expensive (more than 
$90,000 per treatment cycle) and time consuming. The use of Immunobody allows 
the use of a DNA construct incorporating the immunogenic epitope of choice 
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(Pudney et al., 2010). The Fcγ receptors integrated into the ImmunoBody have high 
affinity for CD64, expressed on DC, thereby allowing efficient targeting of DC and 
the proficient stimulation of both CD4+ (helper) and CD8+ (cytotoxic) responses 
(Pudney et al., 2010). Therefore this system elicits an immune response without 
having to isolate the patient’s DC, allowing the production of vaccines to treat any 
number of patients on a large scale (Pudney et al., 2010). In the current study, 
Immunobody incorporating the epitope (IB-PAP-114-128) was assessed for the 
ability to induce specific T cell immunity. In vitro analysis of splenocytes isolated 
from C57Bl/6 mice immunised with either the Immunobody or the peptide vaccine 
showed significantly enhanced  responses, CD8 specific cytotoxicity and CD4 
specific proliferative response. This increased T cell response observed following 
IB-PAP-114-128 immunisations correlated well with a better protection against 
established subcutaneous TRAMP-derived tumours in vivo. Earlier pre-clinical 
studies comparing ImmunoBody DNA vaccine encoding the melanoma TRP-2 
epitope to TRP-2 peptide reported an enhanced response to ImmunoBody 
immunisation (Metheringham et al., 2009). A similar enhanced response was also 
seen when compared to whole murine TRP2 antigen DNA immunisation 
(Metheringham et al., 2009) and suggests that the high frequency responses obtained 
following Immunobody immunisations could be a result of both direct and cross 
presentation (Metheringham et al., 2009). Interestingly, phase I/II clinical studies 
using Immunobody vaccine, SCIB1 elicited melanoma-specific immune responses 
and clinical benefit in patients and a phase III study is currently underway (Pudney et 
al., 2010). 
6.6. Enhanced immunogenicity of IB-PAP-114-128 was associated with 
enhanced CD8+ T cell infiltration and the production of higher avidity T cells:  
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On further investigation on the tumours from both groups of immunised mice, it was 
observed that the number of CD8+ T cells infiltrating the tumour mass was 
significantly increased in IB-PAP-114-128 immunised group compared to mice 
immunised with PAP-114-128 peptide or the empty vector. This clearly shows that 
IB-PAP-114-128 could successfully recruit CD8+ TILs into the tumour site while 
PAP-114-128 failed to elicit the same degree of TILs. It was observed that 
splenocytes isolated from IB-PAP-114-128 immunised mice secreted significantly 
higher levels of IFNγ and could be stimulated in vitro with far smaller amount of 
peptide compared to PAP-114-128. The amount of peptide required to stimulate T 
cells isolated from IB-PAP-114-128 was 10 times less compared to PAP-114-128 
group. Collectively, this data shows that although both immunisation strategies 
generated similar number of antigen specific T cells, the T cells generated in IB-
PAP-114-128 are of higher avidity compared to PAP-114-128 immunisation. Recent 
reports suggest that it is important to generate high avidity T cells for effective 
tumour clearance, since tumour cells naturally express very low levels of tumour 
antigen in situ (Brentville et al., 2012) and is one way to naturally evade the immune 
detection/rejection. Generation of high avidity T cells would therefore allow 
recognition of tumour cells that express very low levels of antigens and more likely 
to destry them.  
 
 
6.7. Immunogenicity of PAP-115-123 is enhanced following substitution of the 
anchor residues:  
156 
 
Recent reports suggest that the immunogenicity of known tumour antigens could be 
enhanced by modifications/substitutions of the amino acid sequences at MHC anchor 
positions of known peptide epitopes (Buhrman et al., 2013).  Substituting a 
methionine for the native threonine at position 2 of the melanomal HLA-A2 peptide 
epitope gp100:209-217 was shown to enhance the peptide binding to 9-fold 
(Parkhurst et al., 1996). The enhanced binding was also found to be associated with 
an enhanced immunogenicity of the epitope in vitro and in vivo with the generation 
of T cells having an enhanced capacity to recognize tumour cells (Parkhurst et al., 
1996). Another study reports that a substitution of valine for cysteine at position 9 of 
the HLA-A2 epitope NY-ESO-1:155-163 not only enhances the binding to HLA-A2, 
but also prevents disulfide bridge formation, thus eliminating dimerization of the 
peptide in solution (Vertuani et al.,2004).  In the current study, when the amino acid 
alanine in the 2nd position was replaced by lysine in the PAP-115-123 epitope, the 
binding score of the epitope to HLA-A2 was enhanced and correlated with an 
enhanced  response in HHDII/DRI and in C57Bl/6 mice. The T cells generated 
in C57Bl/6 mice immunised with the modified peptide were able to lyse TRAMP 
cells that express PAP, showing that the peptide was naturally processed. The 
enhanced IFNγ response was observed over a range of PAP-115-123 peptide epitope 
concentrations used for stimulating the splenocytes. Interestingly, the PAP115-123 
analogue peptide was also able to produce significantly high IFNγ responses in PC 
patient PBMC. No specific T cell responses were observed in benign samples and 
hence the response generated by PAP-115-123 analogue peptide displayed a similar 
specificity to that of wild type PAP-115-123 epitope. A recent study reported that 
one of the modified epitope for tumour antigen of a mouse colon carcinoma cell line 
elicits antigen-specific T cell response in vivo, but failed to prevent tumour growth 
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(Buhrman et al.,2013). However, priming T cells with the modified peptide epitope 
followed by a boost with wild type peptide significantly enhanced anti-tumour 
immunity compared to prime-boost using the modified epitope alone (Buhrman et 
al.,2013). This enhanced response was found to be associated with the expansion of 
tumour specific T cells with increased avidity (Buhrman et al.,2013). In the current 
study, similar observations were obtained. Mice primed with the analogue PAP 
peptide epitope and boosted with PAP peptide epitope elicited higher IFNγ response 
compared with mice prime-boosted with the analogue epitope alone. Collectively 
these results suggest that incorporation of both native and analogue epitopes into the 
immunisation regime might improve the efficacy of anti-tumour T-cell responses.  
The conclusions from this research highlight several issues that are relevant for 
developing strategies for cancer immunotherapy. 
6.8. The time and mode of prime-boost vaccinations are important factors for 
eliciting optimal immune response:  
The questions such as how and how frequently a patient should be vaccinated still 
remains an open conundrum. In the current study, an enhanced IFNγ response was 
observed when the prime-boost vaccination interval was increased from one week to 
two weeks. It is now well accepted that the efficacy of a cancer vaccine stems from 
its ability to stimulate a strong and long-lasting memory response against relevant 
tumour antigens. The memory T cell compartment can be distinguished as central 
memory (Tcm) and effector memory (Tem) cells, which differ in their functional and 
phenotypic characteristics (Sallusto et al., 1999). A recent study reports that a single 
DC-based vaccination can elicit an antigen specific immune response that lasts for at 
least 5 months even in the absence of subsequent boost or antigen stimulation 
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(Alessia et al., 2013). Though a 2-fold increase was seen in the pool of IFNγ -
secreting cytotoxic CD8+ Tcm cells following a boost compared to non-boosted 
mice, a lag of at least 4 weeks between the prime-boost regimes was required to 
obtain the most potent Tcm response (Alessia et al., 2013). When the vaccination 
interval was reduced to 1 week, a reduced survival was observed in B16F1 
melanoma-bearing mice (Ricupito et al., 2013) and is similar to the observations 
seen in the current study. Surprisingly, prime-boost homologous vaccination proved 
to be of no advantage or even detrimental for the overall survival rate in a 
therapeutic setting in B16F1 and TRAMP models respectively (Ricupito et al., 
2013). This detrimental effect seen in therapeutic setting after multiple vaccinations 
could be due to the fact that the antigens released from the tumours naturally might 
boost vaccine-induced immune response. In such a scenario, exogenous boost might 
expose the T cells to excessive antigen stimulation leading to T cell exhaustion and 
deletion. In the current study it was observed that the prime-boost regime using the 
PAP-114-128 peptide epitope delayed or prevented tumour growth in the 
subcutaneous TRAMP mouse model. This could be due to the fact that in the current 
study, mice were primed with the long 15-mer epitope and boosted with the short 9-
mer MHC class I peptide epitope. It was observed that such a mixed/heterologous 
prime-boost regime generated a better immune response in immunised mice as 
compared with prime alone or prime-boost with single type of PAP peptide epitope. 
Previous studies have shown that if heterologous prime-boost strategy is applied, 
only a subset of the previously generated memory cells is activated (Sallusto et al., 
2010). Therefore such prime-boost regimes could be advantageous as this would 
result in generation of heterogenous population of memory T cells at various stages 
of differentiation. It was earlier reported that heterologous prime-boost vaccination 
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using the same antigen but with different vaccine vector gives better immune 
response (Welsh et al., 2010). Also, DNA prime and peptide boost immunisation 
protocols were shown to enhance protective immunity in pre-clinical mouse models 
(Min et al., 2013). These studies provide strong evidence that heterologous prime-
boost vaccination regimes would be an effective way to prevent T cell memory 
exhaustion and deletion.  
6.9. Optimal antigen persistence as a critical feature for generating the most 
favourable immune response:  
In the current study it was observed that IB-PAP-114-128 immunised mice had a 
higher percentage of CD8+ T cells infiltrated into the tumours compared with PAP-
114-128 immunised mice. Interestingly, the number of PAP-115-123 specific T cells 
as assessed by dextramer staining, remained similar in both vaccination groups. This 
demonstrates that PAP-114-128 peptide in IFA immunisation, generated antigen-
specific T cell responses but T cells failed to traffic to the tumour site. Recent studies 
have shown that the use of IFA as an adjuvant allows the slow release of antigen 
which is beneficial for inducing B-cell responses but is profoundly detrimental in 
eliciting T-cell responses (Yared et al., 2013). Owing to the persistent, large amount 
of antigen at the injected site compared to the tumours, lead to the accumulation of T 
cells at injection site which eventually became a T-cell graveyard (Yared et al., 
2013). It was reported that replacing IFA with saline alone to reduce antigen 
persistence was not successful since the antigen presentation was too short causing 
weak T-cell priming (Yared et al., 2013). But this was successfully overcome by the 
use of peptide in saline along with DC activation with immunostimulatory cocktails 
(Yared et al., 2013). It was reported that the local presentation of peptide lasted for 2 
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days when saline was used whereas with IFA formulations peptide lasted for upto 3 
months at the injection site (Blair et al., 2011). Our natural immune system usually 
eliminates acute infections, often within a week; therefore such a time-frame for 
antigen presentation might elicit optimal immune responses (Blair et al., 2011). Thus 
collectively it could be understood that optimal antigen persistence that is neither too 
short nor too long is a crucial factor for eliciting effective anti-cancer immunity.   
6.10. Modulation of high and low avidity T cells to induce long lasting 
protection:  
T cell avidity is defined based on the antigen requirement of the T cell population 
and is reported to be a better indicator of clinical response than affinity (Selena et al., 
2012). Affinity is a measure of strength of binding of peptide-MHC complex to the 
TCR whereas functional avidity is a measure of the combination of stimulation via 
TCR, co stimulatory molecules, adhesion molecules and cytokines and is indicative 
of the overall strength of interaction between T cell and antigen (Viganò et al., 
2012). High avidity T cells are characterised as being extremely sensitive to low 
levels of antigens while low avidity T cells require higher levels of antigen 
concentration for effective activation (Hodge et al., 2005). A growing list of reports 
have shown that high avidity T cells mediate better viral clearance and tumour 
eradication compared to low avidity T cells (Hodge et al., 2005, Von Essen et al., 
2012). In line with this, in the current study the enhanced response seen with IB-
PAP-114-128 was found to be associated with the production of T cells with higher 
avidity. It was recently reported that in mice immunised with Immunobody 
incorporating a TRP-2 CD8 epitope generated high avidity CTLs that were pre-
dominantly recruited to the memory response and could be efficiently boosted by 
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DNA immunisation (Brentville et al., 2012). However the enhanced avidity of the 
memory response was dramatically reduced when boosted with peptide immunogen 
(Brentville et al., 2012). This avidity loss was permanent since a DNA boost could 
only partially recover the avidity of the original DNA prime suggesting that peptide 
boost had deleted the original high avidity memory response (Brentville et al., 2012). 
This data is in line with other results showing that repeated peptide immunisations 
showed loss of high avidity T cell responses correlating with minimal anti-tumour 
efficacy (Alessia et al., 2013). However, the observation that the DNA boost appears 
to partially recover the avidity after peptide boost is an interesting finding, 
suggesting that a very low avidity population could be modulated towards higher 
avidity. A recent report demonstrates that a single cell can differentiate into clones of 
high or low avidity depending on the initial encounters with the antigen (Charles et 
al., 2007). However, this window of ‘tunability’ was seen to only last for the initial 
two or three stimulations after which the avidity become fixed (Charles et al., 2007). 
Thus with majority of T cells there is a window of opportunity during which the 
antigen sensitivity could be modulated to high or low avidity (Charles et al., 2007). 
This is particularly relevant because the goal of immunotherapy against acute 
infection and complete tumour clearance should be the induction of high avidity T-
cells since they are most effective in eliminating infected cells. But when complete 
clearance is not possible such as chronic infections, then immunotherapy should be 
designed to generate low avidity T cells. Low avidity T cells would be more suitable 
in such a situation since tolerance-enforcing mechanisms effectively remove high 
avidity self and tumour antigen reactive T cells in chronic infections (McMahan et 
al., 2007). Hence the tumour burden of the patient that is being immunised should be 
carefully considered before the vaccine strategy is designed. The vaccine that could 
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clear tumours in the initial stages might not be effective as such in the later stages of 
tumour burden.  
6.11. Conclusions and Future work:  
In the current study a novel 15-mer PAP-114-128 peptide epitope and an 8-mer 
PAP-115-123 MHC class I epitope were identified and shown to elicit both CD4+ 
and CD8+ T cell response in C57Bl/6 and HHDII/DRI mice. The 100% homology in 
the sequence between human and mouse would allow easier clinical translation of 
pre-clinical observations. cDNA immunisations using gene gun allowed 
identification of the PAP-114-128 and PAP-115-123 peptide epitopes. However it 
would be important to perform further screening of the whole PAP protein to 
identify other immunogenic ‘hot spots’ in the antigen. Increasing the length of the 
epitope to 36-40 mer would allow incorporation of multiple epitopes that would 
cover a wider range of HLA molecules. A subcutaneous TRAMP model was 
successfully established in C57Bl/6 mice to further study the effect of vaccine 
therapy. Establishment of a subcutaneous TRAMP model would allow investigating 
the effect of vaccines in older mice since PC affects the older population. Another 
follow up study that evaluates the identified PAP epitopes along with Shigella STxB 
vector as delivery system is currently underway on the established subcutaneous 
TRAMP mouse model. It would also be important to establish an autochthonous PC 
tumour model in C57Bl/6 mice that would better mimic the tumour in the original 
site rather than being subcutaneous. In this study, the immunogenicity of the 
epitopes was found to be significantly enhanced by tagging with the Immunobody 
vector. The enhanced IFNγ response seen in C57Bl/6 mice correlated with better 
tumour protection in therapeutic and prophylactic settings. This enhanced 
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immunogenicity of IB-PAP-114-128 was found to be associated with increased 
CD8+ TIL infiltration into the tumours and also due to the production of T cells with 
higher avidity. PAP-115-123 specific T cell responses were also identified in 6/10 
HLA-A2+ PC patients and no specific response was seen in benign samples. 
Importantly, PAP-115-123 specific IFNγ response was found in PC patients that 
responded to a DC based vaccine pulsed with mRNA isolated from PAP+ PC cell 
lines. No response was found in patients that failed to respond to the vaccine. 
Presence of PAP-115-123 specific IFNγ secreting Th1-type cells in the patient body 
is quite encouraging as it suggests the presence of an immune environment capable 
of supporting PAP specific immune responses. Analogue PAP-115-123 epitope 
obtained by substituting the second anchor residue alanine with lysine gave high 
binding score to HLA-A2. An enhanced IFNγ response was seen in spleens isolated 
from HHDII/DRI mice and C57Bl/6 mice following immunisations with the 
analogue peptide. It was observed that giving heterologous prime-boost vaccination 
strategy give a better response rather than following homologous prime-boost 
vaccination strategy. Hence it would be ideal to include both analogous PAP epitope 
and native PAP epitope in the vaccination schedule. Also, it would be important to 
increase the time span between prime and boost doses to atleast 2-4 weeks to 
enhance the immune response. It is an emerging fact that every adaptive immune 
response involve recruitment and activation of T regulatory cells (CD4+CD25+) 
along with effector T and B cells (Shimon et al.,2008). Therefore it is crucial to 
check the T regulatory population in the established tumour model. If an increase in 
T regulatory population is identified, anti-T regulatory strategies such as use of 
CTLA-4, cyclophosphamide needs to be implemented along with the vaccination. 
This would benefit further the establishment of adoptive T cell anti-tumour 
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immunity and circumvent tumour escape through T regulatory cells. Another 
important factor that should be considered is the generation/activation of memory 
response to the immunising antigen. An ideal vaccine should be able to induce a 
long-lasting memory response that would check tumour recurrence. Hence the future 
work should also involve investigating the effect of immunisation strategies on 
central (CD44+CCR7highCD62Lhigh) and effector (CD44+CCR7lowCD62Llow) memory 
cells.  
In conclusion, this study sets in place a rationale approach to PAP-peptide 
immunotherapy for PC, based on pre-clinical studies using an appropriate mouse 
model. Consideration of the above observations would help to allow improvements 
in the current strategies.  
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